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Multifunctional nanocarriers have been regarded as potent candidates for efficient 
cancer nanomedicine. Nanoparticles of biodegradable polymers were postulated as 
promising platforms to establish the multiple functions for anticancer purposes such as 
delivery of therapeutics, targeting the desired site, imaging the diseased cells, and 
monitoring the effects of treatment. In this PhD work, the proof-of-concept 
experiments were conducted based on the surface modified and functionalized PLGA 
nanoparticle systems in order to develop the multifunctional nanocarriers as novel 
formulations of cancer nanomedicine, especially for breast cancer. The desired 
properties of such developed nanoparticle formulations for drug delivery include small 
size, narrow size distribution, high stability, effective drug loading, sustained and 
controlled release of the drug, strong interaction with cells, specific uptake by cancer 
cells as well as efficient anticancer activity. Phospholipids were, at first, used to 
improve the features of polymeric nanoparticles through development of lipid shell 
polymer core nanoparticles. Optimization was carried out in order to identify the 
optimal type and amount of phospholipids for the fabrication of particles with desired 
properties in terms of particle size, size distribution, surface charge, shape and 
morphology, surface composition and drug loading. The feasibility of the optimal 
formulation for anticancer drug delivery was proved by the in vitro drug release, in 
vitro cellular uptake, and in vitro cytotoxicity studies. All the consistent results show 
that nanoparticles of DLPC shell and PLGA core could be a prospective drug delivery 
carrier which is able to provide greater cytotoxicity effect but at the same time 
alleviate the side effects. Subsequently, more advanced nanoparticles of lipid shell and 
polymer core was developed with the conjugation of molecular ligands to achieve 
 viii 
 
targeted nanomedicine by using the optimal formulation investigated in the previous 
work. An illustration of the formulation was shown to prove the potential of the 
designed nanocarrier as a versatile platform for targeted cancer nanomedicine. 
Development of the strategy to precisely control the quantity of targeting ligands on 
nanocarriers and investigation on the impact of the quantity on the targeting effects, i.e. 
cellular uptake efficiency and cell inhibition performance was also included in this 
work. A copolymer blend of PLGA and PEGylated PLGA was used to achieve the 
quantitative control of the antibodies attached on the nanoparticles, after which the 
antibody conjugated polymeric nanoparticles with drug loaded was produced to show 
the prospect of the formulation to deliver drugs. The targeting effect on HER2-
overexpressed breast cancer cells was presented by using the receptor overexpressed 
cancer cells. The development of cutting-edge nanoparticles of biodegradable 
polymers with overall fascinating performance demonstrates the progress in the field 
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Chapter 1 : Introduction  
1.1 Background 
Cancer is one of the most dreaded diseases today (Jemal et al., 2009). Nevertheless, 
there has been no substantial progress in fighting against cancer in the past 50 years. 
The mostly used cancer therapies in the current stage have still been surgery followed 
by chemotherapy and/or radiotherapy, which are not satisfactory enough to suppress 
the disease and the survival rate of the patients is still not favorable. As a result, 
reevaluation of basic assumptions concerning the nature of cancer and how to better 
assess risk, prevent, and medically manage is a high priority. While it is quite old 
already, chemotherapy has still been one of the most important components in cancer 
therapies due to the systemic property. Although chemotherapy is a complicated 
procedure and carries a high risk due to dosage form, drug toxicity, restricted 
pharmacokinetics and pharmacodynamics (ADME), severe side effects and drug 
resistance at various physiological levels (Feng, 2006), the problems could be readily 
solved by chemotherapeutic engineering, which was defined as application and further 
development of engineering especially chemical engineering principles to solve the 
problems in the current regimen of chemotherapy to achieve the best efficacy with the 
least side effects (Feng and Chien, 2003).  
As a major technology for engineering chemotherapy, nanotechnology has been 
regarded as one of the most promising approaches to deal with cancer and has been 
extensively exploited to improve conventional chemotherapy in the recent years 
(Farokhzad and Langer, 2009; Ferrari, 2005; Sinha et al., 2006). Nanoparticles (NPs) 
of biodegradable polymers have become promising platforms for sustained, controlled 
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and targeted drug delivery to improve the therapeutic effects and reduce the side 
effects against cancer (Kataoka et al., 2001; Farokhzad and Langer, 2006; van Vlerken 
et al., 2007). They may provide an ideal solution for the problems encountered in 
current regimen of chemotherapy owing to their unique properties such as the small 
size, acceptable biocompatibility, high drug encapsulation efficiency especially for 
hydrophobic drugs, controlled and sustained drug release manner, high cellular uptake 
efficiency, desired pharmacokinetics, long circulation half-life, and highly tailored 
functions (Cho et al., 2008; Tong and Cheng, 2007; Zhang et al., 2008a). With the aid 
of NPs, the problems of traditional chemotherapy, i.e. the dosage form, toxicity, severe 
side effects, and unfavorable pharmacokinetics could be settled with satisfaction.  
Nanomedicine is designed to provide an ideal method by application of 
nanotechnology to solve the problems in medicine, which means to diagnose and treat 
the disease at cellular and molecular level and thus will radically change the way we 
diagnose, treat and prevent diseases. Nanoparticles of biodegradable polymers as 
delivery carriers for transportation of therapeutic agents are one of the promising 
platforms to fulfill the purpose. To achieve optimized anticancer effect, the NPs should 
be properly tailored by the selection of biomaterials and the engineering of the 
nanoparticulate systems that are able to be efficiently carry desired payloads, 
specifically taken up by targeted diseased cells and subsequently release the payloads 
at a plasma concentration between the minimum effective level and the maximum 
tolerable level in a sustained manner (Gref et al., 1994; Langer, 2001; Ferrari, 2005).  
In addition, by using nanotechnology, multifunctional NPs with multiple functions to 
treat cancers are also able to be produced. Since cancer is a very complicated system, 
powerful anticancer weapons equipped with a variety of functions are highly desired. 
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The functions such as targeting, diagnosing, therapy-delivering, long circulating and 
result-reporting could be developed for cancer diagnosis and treatment. Cancer will 
thus become curable at its earliest stage by molecular imaging guided, targeted and 
sustained chemotherapy since high drug concentration could be delivered to a very 
limited area and the needed amount of the drug could be minimized.  
The screening of biomaterials to build up the matrix (or core) of the NPs is the first 
issue that should be addressed. The favorable features from the NPs, to large extent, 
depend on the properties of the materials. In the past a few years, PLGA approved by 
FDA for therapeutic devices has been one of the most widely used biodegradable 
polymers for anticancer drug delivery. Through engineering methods, the NPs can be 
easily produced from the polymers to load hydrophobic anticancer drugs like docetaxel, 
which is a potent drug used in the treatment of a wide spectrum of cancers like breast 
cancer, ovarian cancer, small and non-small cell lung cancer, prostate cancer, etc. 
PLGA NPs were proved to possess the advantages such as accepted low toxicity, high 
stability in storage, high drug loading capability, controlled and sustained drug release 
behavior, high cell penetration ability and favorable pharmacokinetics (Feng et al., 
2007; Win and Feng, 2006). Moreover, polymeric nanoparticles show some 
advantages with respect to other drug delivery systems besides the stability during 
storage (Müller et al., 2001). After intravenous administration, they may extravasate 
solid tumors and into inflamed or infected sites, where the capillary endothelium is 
defective thus passively targeting drug loaded nanoparticles to the tumor site 
(Musumeci et al., 2006).  
However, at present, NPs should be appropriately engineered prior to taking effect in 
practical cancer chemotherapy in that there are several fundamental problems and 
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technical barriers that must be overcome for anticancer nanomedicine (Nie, 2010), 
which include opsonization and phagocytosis of NPs (Owens and Peppas, 2006), 
capture and retention of NPs in RES (Jain, 1990), difficulties in nanoparticle 
accumulation in vicinity of solid tumors and targeting the cancerous cells followed by 
penetration into solid tumors (Dreher et al., 2006; Minchinton and Tannock, 2006). 
The effective solution is to engineer NPs by tuning their size, polydispersity, surface 
area, surface charge, morphology, as well as surface chemical property through 
introducing versatile materials on NPs to meet the needs. Among those characteristics 
of NPs, surface property plays a key role in determining the performance on 
nanomedicine in the aspects of 1) enhancing the circulation time of the NPs, which 
results by avoiding the recognition by phagocytic system and escaping from the 
adsorption of proteins in bloodstream; 2) prompting cellular uptake efficiency 
benefiting from higher interaction of the surface of NPs with the cell membrane; and 3) 
decorating NPs surface to achieve favorable chemotherapy by coating with various 
functional materials and/or conjugating desired molecules. 
Furthermore, targeted drug delivery or tumor specific drug delivery using NPs is of 
paramount importance since the therapeutic agents can be concentrated in the diseased 
tissues or cells which results in higher anticancer effect with lower side effects exposed 
in healthy organs or normal cells with the aid of accurate guidance to the specific sites 
by targeted molecular imaging to visualize tumors and cancer cells. Once the NPs have 
been attached with targeting ligands, the payloads inside the particles can thus, ideally, 
be only released in the desired sites with the protection from the exposure of 
physiological fluids and plasma components, and subsequently, destroy the targeted 
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enemies, as like the magic bullets (Strebhardt and Ullrich, 2008) or missiles (Barbe et 
al., 2004).  
 
1.2 Objective of the PhD work 
To sum up the objective of this PhD work, we dedicated to developing new 
nanomedicine formulations based on nanoparticles of biodegradable polymers, as more 
powerful weapons with more advanced overall performance, for cancer treatment with 
multiple functions, especially for breast cancer after Stage 1. The focus lies on the 
modification of surface properties of the NPs to achieve the purpose of desired surface 
properties, higher cellular uptake efficiency, better therapeutic effects, targeted therapy 
on cancer, and finally controlling the targeting effect.  
The main body of this thesis includes four chapters. The first one starts from the report 
of proof-of-concept study on the feasibility of using phospholipids to produce lipid 
shell polymer core NPs, which are novel alternative drug formulations with the 
combined merits of liposomes and polymeric nanoparticles. The characterization and 
evaluation on the cellular level exhibits solid evidence of the possibility of developing 
the novel nanocarriers for drug delivery as well as the advantages over commercial 
drug formulations and traditional drug delivery carriers. The study creates a new 
platform of nanotechnology based nanomedicine formulation possessing the high 
potential of further modification for various anticancer applications. Followed by the 
pioneering work, a derived nanoparticle of lipid shell and polymer core with molecular 
ligand attached for targeted cancer nanomedicine is reported in the next chapter. The 
more advanced nanocarrier was fabricated based on the previous optimization study 
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and equipped with more functions to achieve more superior properties and targeted 
drug delivery with the aid of versatile targeting ligands conjugated on the lipid shell. 
Afterwards, the emphasis of the work is still on the research of biomaterials that are 
appropriate to coat on polymeric particles to obtain more desired surface properties. In 
the third part, new PEGylated vitamin E analogues were synthesized as new-
generation surfactants and applied to fabricate nanoparticles. The new and functional 
materials impart advantages to the particles over those coated by traditional surfactants. 
The preliminary research opens a new area of customizing surface functions of 
nanocarriers by simply using the tailored materials to coat on the particle surafce.  
The last chapter displays a preliminary proof-of-concept study on the precision 
engineering of polymeric nanoparticles for quantitative control of targeted drug 
delivery. In other words, we proposed a “post-conjugation” strategy to achieve the 
purpose of precisely control the targeting ligands conjugated on the nanocarriers in a 
quantitative maner. By realization of the objective, it is possible to tune the targeting 
effects for cancer nanomedicine. Moreover, it was proved that the quantity of the 
targeting ligands do have great impact on the anticancer performance of the 
nanocarriers on cellular level. It is thus anticipated to make personalized cancer 




Chapter 2 : Literature Review 
2.1 Cancer 
Cancer is defined as diseases in which abnormal cells divide without control and that 
are able to invade other tissues. Up to date, cancer is the number one cause of death in 
the United States for people less than 75 years old (Mbeunkui and Johann, 2009). The 
recent statistics reported that about 25% of death is due to cancer in US, although the 
combined death rates for men decreased by 21.0% between
 
1990 and 2006 and for 
women, overall cancer death rates between 1991 and 2006
 
decreased by 12.3% (Jemal 
et al., 2010).
 
Every year, more than 11 million people are diagnosed with cancer 
throughout the world and it may likely increase to 16 million by 2020. In 2005, cancer 
accounted for 7.6 million deaths from a total of 58 million deaths worldwide (Jemal et 
al., 2011). Currently, more than 200 different types of cancer have been discovered, 
most of which are named for the organ or type of cell in which they start. For example, 
cancer that begins in the breast is called breast cancer; cancer that begins in ovarian is 
called ovarian cancer. Cancer types can be grouped into broader categories, mainly 
including carcinoma (cancer that begins in the skin or in tissues that line or cover 
internal organs), sarcoma (cancer that begins in bone, cartilage, fat, muscle, blood 
vessels, or other connective or supportive tissue), leukemia (cancer that starts in blood-
forming tissue such as the bone marrow and causes large numbers of abnormal blood 
cells to be produced and enter the blood), lymphoma and myeloma (cancers that begin 
in the cells of the immune system) and glioma (cancers that begin in the tissues of the 




Cancer cells develop because of damage to DNA commonly caused by external factors 
(chemicals, viruses, tobacco smoke, radiation, too much sunlight and infections) and 
internal factors (inherited metabolism mutations, hormones and immune conditions). 
When DNA is damaged or changed, producing mutations that affect normal cell 
growth and division, cells do not die when they should and new cells form while the 
body does not need them. The reason of the damage in DNA, although the exact 
mechanism behind has not been clearly elucidated yet, can be attributed to the 
activation of telomerase that was discovered by Carol W. Greider and Elizabeth 
Blackburn in 1984 who are the Nobel Prize Laureates in Physiology or Medicine 2009. 
For the normal cells, telomeres, which are found at the ends of chromosomes, will be 
shortened after each replication cycle, resulting in the programmed death (apoptosis) 
of the cells. While for the cancerous cells, due to the presence of telomerase which is 
an enzyme that adds DNA sequence repeats to the 3' end of DNA strands in the 
telomere regions, the telomeres will be elongated and will not be shortened after cell 
replication. As a result, the cancerous cells will become immortal (Blackburn, 2005).  
Subsequently, the extra cells may form a mass of abnormally grown tissue in the 
vicinity of blood vessels called a tumor. Among tumors, benign tumors are not 
cancerous, which can often be removed, and, in most cases, do not come back. Cells in 
benign tumors do not spread to other parts of the body. But malignant tumors are 
cancerous, cells in which can invade nearby tissues and spread to other parts of the 
body. The spreading process that cancer cells travel from one part of the body to 
another through bloodstream or lymph system where they begin to grow and replace 
normal tissue is called metastasis (Klein, 2008).  
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The special property of tumor tissues leads to the difficulty of transporting therapeutic 
agents into the matrix and the agents will be usually eliminated from the tissue. Unlike 
most normal tissues, the interstitium of tumor tissues has high hydrostatic pressure, 
leading to an outward convective interstitial flow that can flush the drug away from the 
tumor. Even if the drug is successfully penetrated into the tumor interstitium, it may 
also be removed by multi-drug resistance (MDR) (Brigger et al., 2002). MDR is 
mainly attributed to overexpression of P-glycoprotein (P-gp) on the plasma membrane, 
which is capable of pumping drugs out of the cell (Figure 2.1). Several strategies for 
circumventing P-gp-mediated MDR have been proposed, including the co-
administration of P-gp inhibitors and anticancer drugs encapsulated in nanoparticles 
(Krishna et al., 2000; Patil et al., 2009).  
  
Figure 2.1 Structure of the drug efflux transporter: drug molecules (the balls) 
encounter MDR pumps (the knot) after passing through a cell membrane (adapted 





2.2 Treatments of cancer 
Nowdays, death rates for the four most common cancers (prostate, breast, lung, and 
colorectal), as well as for all cancers combined, continue to decline; the rate of cancer 
incidence has declined since the early 1990s (http://progressreport.cancer.gov/).  
Generally, there are several major types of treatment for cancer diseases: surgery, 
chemotherapy, radiotherapy, immunotherapy, anti-angiogenesis therapy, gene therapy, 
and photodynamic therapy, and usually, the combination of those therapies.  
2.2.1 Surgery 
Surgery is the oldest form of cancer treatment, whose primitive manner can be traced 
back to more than hundred years ago. The majority work of surgery to treat cancer is to 
excise tumors or the tissues invaded by cancer cells. It also has a key role in 
diagnosing cancer and finding out how far it has spread (staging). Advances in surgical 
techniques have allowed surgeons to successfully operate on a growing number of 
patients. Today, less invasive operations often can be done to remove tumors while 
saving as much normal tissue and function as possible. Surgery offers the greatest 
chance to cure for many types of cancer, especially those that have not spread to other 
parts of the body. 
2.2.2 Chemotherapy 
Chemotherapy is usually defined as the use of any medicine to treat any disease. 
Contemporarily, chemotherapy, or "chemo" for short, is most often narrowly regarded 
as taking certain types of drugs to kill or control cancer. Commonly the 
chemotherapeutic agents will be taken combined with surgery and/or radiotherapy. 
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Chemotherapy is also one of the most important therapies due to its systemic character 
which is able to treat the metastatic cancer cells. Cancer chemotherapy has been 
helping people beat cancer since the early 1950s. So far there have been hundreds of 
anticancer drugs available for clinical cancer defeating (Feng and Chien, 2003) and 
proved to be effective. 
2.2.3 Radiotherapy  
Radiotherapy has been made an important part of cancer treatment today. In fact, about 
half of all people with cancer will get radiation as one part of their cancer treatment, 
usually after surgery and combined with chemotherapy. Radiation is energy that is 
carried by waves or a stream of particles. It can change the genes (DNA) and some of 
the molecules of a cell. These genes control how cells in the body grow and divide. In 
cell cycle, radiation usually kills the cells that are actively or quickly dividing to 
inhibit cell mitosis.  
2.2.4 Immunotherapy 
Immunotherapy, also called biologic therapy or biotherapy, is a treatment that uses 
certain parts of the immune system to fight disease, including cancer. This can be done 
by stimulating own immune system to work harder or smarter, or giving immune 
system components, such as man-made immune system proteins. It is most likely to be 
effective when treating smaller, early stage cancers, whose main role at this time is 
making other forms of treatment better or providing cancer patients with another, often 
less toxic, treatment option. 
2.2.5 Angiogenesis therapy 
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Angiogenesis is the creation of new blood vessels. Normally, it is a healthy process. 
As the human body grows and develops, it needs to make new blood vessels to deliver 
blood to all of its cells. But in a person with cancer, this same process creates new, 
very small blood vessels that provide a tumor with its own blood supply and allow it to 
grow. Anti-angiogenesis is a form of targeted therapy that uses drugs or other 
substances to inhibit the creation of new blood vessels for tumors. Without a blood 
supply, tumors cannot grow. Anti-angiogenesis drugs do not attack cancer cells 
directly. Instead, they target the blood vessels these cells need to survive and grow. By 
this mean, they may prevent new tumors from growing or shrink large tumors as long 
as their blood supply is cut off. 
2.2.6 Gene therapy 
Gene therapy involves inserting genetic material (DNA or RNA) into cells to restore a 
missing function or to give the cells a new function. Because missing or damaged 
genes cause certain diseases such as cancer, it makes sense to try to treat these diseases 
by adding the missing gene(s), fixing those which are damaged or replacing the 
abnormal ones by normal ones. Gene therapy is being used to treat cancers by adding 
functioning genes to cells that have diseased or missing genes, stopping oncogenes or 
other genes important to cancer from working, adding or changing genes to make 
cancer cells more unstable, adding or changing cancer cell genes to make them more 
vulnerable to cancer treatments, making tumor cells more easily detected and 
destroyed by the body's immune system and stopping genes that play a role in new 
blood vessel formation (angiogenesis) or adding genes that stop it.  
2.2.7 Photodynamic therapy 
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Photodynamic therapy is also called photoradiation therapy, phototherapy, or 
photochemotherapy. The photosensitizing agents are used along with light to kill 
cancer cells in this treatment. The drugs only work after they have been activated or 
"turned on" by certain kinds of light. Depending on the part of the body being treated, 
the photosensitizing agent is either injected into the bloodstream or put on the skin. 
After the drug is absorbed by the cancer cells, light is applied only to the area to be 
treated. The light causes the drug to react with oxygen, which forms singlet oxygen 
that kills the cancer cells. PDT may also work by destroying the blood vessels that feed 
the cancer cells and by alerting the immune system to attack the cancer.  
 
2.3 Problems of cancer therapies 
With the more biological knowledge of cancer, deeper research in current treatments of 
cancer and the discovery of “better” anticancer weapons, those therapies will be 
undoubtedly much stronger, more specific and more effective in the future. However, 
presently, there are still some worrying statistics here. The incidence rates of cancer of 
the liver, pancreas, kidney, esophagus, and thyroid have continued to rise, as have the 
rates of new cases of non-Hodgkin lymphoma, leukemia, myeloma, and childhood 
cancers. The incidence rates of cancer of the brain and bladder and melanoma of the 
skin in women, and testicular cancer in men, are rising. Lung cancer death rates in 
women continue to rise, but not as rapidly as before. Death rates for cancer of the 




One of the reasons that cancer therapies are still not ideal is that there are various 
problems, drawbacks and side effects in those therapies. To some extent, surgery is 
severe to human bodies. Possible complications during surgery may be caused by the 
surgery itself, the anesthesia, or an underlying disease, such as externally bleeding, 
damage to internal organs and blood vessels, reactions to anesthesia or other medicines. 
Also, problems after surgery are fairly common, like pain, infection, pneumonia, 
internally bleeding, blood clots and slow recovery of other body functions. Besides, 
long-term side effects depend on the type of procedure done. For example, people who 
are having colorectal cancer surgery may need a colostomy (an opening in the 
abdomen to which the end of the colon is attached). Men undergoing radical 
prostatectomy (removal of the prostate) are at risk for losing control of urination or 
becoming impotent. But what is worse is that surgery sometimes cannot cut the tumors 
completely, kill all spread cancer cells or prevent metastasis. Radiotherapy attacks 
cancer cells that are dividing, but it also affects dividing cells of normal tissues. The 
damage to normal cells is what causes side effects. Each time radiotherapy is given it 
involves a balance between destroying the cancer cells and sparing the normal cells. 
For instance, fatigue, damage of skin, inflammation of mouth or throat, changes in 
brain function that can lead to memory loss, poor tolerance for cold weather, nausea, 
unsteadiness, and changes in vision are usual symptoms caused by radiation. Moreover, 
radiotherapy, one of the local therapies, might only be effective to local tumors but not 
spread cancer cells. The systemic treatment, anti-angiogenesis, similar to 
chemotherapy, for the most part, tends to have milder side effects than chemotherapy 
drugs because the anti-angiogenesis drugs only act where new blood vessels are 
forming. But they can still have serious or even life-threatening side effects such as 
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bleeding or holes in the digestive tract, raised blood pressure, surgery risks (affect 
wound healing), and pregnancy risks (affect a developing fetus). For the 
immunotherapy, the idea of using one's own immune system to fight cancer is 
tempting, but it still has a fairly small role in treating most cancers since it is too 
specific and only a few immunotherapies have been proved by FDA. So far, in most 
cases, it has not been shown to be clearly better than other forms of treatment. And it 
may be less helpful for more advanced diseases. Although the ideas of gene therapy 
are promising, figuring out how to insert specific genes into specific sites to solve 
specific problems has not been simple and has not been used for common clinical trials. 
Studies have shown that PDT can work as well as surgery or radiotherapy in treating 
certain kinds of cancers and pre-cancerous conditions. The definite advantages cannot 
be neglected, such as it has no long-term side effects when used properly; it is less 
invasive than surgery; it can be targeted very precisely; it can be repeated many times 
at the same site if needed; there is little or no scarring after the site heals. However, the 
limits of PDT are inclusive. It can only treat areas where light can reach, so it is mainly 
used to treat problems on or just beneath the skin, or in the lining of internal organs. 
While the drugs may travel throughout the body, the treatment only works at the area 
exposed to light, so PDT cannot be used to treat advanced cancers. Also, the drugs that 
are now in use leave people very sensitive to light, and during this time special 




2.4 Chemotherapy and challenges 
Chemotherapy is a complicated procedure. The general working process of 
chemotherapy drugs, which are very strong and carry high risk due to the toxicity, 
against cancer cells, is by attacking cells in the body that divide quickly. But 
meanwhile they can also harm other normal, healthy cells that divide quickly, such as 
those in the bone marrow, the skin, and in the mouth and intestines. This can lead to 
serious side effects like low blood cell counts (which can cause fatigue, infections, and 
bleeding), hair loss, mouth sores, nausea, and diarrhea. However, unfortunately, 
chemotherapy still is of paramount importance to fight against cancer due to the 
systemic feature, effects to a spectrum of cancers, easily to be treated and some proven 
successful trails although patients have to tolerate severe side effects and sacrifice the 
life quality. What is worse is that the effectiveness of chemotherapy depends upon 
many factors which are not easily to compromise (Feng and Chien, 2003).  
The first factor is the dosage form. Most anticancer drugs are highly hydrophobic, and 
hence are not soluble in water and most pharmaceutical solvents. Adjuvants such as 
Cremophor EL for paclitaxel and Tween-80 for docetaxel have to be used for the 
clinical administration of the anticancer drugs, which may cause serious side effects, 
some of which are life-threatening (Rowinsky et al., 1992; Webster et al., 1993; 
Fjallskog et al., 1993).  
The second is the pharmacokinetics. In order to achieve successful anticancer effect, 
the cancer cells should be exposed to sufficiently high concentration of the drug for 
long enough duration. It would be ideal if a single administration can lead to effective 
chemotherapy that can last for days, weeks, or even months (Feng and Chien, 2003). 
Additionally, the ideal goal for chemotherapy is to deliver the drugs of high efficacy at 
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the right time to the desired location with a high enough concentration over a 
sufficiently long period (Feng and Chien, 2003). However the problems are that the 
principles, theories, and devices in chemotherapy are difficult to be modified and 
developed to meet those requirements to achieve effective delivery of drugs.  
The third one is the toxicity. Anticancer drugs can also affect healthy cells. Certain 
cells with rapid turnover, such as bone marrow cells and intestinal epithelium cells, 
however, may also be seriously affected (Feng and Chien, 2003). The important organs 
for metabolism and excretion, liver and kidney may also be damaged by chemotherapy. 
It would be ideal if the chemotherapeutic agents could exert their actions only on the 
cancerous cells.  
The fourth factor is the drug resistance. Chemotherapy often fails in the long-term 
because of the development of drug resistance, like MDR, by the cancer cells. There 
are three major categories of drug resistance: pharmacokinetic resistance due to the 
low concentration of drug in the tumor, kinetic resistance due to the presence of only a 
small fraction of cells in a susceptible state, and genetic resistance due to the 
biochemical resistance of the tumor cells to the drug (Feng and Chien, 2003). Another 
problem is the microcirculatory barrier. The therapeutic molecules must penetrate into 
the blood vessels of the tumor to reach the cancer cells. Unfortunately, tumors often 
develop in ways that hinder the penetration (Jain, 2001).  
 
2.5 Taxanes, the potent anticancer drugs 
Taxanes, including paclitaxel and docetaxel, are one family of plant alkaloids which 
are nitrogen containing organic bases that are naturally occurring. This group of 
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compounds is often characterized by their bitter tastes as well as their physiological 
activities (Manske and Holmes, 1952).  
2.5.1 Paclitaxel 
Paclitaxel (Figure 2.2) is one of the antineoplastic drugs discovered from nature in the 
early 1960s. It is identified as the crude extract from the bark of the North American 
pacific yew tree, Taxus Brevifolia (Lopes et al., 1993). It was found to have excellent 
therapeutic efficacy against a spectrum of cancers, such as breast cancer, ovarian 
cancer, small and non-small cell lung cancer, colon cancer, head and neck cancer 
multiple myeloma, melanoma, and Kaposi‟s sarcoma (Feng et al., 2004). It was 
approved by US FDA to treat a range of cancers in 1990s (Feng and Chien, 2003). The 
action mechanism of paclitaxel is that is inhibits mitosis in tumor cells by binding to 
microtubules, which involve in various cellular functions, such as movement, nutrition 
ingestion, shape control, and spindle formation during cell division. The microtubules 
formed by paclitaxel action are stable, thus dysfunctional, leading to cell death (Lopes 
et al., 1993; Rowinsky et al., 1990; Donehower et al., 1987).   
However, there are several limitations for clinical applications of paclitaxel (Feng and 
Chien, 2003). One is its availability. Four yew trees more than 100 years old have to 
be sacrificed to produce 2 gram of the drug. Another limitation is its difficulty in 
clinical administration. Due to the high hydrophobicity of paclitaxel, the dosage form 
available for the current clinical administration uses an adjuvant consisting of 
Cremophor EL (polyoxyethylated castor oil) and dehydrated alcohol. It has been 
shown that Cremophor EL causes serious side effects, including hypersensitivity 
reactions, nephrotoxicity, neurotoxicity and cardiotoxicity (Feng and Chien, 2003). 
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Moreover, the delivery of clinical formulation of paclitaxel, Taxol
®
 cannot be specific 
to the cancer cells in appropriate time with sufficient amount kept in a long enough 
duration in administration. Furthermore, due to the existence of some biological 
barriers, like GI barrier and blood-brain barrier, paclitaxel cannot be effectively 
delivered to intestines and brains.  
 
Figure 2.2 Chemical structure of paclitaxel. 
 
2.5.2 Docetaxel 
Docetaxel (Figure 2.3) is a more advanced taxane analogue commonly used, similar to 
paclitaxel, in the treatment of a wide spectrum of cancers such as breast cancer, 
ovarian cancer, small and non-small cell lung cancer, prostate cancer. It is a 
semisynthetic compound produced from 10-deacetylbaccatin-III, which is found in the 
needles of the European yew tree, Taxus baccata (Gelmon, 1994). The semisynthetic 
production process of docetaxel circumvented the availability problems of taxnes. 
Docetaxel is slightly more water soluble than paclitaxel (Hennenfent and Govindan, 
2006). It also acts by disrupting the microtubular network and promotes the assembly 
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of tubulin into stable microtubules and inhibits their disassembly, resulting in 
inhibition of cell division and eventual cell death. Pre-clinical studies and a clinical 
randomized Phase III study demonstrated that docetaxel have greater efficacy than 
paclitaxel (Jones, 2006; Jones et al., 2005). Docetaxel shows 1.9-fold higher affinity 
than paclitaxel for microtubule (Musumeci et al., 2006). Docetaxel also shows wider 
cell-cycle bioactivity and slower efflux from the tumor cells (Riou et al., 1992; Riou et 
al., 1994; Brunsvig et al., 2007). Docetaxel was reported to exhibit 11-fold higher 
cytotoxic activity than paclitaxel (Riou et al., 1992; Hanauske et al., 1994; Lavelle et 
al., 1995).  
Due to the low water solubility of docetaxel, the commercial formulation, Taxotere® 
consists of a solution (40 mg/ml) in a vehicle containing high concentration of Tween-
80. The adjuvant has been associated with several hypersensitivity reactions and has 
shown incompatibility with common polyvinyl chloride intravenous administration 
sets (Gelderblom et al., 2001). Therefore, alternative drug formulations deserve to be 
developed to avoid the problems and increase the therapeutic effects.  
 




2.6 Nanotechnology for drug delivery and nanomedicine 
Are there any effective solutions for those problems? Fortunately, nanotechnology and 
emerged nanomedicine provides strong weapons for cancer treatment. Nanotechnology 
is making an intensive and significant impact on drug delivery in the past decades. 
Nanotechnology, featured by the technology on nanoscale, provides a new way for 
human beings to visualize the human body, which can make dramatic differences in 
medical treatments. Contemporarily, there is a growing interest in integrating 
nanotechnology with medicine, creating so-called nanomedicine aiming for disease 
diagnosis and treatment with unprecedented precision and efficacy (Farokhzad and 
Langer, 2006). Specifically, in drug delivery area, nanomedicine is a recently 
developed term to describe nanometer sized, multi-component drug or drug delivery 
systems for disease treatment (Duncan, 2006).  
Analogically, a nanocarrier for cancer treatment is just like a missile (Barbe et al., 
2004). The anticancer drugs loaded in the carrier resembles the explosive in the 
warhead of the missile, which should have enough amounts and high efficacy to 
destroy targets (cancer cells). The following key step is to find the hit target and avoid 
being detected by radars and intercepted by defense system. The overall human body is 
large radar to detect intrusion and leucocytes are guards to protect body. Therefore the 
carrier needs to quickly receive the „signals‟ from the receptors on the targeted cells 
and accurately locate the targets by its own „GPS‟ by the molecular ligands attached 
and „swim‟ to the specific site safely by the protection of, for instance, polyethylene 
glycol. After reaching the target, the carrier will release the loads to kill cancer cells 
just like the missile explodes. But what is more complex, the carrier should penetrate 
into cell membranes to sustainably release drugs towards intracellularly. That is the 
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pharmacokinetics matter: how to reach the controlled release. The distinctive 
advantage of controlled release systems is increasing the overall efficacy of the drug 
by maintaining the drug concentration in the body within the optimum therapeutic 
range and under the toxicity threshold. For the better carriers, after fulfilling the task, 
they can be properly disposed by body. 
The existing challenge of drug delivery is to design vehicles that can carry sufficient 
drugs, efficiently cross various physiological barriers to reach disease sites, image the 
diseased tissues, and cure diseases in a less toxic and prolonged manner. A few 
decades ago, Paul Ehrlich, the founder of chemotherapy, postulated the creation of 
„magic bullets‟ for use in the fight against human diseases inspired generations of 
scientists to devise powerful drug delivery carriers of molecular cancer therapeutics 
(Strebhardt and Ullrich, 2008). As most physiological barriers prohibit the permeation 
or internalization of particles or drug molecules with large sizes and undesired surface 
properties, the main input of nanotechnology on nanomedicine is to miniaturize and 
multi-functionalize drug carriers for improved drug delivery in a time- and disease-
specific manner. In sum, the desired features of ideal drug delivery systems for 
nanomedicine include the small size, optimal morphology, biodegradability and 
biocompatibility, appropriate surface coatings, high content of a drug inside the system, 
sustained circulation in the blood, and, ideally, the ability to target required areas 
passively (via the EPR effect) or actively (via receptor-ligand interaction) (Agarwal et 




2.7 Nanotechnology based drug carriers 
Although nanomedicine was conceptualized only recently (Farokhzad and Langer, 
2006; Duncan, 2006; Ferrari, 2005; Nishiyama and Kataoka, 2006; Moghimi et al., 
2005), nanotechnology has been employed in drug delivery for decades (Bangham et 
al., 1965; Marty et al., 1978). For example, nanoparticulate liposomes were first 
introduced more than 40 years ago (Bangham et al., 1965). The use of colloidal 
nanoparticles in drug delivery can date back to almost 30 years (Marty et al., 1978). 
Nowadays, a handful of liposome based, nanoparticulate delivery vehicles have been 
approved by the FDA for clinical applications (Barenholz, 2001; Duncan, 2006). They 
became clinically promising when long circulating, stealth polymeric nanoparticles 
were developed (Gref et al., 1994). Both micelles and polymer-drug conjugates have 
been investigated for more than two decades for the treatment of various diseases 
including cancer (Nishiyama and Kataoka, 2006; Lavasanifar et al., 2002).  
The application of nanotechnology to clinical cancer therapy, also known as cancer 
nanotechnology, was recently detailed (Ferrari, 2005). There are several categories of 
promising drug carriers for anticancer nanomedicine: liposomes, micelles, 
nanoparticles, polymeric vesicles, polymer-drug conjugates, dendrimers, hydrogels, 




Figure 2.4 Illustration of typical drug delivery carriers (Alexis et al., 2008). 
 
2.7.1 Liposome 
Liposomes, which are phospholipid bilayer vesicles with aqueous center, have been 
extensively reviewed (Park et al., 2004; Noble et al., 2004; Cattel et al., 2003; Patel et 
al., 1999). They have received a lot of attention during the past 30 years as 
pharmaceutical carriers of great potential since the pioneering observation of Alec 
Bangham roughly forty years ago (Bangham et al., 1965). Although they were just 
regarded as one of exotic objects of biophysical research originally, they have been 
gradually become a pharmaceutical carrier for numerous practical applications. The 
real breakthrough developments in the area during the past 15 years have resulted in 
the approval of several liposomal drugs, and the appearance of many unique 
biomedical products and technologies involving liposomes (Torchilin, 2005). More 
recently, a variety of new developments have been seen in the area of liposomal drugs: 
from clinically approved products to new experimental applications, with gene 
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delivery and cancer therapy as the principal areas of interest. The reasons that 
liposomes can be applied for drug delivery are the several attractive biological 
properties, including their biocompatibility, the entrapment of water-soluble 
(hydrophilic) pharmaceutical agents in their internal water compartment and water-
insoluble (hydrophobic) pharmaceuticals into the lipid wall, the protection of 
liposome-incorporated pharmaceuticals from the inactivating effect of external 
conditions, yet without undesirable side reactions, the unique opportunity to deliver 
pharmaceuticals into cells or even inside individual cellular compartments, as well as 
the size, charge and surface properties of liposomes that can be easily changed simply 
by adding new ingredients to the lipid mixture and/or by variation of preparation 
methods (Torchilin, 2005). Nevertheless, one of the drawbacks of liposomes is the fast 
elimination by the blood circulation and reticuloendothelial system, primarily in the 
liver. A number of developments have aimed to reduce this problem. To increase 
liposomal drug accumulation in the desired tissues and organs, the use of targeted 
liposomes with surface-attached molecules capable of recognizing and binding to cells 
of interest (immunoliposomes) has been suggested. IgG class and their fragments are 
the most widely used targeting moieties for liposomes, which can be attached to 
liposomes, without affecting liposomal integrity or the antibody properties, by covalent 
binding to the liposome surface or by physical adsorption onto the liposomal 
membrane after modification with hydrophobic residues (Torchilin, 2005). HER2 
directed immunoliposomes were investigated and shown a distinct mechanism for the 
drug delivery to tumor cells in vivo, which exploits mAb-dependent binding and 
internalization in tumor cells (Kirpotin et al., 2006). The results suggest that HER2 
immunoliposomes are capable of penetrating tumor tissue, internalizing specifically in 
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HER2-overexpressing cancer cells and intracellularly releasing encapsulated drugs, 
representing a potentially advantageous strategy for molecularly targeted drug delivery. 
Still, despite improvements in targeting efficacy, the majority of immunoliposomes 
accumulate in the liver as a consequence of insufficient time for the interaction 
between the target and targeted liposome. Better target accumulation can be expected 
if liposomes can be made to remain in the circulation long enough. Therefore, different 
methods have been suggested to achieve long-circulating liposomes (stealth 
liposomes), including coating the liposome surface with inert, biocompatible polymers, 
such as PEG, which form a protective layer over the liposome surface and slow down 
liposome recognition by opsonins and subsequent clearance of liposomes (Klibanov et 
al., 1990; Blume and Cevc, 1993). Long-circulating liposomes are now being 
investigated in detail and are widely used in biomedical in vitro and in vivo studies 
(Gabizon, 2001). An important feature of protective polymers is their flexibility, which 
allows a relatively small number of surface-grafted polymer molecules to create an 
impermeable layer over the liposome surface (Torchilin and Trubetskoy, 1995). Long-
circulating liposomes demonstrate dose-independent, non-saturable, log-linear kinetics 
and increased bioavailability (Allen and Hansen, 1991). Current research on PEG 
liposomes focuses on attaching PEG in a removable fashion. Novel detachable PEG 
conjugates have been described (Zalipsky et al., 1999), in which the detachment 
process is based on the mild thiolysis of the dithiol linkage. Continuing interest in 
using long-circulating liposomes in cancer chemotherapy is supplemented by their 
potential use for other purposes, such as carrying imaging agents and the treatment of 
infection (Gabizon, 2003; Bakker-Woudenberg, 2002). The further development of 
liposomal carriers involved the attempt to combine the properties of long-circulating 
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liposomes and immunoliposomes in one preparation (long-circulating 
immunoliposomes) (Abra, 2002). To achieve better selectivity of PEG-coated 
liposomes, it is advantageous to attach the targeting ligand via a PEG spacer arm, so 
that the ligand is extended outside of the dense PEG layer, which reduces steric 
hindrance of binding to the target.  
2.7.2 Micelle 
Micelle is a core-shell structured aggregation with a hydrophobic core and a 
hydrophilic shell, created by a spontaneous self-assembly of amphiphilic molecules. 
The core is an ideal reservoir for potential application, such as microreactor, 
microelectric unit and drug carrier. Meanwhile, the shell provides the solubility of 
micelle in solvent and serves as the steric barrier to core-core interaction and 
agglomeration. The aggregated shapes are various, including spherical, as the most 
common, and cylindrical, rod-like, worm-like, disc-like, flower-like, etc. The sizes of 
polymeric micelles (no swollen) are typically nanosized, from 10 to 100 nanometers, 
some of which are several hundred nanometers. Polymeric micelles were first 
introduced as drug delivery vehicles in the early 1980s by Helmut Ringsdorf (Gros et 
al., 1981; Pratten et al., 1985). Polymeric micelles have a condensed, compact inner 
core, which serves as the nanocontainer of hydrophobic compounds. As polymer 
micelles are generally more stable than hydrocarbon based micelles, sustained drug 
release from polymeric micelles becomes possible. Numerous types of amphiphilic 
copolymers have been employed to form micelles (Lavasanifar et al., 2002; Kakizawa 
and Kataoka, 2002; Nishiyama and Kataoka, 2006; Torchilin, 2005; Huang and 
Remsen, 1999; Hagan et al., 1996; Kabanov et al., 2002). Polymeric micelles can 
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accumulate in tumors after systemic administration. Their biodistributions are largely 
determined by their physical and biochemical properties, such as sizes, hydrophobicity, 
and hydrophilicity of the polymers and drugs, and surface biochemical properties 
(Avgoustakis, 2004).  A major issue that limits the systemic application of micellar 
nanocarriers is the non-specific uptake by the RES. It is critical to have systems that 
can circulate for a long time without significant accumulation in the liver or the spleen. 
The sizes and the surface features of micelles have to be controlled for favored 
biodistribution and intracellular trafficking (Gref et al., 1994). The hydrophilic shells 
of micelles usually consist of PEG which prevents the interaction between the 
hydrophobic micelle cores and biological membranes, reduces their uptake by the RES, 
and prevents the adsorption of plasma proteins onto micelles (Kataoka et al., 2001). 
Polymeric micelles that are responsive to pH, temperature or light are potentially 
exciting nanomedicine modalities (Tong and Cheng, 2007). The stimuli-responsive 
capacity is advantageous for both targeted delivery and controlled release. Basically, 
the stimuli to micelles are the tools to control the micellization (keep stability) and 
micelle disruption (release contents) in proper time and site. The first category is pH-
responsive micelles. The mildly acidic pH in tumor and inflammatory tissues (pH~6.5) 
as well as in the endosomal intracellular compartments (pH~4.5-6.5) (lower than that 
in normal tissues (pH~7.2)) (Rapoport, 2007), may trigger drug release from pH 
sensitive micelles upon their arrival at the targeted disease sites. One process is that the 
core which is stable in one pH value will be swollen even disrupted when exposed to 
other pH values, thus release encapsulated cargos faster. This phenomenon has been 
employed in the design of numerous pH-sensitive polymeric micellar systems for the 
delivery of anticancer drugs to tumors (Bae et al., 2003; Lee et al., 2003; Bae et al., 
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2005; Sethuraman and Bae, 2007). Another type of responsive micelles is thermo-
sensitive micelles. Developing this kind of polymeric micelles as intelligent drug 
carriers that would react by a sharp change of properties in response to a small change 
of temperature is perspective (Rapoport, 2007). The thermo-responsive fragment can 
be incorporated to either micelle core or shell. In particular, LCST polymers such as 
poly (N-isopropylacrylamide) with a transition temperature around 32 °C are one of 
candidates (Neradovic et al., 2004). Also a synthesized thermo-sensitive micellar drug 
delivery system with an increased physical stability but with a retained 
biodegradability was proven to be due to the core-crosslinking (Rijcken et al., 2007). 
Moreover, lipid based polymeric micelles, like PEG-PE, can increase the tumor 
penetration and accumulation, thus the antitumor efficacy in vivo (Tang et al., 2007). 
Alternatively, the ultrasound-responsive micelle is another kind of external stimuli-
responsive micelles. Ultimately, by using convenient ultrasonic dispersion, 
intracellular uptake of drugs will be increased as well as the distribution of the micelles 
and drug throughout the tumor volume will be more uniform resulting in effective 
tumor targeted drug delivery and suppression of tumor growth for drug sensitive and 
multidrug-resistant tumors (Rapoport, 2007). The light-responsive micelles, by the use 
of light, including infrared, ultraviolet and fluorescence, as an external stimulus to 
control micellization/micelle disruption processes, has just started being exploit. 
Pyrene and azo are ideal light sensitive molecules, though biocompatibility still need 
to be investigated (Jiang et al., 2005). The light irradiation will destabilize the micelles 
and cause drug releasing. This design may potentially be used to control drug release 




NPs are colloidal systems with the size range from 10 to 1000nm. Drug safety and 
efficacy can be greatly improved when a pharmaceutical agent is encapsulated within 
nanoparticles or attached onto surface of nanoparticles (Langer, 1998). This may lead 
new therapies, and change the way we diagnose and treat cancers. Nanoparticles have 
been regarded as perspective drug delivery carriers years ago and there are a lot of 
investigations and inventions on design of ideal nanoparticles these years. Inorganic 
nanoparticles, such as gold and silica nanoparticles (Barbe et al., 2004), are good 
candidates because of their biocompability and stability in blood circulation. 
Nonetheless, the rapid clearance by RES and non-biodegradability may cause 
confusion on the sustained efficacy and prolonged safety issues. Therefore, 
biodegradable polymeric nanoparticles might be better choice. The polymers used for 
the formulation of nanoparticles will be degraded into harmless molecules such as 
carbon dioxide and water and excreted from the body (Parveen and Sahoo, 2008). A 
hydrophobic drug can be introduced into the nanoparticle matrix, thereby improving its 
bioavailability. These formulations can also be bound with biocompatible and non-
biodegradable polymers like PEG to keep them in circulation for longer periods. 
Moreover, the problem of sustained, controlled release of anticancer drugs can be 
addressed by various nanoparticle formulations. The drug release from nanoparticles 
can be controlled by modulating the polymer characteristics to achieve the desired 
therapeutic level in target tissues for required durations with optimal therapeutic 
efficacy and release of a constant amount of drug per unit time (Parveen and Sahoo, 
2008). In the case of central nervous system cancers, many drugs have difficulty in 
reaching the therapeutic site due to BBB. Drug loaded nanoparticles, with appropriate 
size and surface decoration, have potential to breach this barrier and thus show greatly 
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increased therapeutic concentrations of anticancer drugs in brain. Those nanoparticles 
can also solve the multidrug resistance problem caused by P-gp and the characteristics 
of higher hydrostatic pressure of tumors. Recently, nanoparticles for cancer 
chemotherapy have been extensively investigated. A number of biodegradable 
polymers, such as PLGA, PLA, PCL, chitosan, and HSA have been employed to 
produce nanoparticles for controlled delivery of various effective anticancer agents to 
avoid the using of toxic adjuvants, to realize the desired pharmacokinetics, and to 
enhance their uptake by cancer cells (Feng and Chien, 2003). 
2.7.4 Polymersome 
Apart from forming micelles, amphiphilic block copolymers can also construct 
vesicles when the fraction of the hydrophobic domain relative to the hydrophilic 
domain is controlled within a certain range (0.2-0.42) (Discher and Eisenberg, 2002; 
Discher and Ahmed, 2006). The liposome-like structures possess a hydrophobic 
membrane and a hydrophilic inner cavity; therefore they are also called polymersomes. 
Compared to liposomes, polymeric vesicles are more stable because their membrane-
making polymers form much stronger hydrophobic interactions than the short 
hydrocarbon segments of liposomes (Tong and Cheng, 2007). Although polymeric 
vesicles have only been studied for a few years, they have shown great promise in 
controlling drug loading, systemic biodistribution, and drug release (Ahmed and 
Discher, 2004; Geng et al., 2007). In polymeric vesicles, precise tuning of the drug 
release rates can be achieved through blending vesicle-forming copolymers with a 
hydrolyzable copolymer. Recently, a polyarginine-polyleucine copolymer vesicle was 
 32 
 
demonstrated to have excellent intracellular trafficking properties (Holowka et al., 
2006). 
2.7.5 Polymer-drug conjugation 
Polymer-drug conjugation (prodrug) was seen as a mean of improving the cell 
specificity of low molecular-weight drugs. It is needed to design an effective polymer-
drug conjugate with the desired features: a bio-responsive polymer-drug linker that is 
stable during conjugate transport and able to release drug (via broken of the linking 
bond) at an optimum rate on arrival at the target site; adequate drug carrying capacity 
in relation to the potency of the drug being carried; and the ability to target the 
diseased cell or tissue. As the drugs carried often exert their effects via an intracellular 
pharmacological receptor, it is essential that they eventually access the correct 
intracellular compartment (Duncan, 2003). A number of polymer-drug conjugates have 
been tested clinically (Duncan, 2003). Covalent attachment of drug to a polymeric 
vehicle is particularly attractive, as the increased molecular weight produces a radical 
change in the pharmacokinetics at both the whole body and cellular levels (Duncan, 
2003). Careful tailoring of polymer-drug linkers is essential to the creation of a 
polymeric prodrug that is inert during transport but allows drug liberation at an 
appropriate rate intratumorally. Polymer-drug linkers were popularized by the 
successful design of HPMA copolymer-doxorubicin conjugates which is stable in the 
circulation, but is cleaved by the lysosomal thiol-dependent protease cathepsin B 
following endocytic uptake of conjugate from the tumor interstitium (Duncan  et al., 
1992; Vasey et al., 1999; Seymour et al., 2002). HPMA copolymer conjugates of 
paclitaxel have also emerged into clinical evaluation (Meerum et al., 2001). PLA and 
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PEG have also been used to produce drug conjugates via ester bonds which are rather 
interesting and attractive (Li et al., 1998; Denis et al., 2000; Greenwald et al., 2003). 
2.7.6 Dendrimer 
A dendrimer is a synthetic polymeric macromolecule of nanometer dimensions, 
composed of multiple highly branched monomers that emerge radically from the 
central core (Cho et al., 2008), which was first reported in the late 1970s and early 
1980s (Tong and Cheng, 2007). Properties associated with these dendrimers such as 
their monodisperse size, modifiable surface functionality, multivalency, water 
solubility, and available internal cavity make them attractive for drug delivery 
(Svenson and Tomalia, 2005). Dendritic polymers also have a number of beneficial 
attributes for biomedical applications, including biodistribution and pharmacokinetic 
properties that can be tuned by controlling dendrimer size and conformation, high 
structural and chemical homogeneity, ability to be functionalized by multiple copies of 
drugs or ligands, high conjugation density and controlled degradation (Lee et al., 2005). 
In the past decade, significant efforts have been devoted to exploiting the potential 
applications of dendrimers as drug carriers (Lee et al., 2006; Qiu and Bae, 2006; 
Esfand and Tomalia, 2001). Drug molecules can either be conjugated onto the surface 
of dendrons or encapsulated inside the branches. The periphery of a dendrimer usually 
contains multiple functional groups for the conjugation of drug molecules or targeting 
ligands. Drugs are majorly covalently conjugated onto the surface because of the 
straightforward attachment and easy control (Tong and Cheng, 2007). Despite 
numerous designs of dendrimer based carriers, only a few of them have been evaluated 
for their in vivo antitumor activities (Malik et al., 1999; Maeda et al., 2000; Kukowska-
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Latallo et al., 2005). One early example is a sodium carboxyl-terminated PAMAM 
dendrimer for the conjugation of cisplatin. The drug-dendrimer conjugation displayed 
ten-fold enhancement of anticancer activity when administered intravenously to treat a 
subcutaneous B16F10 melanoma, compared to free cisplatin (Malik et al., 1999). 
Moreover, dendrimer-doxorubicin displayed comparable in vivo antitumor efficacy as 
Doxil
®
, an FDA approved, liposome-based doxorubicin delivery vehicle (Tong and 
Cheng, 2007). Compared to liposomes and micelles, dendrimer-drug conjugates may 
be more stable owning to their covalent attachment and uniform molecular structures, 
thus are easier to be formulation, sterilization, transportation and storing. However, in 
spite of the benefits as well as high biocompatibility of dendrimers, the toxicity issues 
still need to be investigated and the multistep precise synthesis and accompanied 
higher preparation costs hinder the moving from the laboratory to the clinic. In 
addition, improved quality control assays need to be devised to ensure that 
multicomponent dendritic polymers contain the correct components in the correct 
ratios (Lee et al., 2005).  
2.7.7 Hydrogel 
Hydrogels are water-swollen polymeric materials that can retain a significant amount 
of water while maintaining a distinct three-dimensional structure (Xu and Kopecek, 
2007; Kopecek, 2007). It has been proposed that hydrogels can be used as biomaterials 
as early as 1960 (Wichterle and Lím, 1960). They are also the first biomaterials 
designed for use in the human body (Kopecek, 2007a). Nowadays, numerous 
applications have been proposed and investigated for the self-assembled hydrogels in 
drug delivery area (Xu and Kopecek, 2007). Especially, hydrogels that can respond to 
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environmental stimuli, such as temperature, pH, electric field, light, or chemical 
signals are catching more and more attraction. N-Isopropylacrylamide-based hydrogel 
systems are the most intensively investigated thermo-responsive systems, including 
their use for drug delivery (Liu et al., 2006; Yin et al., 2006), cell encapsulation and 
delivery (Na et al., 2006) and cell culture surfaces (Hatakeyama et al., 2006). These 
hydrogels can swell in situ under physiological conditions and provide the advantage 
of convenient administration (Klouda and Mikos, 2008). However, several challenges 
remain to be improved. One of the major challenges relates to the ease of clinical 
usage. There are also persistent challenges in expanding the types of kinetic release 
profiles which can be achieved using hydrogels. There is also a need for continued 
improvement in the delivery of not only hydrophobic molecules, but also the delivery 
of more sensitive molecules such as proteins, antibodies, or nucleic acids which can 
readily be deactivated or unfolded by interactions with the hydrogel delivery vehicle 
(Hoare and Kohane, 1993). 
2.7.8 Carbon nanotube 
CNTs belong to the family of fullerenes, the third allotropic form of carbon along with 
diamond and graphite. They are comprised exclusively of carbon atoms arranged in a 
condensed polyaromatic surface rolled-up in a tubular structure with their ends closed 
(Bianco et al., 2005). They are unique materials with exceptional chemical and 
electronic properties and have been applied in biology as sensors for detecting DNA 
and protein, diagnostic devices for the discrimination of different proteins from serum 
samples, and carriers to deliver vaccine or protein (Bianco et al., 2005a). Due to their 
high stability, they also are regarded as promising drug carriers. However, concerns on 
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health and toxicity problems as well as the biocompatibility of CNTs generated. 
Recently, experimental evidence clearly indicates that long, rigid CNTs should be 
avoided for in vivo applications and that chemical functionalization should be 
optimized to ensure adequate dispersibility, individualization and excretion rates 
sufficient to prevent tissue accumulation (Kostarelos et al., 2008). But increasing the 
solubility and preventing aggregation to facilitate urinary excretion and decrease tissue 
aggregation might enhance the safety of CNTs in vivo (Kostarelos et al., 2008). In 
addition, early biocompatibility data for CNT and novel nano-structured biomaterials 
suggest that the scientific community could remain cautiously enthused by potential 
biomedical applications of CNT-based materials (Smart et al., 2006). In fact, the 
introduction of chemical modification to CNTs can render them water-soluble and 
functionalized so that they can be linked to a wide variety of anticancer drugs and 
active molecules such as peptides, proteins, and nucleic acids (Bianco et al., 2005b). 
For potential in vivo applications, the significant limitation of CNTs, owing to their 
rapid clearance or high hepatic uptake has been resolved by using PEG to covalently 
bind on the surface of CNTs to escape the capture of reticuloendothelial system, 
making them stealth nanotubes (Yang et al., 2008). Dai‟s group have shown in their 
current work by Raman Spectroscopy that surface chemistry is crucial to the behavior 
of CNTs in vivo, pegylation of CNTs could block the hydrophobicity and enable 
longer blood circulation time and lower RES uptake, and no obvious toxic effect was 
found (Liu et al., 2008). Other studies have demonstrated that the functionalized CNTs 
with aqueous solubility and cationic surface are able to cross the plasma membrane 
and distribute throughout the cellular compartments (Bianco et al., 2005a). In the 
diagnosis area, combining the optical properties of quantum dots with the ability of 
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CNTs to carry pharmaceutical cargos could provide high benefits (Zerda et al., 2007). 
Even though the safety issue of CNTs for clinical application still deserves huge 
investigation, promising biomedical applications of functionalized CNTs are obvious, 
if the toxicity can be well defined. More recently, an in vivo tumor uptake study using 
graphene, a two-dimensional structure of CNT was conducted, announcing the 
potential anticancer effects of the rising star material (Yang et al., 2010).  
 
2.8 Polymeric nanoparticles 
In particular, polymeric nanoparticles fabricated by biodegradable polymers as drug 
carriers have been extensively investigated over the past 30 years. One of the most 
distinctive advantages of those polymers over other materials is that the behavior of 
drug release is able to be finely tuned by precise control on the molecular structure of 
the polymers. Ideally, a zero-order drug release is desired that can maintain a constant 
drug concentration over long period, which was termed as controlled and sustained 
release. Among various synthetic biodegradable polymers with biocompatibility, 
PLGA is the mostly used one for clinical use (Anderson and Shive, 1997) as drug 
delivery carrier and therapeutic devices with confirmed biocompatibility (Shi et al., 
2002).  
PLGA is a block copolymer composed of polylactic acid block and polyglycolic acid 
block (Figure 2.5). The common synthesis route is by means of random ring-opening 
copolymerization of the monomers glycolic acid and lactic acid. During 
polymerization, successive monomeric units (of glycolic or lactic acid) are linked 
together in PLGA by ester linkages, thus yielding a linear, aliphatic polyester as a 
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product (Astete and Sabliov, 2006). The characteristics of PLGA can be easily 
obtained by engineering the molar ratio of lactide to glycolide used in the 
polymerization. For example, PLGA 50:50 identifies a copolymer whose composition 
is 50% lactic acid and 50% glycolic acid. PLGA is amorphous rather than crystalline 
and shows a glass transition temperature in the range of 40-60 °C. From the polymer 
chemistry point of view, the polylactic acid block is more hydrophobic while the 
polyglycolic acid block is more crystalline. Hence the degradation properties of PLGA 
and the drug release behavior from the PLGA nanoparticles is in close relationship 
with the ratio of those two blocks.   
 
Figure 2.5 Chemical structure of PLGA. x= number of units of lactic acid; y= number 
of units of glycolic acid. 
 
The dominant process of the degradation of PLGA in water depends on the hydrolysis 
of ester linkages (Figure 2.6). The ratio of the blocks or say net hydrophobicity of the 
copolymers controls the rate of degradation. Higher glycolide ratio results in lower 
hydrophobicity, thus faster degradation. Generally, the half-time of degradation takes 
12-16 weeks (Alexis, 2005; Zweers et al., 2004). The process involves the by-products 
of various metabolic pathways in the body for PLGA and hence causes low systemic 
toxicity, which makes it an ideal drug carrier.  
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For the release of the drugs encapsulated in PLGA spheres, it is very possible to tailor 
the release rate by controlling the degradation time which can be achieved by altering 
the ratio of the monomers used during synthesis. The mechanism of drug release can 
be summarized as the involvement of six main steps: desorption of the surface 
bounded drugs, diffusion of the drugs through the matrix pores, diffusion through the 
polymer barrier, next to the release of drug when the polymer degrades and eventually 
bulk degradation (Jalil and Nixon, 1990; Soppimath et al., 2001). 
 
Figure 2.6 Schematic diagram showing the swelling and degradation of a microcapsule 
when dissolve in aqueous solution (Jalil and Nixon, 1990): (a) Microcapsule 
containing the therapeutic drug. (b) Attached surface drugs dissolve by the aqueous 
environment. (c) Swelling and onset of the erosion. (d) Gradual size reduction of the 
central matrix proportion with extensive erosion and pore formation. (e) Formation of 
fully hydrated microcapsule with the disappearance of the core. (f) Fragmentation and 
degradation into its monomers. 
 
PLGA based nanoparticles have also been deeply investigated in our groups in the past 
ten years for drug delivery (Mu and Feng, 2002; Mu and Feng, 2003; Win and Feng, 
2006; Feng et al., 2007). By using paclitaxel as a prototype anticancer drug 
encapsulated in PLGA NPs, it was concluded that the NP formulation of paclitaxel has 
great advantages versus the commercial paclitaxel formulation. The side effects 
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associated with toxic adjuvant contained in the commercial formulation can be avoided. 
In vitro cell viability experiment on cancer cells showed much higher cytotoxicity of 
paclitaxel in the NP formulation than that in the commercial formulation. The NP 
formulation can result much greater therapeutic effects and sustained chemotherapy in 
vivo of the drug in the NP formulation. 
However, sometimes, using PLGA alone to fabricate NPs is not satisfactory enough in 
terms of, for example, the hydrophilicity and bioavailability. The rapid uptake of 
nanoparticulate drug carriers by the MPS is the main limitation for drug carrier to 
reach tumor sites after circulating in human body (Klibanov et al., 1990). PEG is at 
present the most popular materials to modify particulate surfaces in order to avoid 
recognition by MPS (by decreasing the protein adsorption). PEG presents unique 
properties such as (i) soluble in water; (ii) lack of immunogenicity, antigenicity and 
toxicity; (iii) high hydration and flexibility of the polymer chain; and (iv) approval by 
FDA for human use (Pasut and Veronese, 2007). In order to equip the stealth and long 
circulating properties for the particles in bloodstream, which indicates the escape from 
the recognition by MPS cells, pegylation is a necessary process to decorate the 
particles that is a preferred method of imparting stealth, or sterically stabilized 
properties to nanoparticles (Gref et al., 1994; Owens and Peppas, 2006). PEGylation 
simply refers to the decoration of a particle surface by the covalently grafting, 
entrapping, or adsorbing of PEG chains. PEGylation changes the physicochemical 
properties such as conformation, electrostatic binding, and hydrophobicity, resulting in 
an improvement in the pharmacokinetic behavior of the drug carrier (Veronese and 
Mero, 2008). PEGylation also improves the stability and the retention time of the 
carriers in blood, thereby allowing the prolonged circulation and lifetime of the drug 
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loaded carriers. PEGylation has already become a commonly used strategy to modify 
the biodegradable polymers for better performed drug carriers, such as PLGA-b-PEG 
copolymer. For instance, functional PEG was conjugated with PLGA by covalent 
bonding to form amphiphilic block copolymers which would be used to produce 
polymeric micelles or particles. The other end of functional group on PEG chains 
would be free by applying this strategy which can be reserved to attach with molecular 
ligands for targeted delivery. A few similar studies using paclitaxel or docetaxel 
incorporating in PEGylated PLGA nanocarriers have been reported in recent years 
(Zhao and Yung, 2008; Zhao and Yung, 2009; Esmaeili et al., 2008; Murugesan et al., 
2008; Senthilkumar et al., 2008; Danhier et al., 2009). The results contributed by one 
group demonstrate that the PEGylated NPs strongly enhances the cytotoxicity of the 
drug through sustained delivery. The pharmacokinetic result shows the long circulating 
properties of PEGylated NPs, which could increase the possibility of the NPs to 
penetrate into the tumor tissues. Furthermore, PEGylated NP formulations shows a 
much better tumor suppression effect than docetaxel solution and corresponding PLGA 
NP formulations (Senthilkumar et al., 2008). 
 
2.9 Multifunctional nanoparticles 
The concept of nanoscale devices has led to the development of biodegradable self-
assembled nanoparticles, which can be highly tailored and are being engineered for the 
targeted delivery of anticancer drugs and imaging contrast agents (Sinha et al., 2006). 
Nanocarriers should serve as customizable, targeted drug delivery vehicles capable of 
ferrying large doses of chemotherapeutic agents or therapeutic genes into malignant 
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cells while sparing healthy cells. Such „smart‟ multifunctional nanodevices hold out 
the possibility of radically changing the practice of oncology, allowing easy detection 
and then followed by effective targeted therapeutics at the earliest stages of the disease. 
2.9.1 Targeting 
Targeting, including passive targeting and active targeting, is the first essential 
function to achieve the desired delivery that differentiates tumors from normal tissues.  
Ideally, for anticancer agents to work, they should be able to reach the desired tumor 
location through the various routes and barriers with minimal loss of their volume and 
functional integrity. Upon reaching the tumor site, they should be able to selectively 
kill the cancerous cells without affecting the surrounding healthy cells via controlled 
and targeted release mechanisms, which would drastically improve patient survival, 
mitigate adverse side effects of the drugs, minimize expensive drug wastage and 
improve the overall therapeutic effect. Combinations of physical and chemical 
properties can be utilized to design targeted drug carrier systems. Such properties 
include surface hydrophobicity, surface charge, size and morphology, tumor properties 
and possible biochemical interactions such as ligand-receptor interactions.  
Passive targeting takes advantage of the permeability and unique microenvironment of 
tumor tissue (Wang et al., 2008).  
Rapid neovascularization to serve fast-growing cancerous tissue leads itself to a leaky 
and defective architecture, which in turn, can be easily accessible to chemotherapeutic 
drugs. Tumor blood vessels are generally characterized by abnormalities such as a 
relatively high proportion of proliferating endothelial cells, increased tortuosity, 
pericyte deficiency and aberrant basement membrane formation. Proliferating cancer 
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cells demand the recruitment of new vessels (neovascularization) or rerouting of 
existing vessels near the tumor mass to supply them with oxygen and nutrients 
(Carmeliet and Jain, 2000). The resulting imbalance of angiogenic regulators such as 
growth factors and matrix metalloproteinases makes tumor vessels highly disorganized 
and dilated with enlarged gap junctions between endothelial cells and thus more 
permeable towards macromolecules than the capillary endothelium in normal tissues as 
well as compromised lymphatic drainage resulting in drug accumulation (Carmeliet 
and Jain, 2000). Because of the decreased lymphatic drainage, the permeate 
nanocarriers are not removed efficiently, and are thus retained in the tumor. This is the 
EPR effect (Matsumura and Maeda, 1986; Maeda, 2001). Most polymeric 
nanoparticles can be used to target such effect due to their small size and large surface 
area (Figure 2.7). If a chemotherapeutic agent is loaded in a suitable polymeric carrier, 
the system then has the potential of increasing the concentration of the 
chemotherapeutic agent accumulated in the tumor tissue. However, it should be noted 
that the vessel permeability that forms a cornerstone of the EPR effect varies during 
tumor progression and tumor types. In addition, extravasation of polymeric 
nanomedicines will depend on the tumor type and anatomical location, as well as the 




Figure 2.7 Tumor targeting of nanoparticles passively by EPR (Duncan, 2003). 
 
Meanwhile, the unique microenvironment surrounding tumor cells, which is different 
from that of normal cells also contributes to passive targeting. Hyperproliferative 
cancer cells possess a high metabolic rate, and the supply of oxygen and nutrients is 
usually not sufficient for them to maintain this. Therefore, tumor cells use glycolysis 
(hypoxic metabolism) to obtain extra energy for tumor migration, invasion, and 
metastasis, resulting in an acidic environment (Yatvin et al., 1980; Pelicano et al., 
2006). The drug can be conjugated to a tumor-specific molecule and is administered in 
an inactive state, and once it reaches its destination, the tumor microenvironment is 
able to convert it to an active and volatile substance by pH and/or specific enzymes, 
so-called tumor-activated prodrug therapy (Sinha et al., 2006). Also, direct local 
application allows the drug to be given directly to tumor tissue, avoiding systemic 
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circulation. Direct delivery of drugs into the tumor tissue prevents the drug from 
circulating throughout the body and rendering itself to metabolism by various systems. 
The disadvantage of direct inoculation of drug into tumors is that this method can be 
highly invasive, tumor localization is not feasible, and accessibility to certain tumors, 
for example lung cancer, can be problematic (Sinha et al., 2006).  
Passive targeting systems which use a binary structure conjugate inevitably have 
intrinsic limitations to the degree of targeting specificity they can achieve. In the case 
of the EPR effect, while poor lymphatic drainage on the one hand helps the 
extravasated drugs to be enriched in the tumor interstitium, on the other hand, it 
induces drug outflow from the cells as a result of higher osmotic pressure in the 
interstitium, which eventually leads to drug redistribution in some portions of the 
cancer tissue. As a consequence, the efficacy is not as high and there is precious drug 
wastage to an extent (Wang et al., 2008; Stohrer et al., 2000). Apart from that, passive 
targeting strategy is not adaptable on the molecular or cellular level, leading the non-
specific interaction of the drug carriers with cells. 
Therefore, to overcome these limitations, a prudent approach is the inclusion of a 
targeting moiety which has molecular recognition and interaction with the cancerous 
cells. Active targeting is usually achieved by conjugating the nanoparticle to a 
targeting moiety, thereby allowing preferential accumulation of the drug within 
individual cancer cells, intracellular organelles, or specific molecules in cancer cells. 
The success of active targeting depends on the selection of the targeting agent, which 
should be abundant, have high affinity and specificity of binding to cell membrane 
receptors and be well suited to chemical modification in conjugation. The receptors 
should be expressed uniquely in diseased cells only or exhibit a differentially higher 
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expression in diseased cells as compared with normal cells (Cho et al., 2008). The 
commonly used molecular ligands for active targeting include folic acids (Yoo and 
Park, 2004), peptides (Brown, 2010), antibodies (Adams and Weiner, 2005), aptamers 
(Farokhzad et al., 2006), and affibodies (Ahlgren et al., 2009). Folic acid is a classical 
targeting moiety that binds the folate receptors on tumor cells. The overexpression of 
receptors in human cancer cells leads it to efficient uptake via receptor-mediated 
endocytosis. This is a process whereby extracellular particles gain entry into the 
intracellular environment (Figure 2.8). In general, the drug bound to a polymer carrier 
is taken into the cell via ligand-receptor interactions. Once localized at the cell surface, 
the targeted drug-polymer carrier complexes may exert its cytosolic action either at the 
plasma membrane or following internalization. Dissociation of the drug from its 
polymer can occur in lysosomes by lysosomal enzymes, resulting in the release of free 
drug into the cytosol. The receptors or antigens should be recycled and take their place 




Figure 2.8 The pathway for receptor-mediated endocytosis (adapted from 
http://www.expresspharmaonline.com/20060815/research03.shtml). 
 
2.9.2 Imaging  
It is straightforward to understand that precaution is more important than treatment for 
cancer as there is virtually no specifically effective therapy to such a leading killer 
disease up to now. Therefore how to detect the symptoms of the disease or visualize 
the tumor skeleton as early as possible by means of practical and simple methods, 
desirably, in routine health check should be addressed as the first issue. Modern 
techniques, in recent years, have provided several diagnosis solutions for the detection 
of cancer indications, particularly, imaging the cancerous cells.  
During the past decades, scientists and engineers have dedicated to developing quite a 
few of practical imaging techniques applicable to clinical imaging, diagnosis and 
treatments. Typically, optical imaging based on eye-visible fluorescence or near 
infrared fluorescence, magnetic resonance imaging, radionuclide imaging such as 
positron emission tomography and single photon emission computed tomography, 
computed tomography, and ultrasound have been widely applied and made superb 
performance in practical medicine. Basically, fluorescent dyes, paramagnetic materials, 
radioactive materials, heavy atom substances, and acoustically active microbubbles 
have been used as imaging agents for OI, MRI, PET, CT, and ultrasound, respectively. 
Practically, each imaging techniques and imaging modalities possesses their merits and 
limitations. In detail, optical imaging or NIRF probes offer sensitivity enhancements 
while compromise tissue penetration depth. On the contrary, MRI provides great 
contrast and spatial resolution among different soft tissues of the body, making it 
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especially useful in neurological, musculoskeletal, cardiovascular and oncological 
imaging, yet the sensitivity is not as high as fluorescence imaging. PET is a 
radionuclide imaging technique which provides high target sensitivity but poor spatial 
resolution. CT, like MRI, is a noninvasive technique and generates three-dimensional 
images of a body object, providing good spatial resolution while sacrificing target 
sensitivity. The major advantage of ultrasound imaging is low cost, high safety but 
both resolution and sensitivity are low. 
For the purpose of diagnosing tumors, imaging agents such as colloidal Au particles 
(Bardhan et al., 2008), IO contrast particles (Huh et al., 2005; Kopelman et al., 2005), 
and QDs (Gao et al., 2004), have been widely used. Loading those agents into 
nanoparticulate carriers may enhance detection sensitivity in medical imaging, 
improve imaging effectiveness, and decrease side effects (Moghimi et al., 2005). For 
imaging modalities with low sensitivity, nanoparticles bearing multiple contrast agents 
provide signal amplification. Nanotechnology can also enhance the colloidal stability 
of the nanosized imaging agents as well as prolong the circulation time in blood by 
protection of polymers to prevent the excretion from the bodies.  
2.9.3 Multifunction 
One nanoparticle can in principal deliver both reporting agents like peptides, genes, or 
dyes and drugs, allowing monitoring of biodistribution and reporting therapeutic 
activity simultaneously (theranostics) (Debbage and Jaschke, 2008). This „therapy‟ 
plus „diagnostics‟, or „theranostics‟ holds the promise in future of monitoring or 
reporting the effectiveness of therapy simultaneously with delivering the therapy, and 
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thus of tailoring the therapy to the individual needs of a patient (personalized 
medicine).  
Combining the targeting, imaging, reporting functions with the long circulating 
therapeutics delivery systems, it is a potent tool for thorough cancer therapy (schemed 
in Figure 2.9). It is clear that the development of multifunctional nanoparticles is 
luring, although has a long way to go and relies on the progress of cellular and 
molecular biology. Moreover, the feasibility to approach to the ultimate 
multifunctional systems should be based on the satisfied performance on single 
specific functions (Feng, 2006).  
 
Figure 2.9 Schematic image of multifunctional nanoparticulate platform (Park et al., 
2009). 
 
2.10 Methods of producing polymeric nanoparticles 
Nanoparticles can be fabricated by various methods (Feng and Chien, 2003; Hans and 
Lowman, 2002). The two main types are one-pot producing from monomer 
polymerization and dispersion of polymer solutions in water. Due to the difficulties on 
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strictly precise control factors to produce biodegradable polymers with desired 
molecular weight, one-pot polymerization method is not ideal. In the dispersion 
methods, some major routes can be utilized. The solvent extraction/evaporation 
technique might be the most important one. Polymer is dissolved in an organic solvent 
immiscible with water such as dichloromethane, or chloroform. The hydrophobic 
anticancer drug is dissolved or dispersed into the preformed polymer solution, and the 
resulting mixture is added into an aqueous solution with emulsification by high-speed 
homogenization or ultrasonication, to make an oil-in-water emulsion with the aid of an 
amphiphilic emulsifier (single emulsification). If the anticancer drug is hydrophilic, the 
technique is slightly modified to form a water-in-oil-in-water emulsion (double 
emulsification). After the formation of a stable emulsion, the organic solvent is 
evaporated by continuous stirring in an increased temperature or a reduced pressure 
(vacuum) environment, with or without the aid of an inertial gas flow. The high output 
energy disperses the oil phase to small and uniform oil droplets. After the coating of 
emulsifiers, stable dispersion will be formed. Particles will solidify after the 
evaporation of organic solvents. Centrifugation or ultrafiltration is applied to collect 
the formed particles, which can then be freeze-dried to form dry powders for storage. 
A brief discussion for the effect of process variables on the properties of nanoparticles 
can be found in the paper published by Scholes et al. (1993). The simple technique is 
fast to operate with high particle yield, but producing monodispersed particles is not 
that easy. Since the solvent extraction/evaporation technique is good only for a 
laboratory-scale operation, other nanoparticle technologies such as spray-dry and 
spray-freeze-dry have also been developed for a large-scale pilot production of drug-
loaded particles. The challenges for spray-drying include how to produce particles with 
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sufficiently small size and how to increase the drug encapsulation efficiency. Other 
alternative techniques employing low-energy emulsification are required. One choice 
is the spontaneous emulsification-diffusion technique, in which a water-miscible 
solvent such as acetone or methanol and a water-immiscible organic solvent such as 
dichloromethane or chloroform are used. Due to the spontaneous diffusion of the 
water-soluble solvent, an interfacial turbulent flow is created between the two phases, 
leading to the formation of nanoparticles. An alternative is the so-called salting out 
method. The detailed mechanism and the factors affecting the products have been 
thoroughly compared by Galindo-Rodriguez et al. (2004).  
Nanoprecipitation is another good technique by diffusion of water-miscible solvents 
containing polymers into aqueous phase by which nanoparticles with small size and 
narrow size distribution can be produced. The method was firstly reported in 1989 
though the term was not clearly stated at that moment (Fessi et al., 1989). Although the 
yield of nanoparticles and encapsulation efficiency of hydrophobic drugs are 
sometimes a little lower, instant fabrication and prospective scale-up possibility are the 
obvious advantages. Especially, by using this method, particles with size less than 100 
nm are able to be easily produced. Nanoprecipitation method differs from the 
emulsification-diffusion and salting-out methods in that formally no precursor 
emulsion is formed during NP preparation. Basically, NP formation is explained in 
terms of the interfacial turbulence and the “diffusion-stranding” processes between two 
unequilibrated liquid phases (Miller, 1988). Typically, the organic phase containing 
the polymer in water-miscible solvent is poured into the aqueous phase with or without 
surfactant under slight magnetic stirring. When both phases are in contact, solvent 
rapidly diffuses from the organic phase into the water and afterwards, the polymer 
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chains entangle with each other and further aggregate to form solidified particles. In 
experiments, three major factors affect the properties of the final polymeric particles, 
which are the polymer concentration in organic solvents, the type of solvent in the 
organic phase, i.e. the miscibility with water, and volume ratio of organic phase to 
aqueous phase. Besides, other factors such as polymer type, phase mixing rate, stirring 
speed, temperature, drug loading, presence of surfactants, etc also have influence. 
Normally, increasing the polymer concentration, or using solvents with lower 
miscibility, or enlarging the oil to water ratio leads to larger particle size and size 
distribution. Detailed comparison and explanations have been extensively reported in 
the past a few years (Beletsi et al., 2008; Fonseca et al., 2002; Bilati et al., 2005; 
Govender et al., 1999; Cheng et al., 2007). Dialysis method holds similar mechanism 
of nanoprecipitation. But precise control of nanoparticle forming should only be 
guided by previous diffusion study, which is specific for different systems. Also, it is 
time wasting and low efficient. From the environmental-friendly point of view, 
production of polymeric nanoparticles by supercritical fluid spraying is an emerging 
technique without the need of using any toxic organic solvent and surfactant. 
Hydrophilic polymers like chitosan can be prepared by ionic gelation technique, which 
involves a mixture of two aqueous phases with different charges. 
 
2.11 Surface coating for producing polymeric nanoparticles 
Generally, extra materials are indispensible when fabricating polymeric nanoparticles 
coating on the surface to provide sufficient colloidal stability, desirable surface 
properties and functions, and sometimes higher therapeutic effect. Emulsifiers are one 
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of the most important components in solvent extraction /evaporation method to 
stabilize the dispersive phase in continuous phase as well as the origin of surface 
coating on fabricated nanoparticles. The often-used emulsifiers, PVA has the 
disadvantages of low emulsification efficiency, low drug encapsulation ability, 
difficulty to clean-up, and possible harms to the body (Feng and Chien, 2003). Other 
better and more efficient emulsifiers, such as gelatin, Tween-80, F-127, F-68 are thus 
preferred. But the potential side effects to human bodies are still not fully clear. 
Moreover, these synthetic macromolecules are not easily washed out of the particles 
(Feng and Huang, 2001). As a result, they may cause troubles in purification of 
products and thus influence the properties of the formed nanoparticles. Therefore, 
natural amphiphilic molecules are better to be emulsifiers for fabricating 
nanoparticulate carriers. Among various natural emulsifiers, TPGS1k is a rising star as 
emulsifier due to the natural origin, biocompatibility, high emulsification effect, high 
encapsulation efficiency of drugs, prolonged circulation time in blood, ability of 
escape from the recognition of mononuclear phagecytic system and interaction with 
lipoproteins as passive targeting. TPGS is a water-soluble derivative of natural vitamin 
E, i.e. a PEGylated Vitamin E, which has amphiphilic structure comprising lipophilic 
alkyl tail and hydrophilic polar portion (Figure 2.10). Its bulky structure and large 
surface area makes it an excellent emulsifier, solubilizer, and bioavailability enhancer 
of hydrophobic drugs. It has also been found that TPGS could inhibit P-gp mediated 
multidrug resistance and thus greatly enhance oral drug delivery (Lukyanov et al., 
2004; Mu et al., 2005; Zhao et al., 2009). Our group has recently shown that TPGS1k 
can result in promising nanoparticles with the features such as drug encapsulation 
efficiency as high as 100%, higher cellular uptake and sustainable chemotherapy effect 
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in vivo, etc (Mu et al., 2004; Win and Feng, 2006; Feng et al., 2007; Lee et al., 2007; 
Zhang and Feng, 2006; Zhang and Feng, 2006a; Zhang et al., 2007; Pan and Feng, 
2008; Gan et al., 2010).  
 
 
Figure 2.10 Chemical structure of TPGS1k (top) and DPPC (bottom). 
 
Phospholipids are another ideal candidate. They have been widely used as emulsifying 
agents and for other purposes in industry (Feng and Huang, 2001). The products in 
which phospholipids are used as emulsifiers include food industry like animal feeds, 
baking products and mixes, chocolate, light industry like cosmetics and soaps, 
manufacturing like insecticides, dyes, paints, and plastics. For example, in foods, they 
promote the suspension of one liquid in another as in the mixture of oil and water in 
margarine, shortening, ice cream, and salad dressing. Phospholipids are also used in 
the skin care area such as preparation of cosmetics, lotions, and certain 
pharmaceuticals, where they prevent separation of ingredients and extend storage life. 
However, their application as emulsifiers in the solvent extraction/evaporation 
technique to fabricate polymeric nanoparticles as drug delivery systems has rarely been 
reported. Only a few publications suggested that the use of DPPC as an additive may 
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be able to improve the performance of the produced PLGA microspheres in blood flow 
(Garti, 1999), enhance the pulmonary absorption of peptides and proteins (Zhen et al., 
1995) and reduce phagocytic uptake of the microspheres (Evora et al., 1998). All these 
facts hint at the potential application of phospholipids as natural emulsifiers for 
polymeric nanoparticle fabrication to load anticancer drugs.  
Moreover, phospholipids are essential biomolecules in the structure and function of 
living matter, besides water, and along with proteins, nucleic acids and carbonhydrates. 
The most abundant lipids are fats, or triglycerids, and waxes which are oily or greasy 
nonpolar substances, insoluble in water. For the emulsifiers, only polar lipids are 
interested, which have amphiphlic properties and are building blocks of cell 
membranes. Generally a polar lipid molecule consists of three parts in its chemical 
structure: a polar head group, carbon chain tail(s) and a phosphorous backbone to 
which the carbon chains and polar head moieties are attached. Polar heads groups vary, 
constructing the so called phosphatidyl choline, phosphatidyl ethanolamine, 
phosphatidyl serine, phosphatidyl glycerol, phosphatidyl acid, and phosphatidyl 
inostiol (New et al., 1990). The water insoluble part consists normally of one or two 
acyl or alkyl (fatty acid) chains. Chain lengths in these synthetic diacyl lipids range 
from 8 carbon atoms to 24, mostly from 14 to 18, and they can be fully saturated or 
unsaturated with 1 to 4 double bonds. The most frequently occurring saturated fatty 
acids in the natural cell membranes are palmitic, stearic, and miristic, which possesses 
16, 18, and 14 carbon atoms, respectively. From the unsaturated fatty acids the oleic, 
which is a stearic acid with one double bond in the middle of the chain with a cis- 
configuration is the most important. Saturated fatty acid chains are very flexible and 
when in a non-frozen state they can exhibit a large number of conformations because 
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each single bond has complete freedom of rotation. In contrast, unsaturated fatty acids 
show one or more rigid kinks due to double bond which are non-rotating. Single-chain 
lipids can have the polar head attached directly to the hydrocarbon chain while natural 
double-chain lipids contain a molecule which serves as a linker between the three 
groups. The backbone of lipid is normally either glycerol or sphingosine. Generally, 
semisynthetic lipids, which can be made by complete organic synthesis or by de- and 
re-acylation of natural lipids, are widely used in research because their phase behavior 
and thermodynamic parameters are much better defined as compared to natural 
analogues with polydisperse hydrocarbon chain populations (Lasic et al., 1993). In 
contrast to the natural ones, such as lecithins prepared from egg yolk or soy beans, the 
physical properties like the phase transition temperature (from solid gel phase to liquid 
crystal phase), enthalpy and entropy value, are more clearly defined and do not vary 
from source to source. Those parameters might be important to the judge of 
experimental conditions to fabricate nanoparticles. Therefore, proper selection of 
phospholipids as emulsifiers should consider the following factors: carbon chain tilt, 
including chain length, degree of saturation (rigidity of the chains); phase transition 
temperature; charge and bulky of head group; and solubility in common solvents (since 
emulsifiers can play better effect in solution). DLPC is a kind of commonly used 
phospholipid because of its normal chain length, saturation, positively charged 
headgroup, proper space volume of the head, phase transition temperature (-1 °C) 





Monoclonal antibody accounts for significant portion for targeted nanomedicine as a 
molecular targeting ligand. Trastuzumab (C6470H10012N1726O2013S42) (Herceptin
®
) is one 
of the most attractive antibodies since it is the first humanized antibody approved by 
the FDA for the treatment of HER2-positive MBC (Smith, 2001; Vogel et al., 2002).  
The progress of cancerous tumor is often accompanied by the over expression of 
special proteins called tumor antigens, which can be used as biomarkers to differentiate 
the cancer cells from the healthy cells for development of targeting strategies. The 
crucial step is to identify the ideal ligand for targeting (Ross et al., 2004; Longo et al., 
2007). The EGFR is a receptor tyrosine kinase overexpressed on many human cancer 
cells. It is regarded as a key receptor for targeted tumor therapy. The human epidermal 
growth factor family includes the EGF receptors (EGFR, HER1), HER2/neu, 
neuregulin/heregulin receptors HER3 and HER4 (Figure 2.11). Under healthy 
conditions, they regulate the cell-to-cell and cell-to-stroma communication through the 
signal transduction system, and consequently, affect cell survival and proliferation, 
angiogenesis, motility and adhesion (Ross et al., 2004). These proteins are composed 
of three membrane portions: the internal tyrosine kinase responsible for signal 
transduction; a short transmembrane part, and the extracellular receptor domain. The 
binding of ligands to EGFR, HER3 and HER4 results in the formation of homodimeric 
or heterodimeric receptor complexes, and HER2 acts as a co-receptor facilitating the 




Figure 2.11 The human epidermal growth factor family (adapted from 
http://www.biooncology.com/). 
 
The MBC is a stage IV breast cancer that HER2 (or HER2/neu or ErbB-2), one of the 
transmembrane tyrosine kinase receptors with partial homology that normally regulate 
cellular responses, overexpresses on the cancerous cell membranes (Yarden, 2001). 20-
30% of breast cancer tumors are found to have overexpressed HER2 gene. The 
advanced cancer highly challenges the common therapies in that patients with the 
advanced cancer cells overexpressing this receptor have decreased overall survival rate 
and may have differential responses to a variety of chemotherapeutic agents (Seidman 
et al., 2001). The overexpressed HER2 gene in breast cancer cells is found to result in 
higher resistance against anticancer drugs such as paclitaxel. Therefore it is of 
paramount importance to invent new strategies to treat MBC. Particularly, HER2 is an 
interesting and promising receptor to be targeted for HER2-overexpressing breast 
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cancer cells (Figure 2.12) (Nahta and Esteva, 2006). Herceptin
®
 (formulated by 
Genentech from Trastuzumab, simply expressed as herceptin afterwards), a humanized 
recombinant anti-HER2 monoclonal antibody, is one of the medications which binds to 
the extracellular juxtamembrane domain of HER2 by its two antigen specific sites and 
inhibits the proliferation and survival of HER2-dependent tumors (Hudis, 2007).  
 
Figure 2.12 Receptor sites for Trastuzumab and mechanism of action of Trastuzumab 
(Bullock and Blackwell, 2008). 
 
Herceptin‟s exact mechanism of action is debatable and appears to differ in vivo 
compared to in vitro. One of the postulation is that the binding effect prevents the 
activation of its intracellular tyrosine kinase (Figure 2.13). It may also prevent the 
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HER2 receptor from dimerization, increase endocytotic destruction of the receptor, and 
inhibit shedding of the extracellular domain and immune activation (Bullock and 
Blackwell, 2008). Another proposed mechanism of cancer cell inhibitory by herceptin 
is that it diminishes signaling from the phosphoinositide 3 kinase and mitogen-
activated protein kinase pathways, causing cell cycle arrest at the G1 phase, promoting 
apoptosis via antibody-dependent cellular cytotoxicity, and inhibiting angiogenesis and 
DNA repair in tumors (Hudis, 2007).  
 






2.13 Precise engineering of polymeric nanoparticles 
The properties of nanoparticles have great impact on the performance of nanomedicine. 
Typically, the size, surface hydrophilicity, surface charge, shape or geometry, and 
surface coating are regarded as judging factors when investigating the cell-particle 
interaction and anticancer effect. However, notably, the nature and density of the 
ligands on the particle surface for targeted drug delivery is as important as other 
biophysicochemical properties of the drug carrier, and can all impact the circulating 
half-life of the particles as well as their biodistribution (Farokhzad and Langer, 2009). 
The presence of targeting ligands can increase the interaction of the drug delivery 
system with the cells in the target tissue, which can potentially enhance cellular uptake 
efficiency by receptor-mediated endocytosis. The optimization of the ligand density on 
the drug carrier surface can facilitate the tissue penetration, cellular uptake, and 
optimal therapeutic efficacy (Farokhzad and Langer, 2009). Moreover, the surface 
density of conjugated ligand is an external indicator for the surface chemistry of NPs 
which is one of the important properties of NPs affecting the safety issues of NPs in 
biomedical applications (Dusinska et al., 2009). Therefore it is highly valuable to 
develop the strategy for quantitatively control the ligand density and further precisely 
engineer the properties of drug carriers.  
The most commonly used method to introduce targeting ligands on the carriers is 
through covalent conjugation which is more easily to be controlled than using physical 
adsorption method. Yet ligand conjugation is a self-assembly process in which no 
direct management is available to control successful conjugation between the ligand 
and the polymeric nanoparticles, which makes it difficult for any quantitative control 
of the targeting effect to meet the treatment needs to be realized. Recently, in the 
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literature, there are two strategies developed for quantitative control of the targeting 
effects by adjusting the ligand density on the nanoparticle surface. The first trial is 
through conjugation of ligand on the polymers which form the particles later before the 
nanoparticle formation, which we call the pre-conjugation method. The other is so-
called the post-conjugation method, i.e. to conjugate the ligand to the particles after the 
nanoparticle formation. For the pre-conjugation strategy, one copolymer such as 
PLGA-PEG of the nanoparticle matrix was firstly conjugated with targeting ligand say 
A10 aptamer, the NPs was then prepared by the nanoprecipitation method (Gu et al., 
2008). The cellular uptake efficiency and biodistribution behavior of the particles with 
various ligand densities was proved have the relationship with the surface density. This 
strategy, however, is not desired enough to precisely control the ligand density due to 
some limitations such as the lost of the ligand in the polymeric matrix and irregular 
distribution of the ligand among different nanoparticles. For the post-conjugation 
strategy, instead, the drug loaded nanoparticles were firstly prepared with the two 
copolymer blend such as functional PLGA-PEG and inert PLGA. The nanoparticles 
were then functionalized by the ligand such as antibodies. Delie‟s group produced the 
thiol-functionalized PLA nanoparticles loading with paclitaxel then conjugated with 
herceptin to compare the therapeutic effects. The density of the thiol groups on the 
formed particles was quantified to control the ligand density, which is an illustration of 
using the post-conjugation strategy (Cirstoiu-Hapca et al., 2007; Cirstoiu-Hapca et al., 
2009). The advantages of such a post-conjugation strategy overcome the weakness of 
the pre-conjugation strategy, which used the ligand much more efficiently and protects 
its bioactivity, thus resulting higher targeting effects. In this work, post-conjugation 
strategy would be applied to control the ligand density on nanoparticles and the impact 
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on anticancer performance of the drug loaded particles with various ligand densities 
would be investigated.  
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Chapter 3 : Nanoparticles of Lipid Monolayer Shell and 
Biodegradable Polymer Core for Anticancer Drug Delivery 
The development of a novel anticancer drug delivery system of nanoparticles of lipid 
monolayer shell and biodegradable polymer core for controlled release of anticancer 
drugs with paclitaxel as a model drug is reported in this chapter, in which the emphasis 
is given to the impact of the lipid monolayer shell type and the lipid amount used in 
the process of nanoparticle preparation on the properties of the nanoparticles. Five 
different types of phospholipids were investigated with various amounts to find 
appropriate formulations for delivery of paclitaxel. The drug loaded nanoparticles were 
characterized by LLS for size and size distribution, zetasizer for surface charge, HPLC 
for drug encapsulation efficiency, FESEM for surface morphology, and XPS for 
surface chemistry. The optimal formulation of lipid coated nanoparticles were also 
compared with PVA emulsified nanoparticles in order to demonstrate the advantages 
of lipids to formulate drug loaded nanoparticles over the traditional emulsifier in terms 
of high emulsification efficiency and desired particle characteristics. MCF7 breast 
cancer cells were employed to evaluate the cellular uptake efficiency and cytotoxicity 
of the newly formulated nanoparticles. After incubation with MCF7 cells at 0.250 
mg/ml NP concentration, the coumarin-6 loaded PLGA NPs of lipid shell showed 
effective cellular uptake efficiency.  The analysis of IC50 upon the cytotoxicity analysis 
demonstrated that the DLPC shell PLGA core NP formulation of paclitaxel could be 
5.88-, 5.72-, 7.29×10
3
- fold effective than the commercial formulation Taxol
®
 after 24, 





Nanotechnology has been regarded as one of the most promising approaches to deal 
with cancer, which is still a leading cause of death all over the world (Ferrari, 2005; 
Jemal et al., 2009; Farokhzad and Langer, 2009). Nonetheless, there are only a few 
nanotechnology based drug formulations so far which are approved by FDA for 
clinical application (Duncan, 2006). It is thus of paramount importance to develop 
smarter and more powerful drug formulations. Liposomes and polymeric nanoparticles 
are two of the utmost investigated nanocarriers for anticancer drug delivery. 
Liposomes have been widely used as a drug delivery vehicle due to high 
biocompatibility, favorable pharmacokinetic profile and ease of surface modification. 
However, liposomes have disadvantages for drug delivery including insufficient 
hydrophobic drug loading, fast release of hydrophobic drugs and instability (Rai et al., 
2008). Polymeric nanoparticles are another dominant platform for drug delivery. Yet 
the biocompatibility of NPs formed by most synthetic polymers is not as high as 
liposomes, especially at the cellular level. It is thus natural to develop novel drug 
carrier which can combine the advantages and avoid the disadvantages of the 
liposomes and the nanoparticles of biodegradable polymers.  
It has been found that the surface decoration of PLGA NPs by lipids is a promising 
approach to improve the drug encapsulation efficiency and mediate cellular uptake of 
the nanoparticles (Feng et al., 2002; Feng et al., 2004). Recently, several researches 
have been reported regarding the polymer-lipid hybrid nanoparticles, which are 
nanoparticles of lipid shell and polymer core produced by various methods, which can 
be summarized in two categories (De Miguel et al., 2000; Wong et al., 2006; Wong et 
al., 2006a; Thevenot et al., 2007; Wong et al., 2007; Li et al., 2008; Zhang et al., 
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2008b; Chan et al., 2009). The first is to prepare the polymeric core firstly and then 
merge them with liposomes to form the desired lipid shell-polymer core structure. A 
typical example is the lipoparticles (De Miguel et al., 2000; Wong et al., 2006; Wong 
et al., 2006a; Thevenot et al., 2007; Wong et al., 2007; Li et al., 2008). The 
formulation process of such structured nanoparticles usually needs two steps, i.e. 
formation of polymeric NP core and mixing of the core NPs liposomes, resulting in 
technical complexity and thus lack of control over the final NP physicochemical 
properties (Zhang et al., 2008b). The second is to produce the core-shell nanoparticles 
in a single step which combines the nanoprecipiation and self-assembly method 
(Zhang et al., 2008b; Chan et al., 2009). Such strategies meet the requirement to 
develop well-defined and predictable lipid-polymer hybrid NPs and facilitate future 
scale-up. Consequently, the novel nanocarriers deserve further investigation 
particularly on the impact of the phospholipid decoration on the performance of NPs. 
In the previous research of our group, it has been concluded that the lipids of short and 
saturated chains such as DLPC, which has the HLB index of 13 (calculated from the 
equation: HLB index = ∑ (Hydrophilic groups) + ∑ (Lipophilic groups) + 7), could 
have high emulsification effects for preparation of polymeric particles of the nanoscale 
size, smooth surface, and desired control release profile of anticancer drugs of high 
hydrophobicity such as of paclitaxel (Feng and Huang, 2001).  
In this research, we continued our earlier work in 2001 to develop a system of 
biodegradable nanoparticles of various lipid shell and PLGA polymer core for 
controlled release of paclitaxel which is an excellent antineoplastic agent against a 
wide spectrum of cancer. The emphasis was given to investigation on the lipid 
decoration type and optimization of the lipid amount in favor of the particle 
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characteristics and performance as well as to demonstrate the advantages of the lipid 
coated NPs over those emulsified by the traditional chemical emulsifier PVA. The NPs 
were characterized by LLS for size and size distribution, zetasizer for surface charge, 
HPLC for drug encapsulation efficiency, FESEM for surface morphology, and XPS for 
surface chemistry. MCF7 human breast cancer cells were employed to evaluate the 
cellular uptake of the coumarin-6 loaded NPs and the cytotoxicity of the drug 




3.2 Materials and methods 
3.2.1 Materials 
Paclitaxel (99.8%) was purchased from Dabur Pharma Ltd. (India). Taxol
®
 was 
provided by National Cancer Center (Singapore). PLGA (75:25, Mw: 90,000-126,000), 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-
dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dicapryl-sn-glycero-3-
phosphocholine (DCPC), PVA, coumarin-6, PBS (pH 7.4), MTT, and PI were all 
purchased from Sigma-Aldrich (St. Louise, MO, USA). DMEM, FBS, penicillin-
streptomycin solution, and trypsin-EDTA solution were all from Invitrogen 
Corporation. All solvents used in this study were HPLC grade and offered by Sigma-
Aldrich. MCF7 breast cancer cells were provided by American Type Culture 
Collection. The water used was pretreated with the Milli-Q
®
 Plus System (Millipore 
Corporation, Bedford, USA). 
3.2.2 Preparation of the NPs 
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Preparation of the drug loaded, lipid shell and PLGA core NPs is based on a modified 
solvent extraction/evaporation method (Feng et al., 2007). Briefly, weighed amount of 
PLGA and paclitaxel were dissolved in dichloromethane as the oil phase. The aqueous 
phase was prepared by dispersing designated amount of lipid (%, w/v as the unit) in 
ultrapure water by bath sonication. Afterwards, the oil phase was mixed with the 
aqueous phase under stirring and then the mixture was sonicated by probe 
ultrasonicator at 20 W output under ice bath for 5 minutes. The produced emulsion 
was placed on magnetic stirrer to evaporate the solvent with moderate speeding 
overnight. The particle suspension was centrifuged at 12,000 rpm for 15 minutes to 
collect the NPs. After washing three times, the particles were resuspended in a fixed 
volume of water with 3% (w/w) sucrose as cryoprotectant and freeze-dried to obtain 
the fine powder. The blank NPs and the coumarin-6 loaded NPs were prepared in a 
similar procedure. The PVA emulsified NPs were produced in a similar manner with 
2% (w/v) PVA in water as the aqueous phase.  
3.2.3 Characterization of the NPs 
For the statistical analysis, data were expressed as the means with 95% confidence 
intervals. Statistical tests were performed with the Student‟s t test. For all tests, P 
values less than 0.05 were considered to be statistically significant. All statistical tests 
were two-tailed. 
Average particle size and size distribution of the NPs were measured by laser light 
scattering (90Plus Particle Sizer, Brookhaven Instruments Co. USA). The surface 
charge of the NPs in water was determined by ZetaPlus zeta potential analyzer 
(Brookhaven Instruments Co. USA) at room temperature. The amount of paclitaxel 
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encapsulated in the NPs was measured by high performance liquid chromatography 
(Agilent LC1100) equipped with a reversed phase Inertsil
®
 ODS-3 column (250×4.6 
mm, particle size 5 µm, GL Science Inc., Tokyo, Japan) and 50:50 (v/v) 
acetonitrile/water solution as mobile phase. Encapsulation efficiency is equal to 
(amount of drug encapsulated in the yielded NPs) / (amount of drug used in the feed of 
fabrication). The shape and surface morphology of the NPs were analyzed by field 
emission scanning electron microscope (JSM-6700F, JEOL, Tokyo, Japan) at an 
accelerating voltage of 5 kV. The dry particles were coated by platinum coater (JEOL, 
Tokyo, Japan) for 30 s at 30 mA current. The surface chemistry of the NPs was 
analyzed by X-ray photoelectron spectroscope (AXIS His-165 Ultra, Kratos Analytical, 
Shimadzu Corporation, Japan). The data were processed by software provided by the 
instrument corporation. 
3.2.4 In vitro evaluation 
For the in vitro drug release study, the drug loaded NPs were dispersed in PBS (0.1 M, 
pH 7.4) containing 0.1% w/v Tween-80, which can improve the solubility of paclitaxel 
in PBS. The dispersion was then put in an orbital shaker shaking at 120 rpm with water 
bath at 37°C. At designated time intervals, the suspension was centrifuged at 11,000 
rpm for 30 min. The pellet was resuspended in fresh medium to continue the drug 
release. The drug released in the supernatant was extracted by dichloromethane and 
transferred in the same mobile phase as abovementioned. After the evaporation of the 
solvent, paclitaxel quantity was determined by the same HPLC procedure 
aforementioned. The error bars were obtained from triplicate samples. 
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DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin was 
utilized as cell culture medium. Cells were cultivated in this medium at 37°C in 
humidified environment with 5% CO2. For cellular uptake study, MCF7 cells were 
seeded into 96-well black plates (Costar, IL, USA) at 5×10
3
 cells/well (0.1 ml) and 
after the cells reached 80% confluence, the medium was changed to the suspension of 
coumarin-6 loaded NPs at a NP concentration of 0.250 mg/ml for 0.5 and 2 hr, 
respectively. After incubation, the NP suspension in the testing wells was removed and 
the wells were washed with 0.1 ml PBS three times to remove the NPs outside the cells. 
50 μl of 0.5% Triton X-100 in 0.2 N NaOH solution was subsequently added to lyse 
the cells. The fluorescence intensity presented in each well was then measured by 
microplate reader (Genios, Tecan, Switzerland) with excitation wavelength at 430 nm 
and emission wavelength at 485 nm. For confocal microscopy study, MCF7 cells were 
cultivated in the 8-well coverglass chamber (LAB-TEK
®
, Nagle Nunc, IL) till 70% 
confluence. The courmarin-6 loaded NPs dispersed in the cell culture medium at 
concentration of 0.250 mg/ml were added into the wells. Cells were washed three 
times after incubation for 0.5 and 2 hr and then fixed by 70% ethanol for 20 min. The 
cells were further washed twice by PBS and the nuclei were then counterstained by PI 
for 45 min. The cell monolayer was finally washed thrice by PBS and observed by 
confocal laser scanning microscope (Olympus Fluoview FV1000). 
For the cytotoxicity study, MCF7 cells were incubated in 96-well transparent plates 
(Costar, IL, USA) at 5×10
3
 cells/well (0.1 ml) and after 12 hr, the old medium was 
removed and the cells were incubated for 24, 48 and 72 hr in the media containing 
Taxol
®
 or paclitaxel loaded NPs suspension at an equivalent paclitaxel concentration 
of 25, 10, 2.5, 0.25 μg/ml. The NPs were sterilized with UV irradiation for 1 day prior 
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to use. At given time intervals, the cultured cells were assayed for cell viability with 
MTT. The wells were washed twice with PBS and 10 μl of MTT supplemented with 
90 μl culture medium was added. After 3 hr incubation, the medium was removed and 
the precipitate was dissolved in DMSO. The absorbance of the wells was measured by 
the microplate reader (Genios, Tecan, Switzerland) with wavelength at 570 nm and 
reference wavelength at 620 nm. Cell viability was calculated by the following 
equation: cell viability = Ints / Intcontrol × 100%, where Ints is the absorbance of the 
wells containing the cells incubated with the NP suspension and Intcontrol is the 
absorbance of the wells containing the cells incubated with the culture medium only 
(positive control). 
 
3.3 Results and discussion 
3.3.1 Preparation and structure of the NPs 
The schematic structure of the paclitaxel loaded, lipid shell and PLGA core NPs 
developed in this work is represented in Figure 3.1. The NPs were produced by the oil-
in-water (O/W) single emulsion solvent extraction/evaporation method with 
phospholipid as emulsifier. After emulsification of the oil phase in the aqueous phase 
by applying ultrasonication, the amphiphilic lipids were adsorbed onto the surface of 
the oil droplets containing PLGA and paclitaxel by hydrophobic interaction. Followed 
by the evaporation of DCM under continuous magnetic stirring, the drug loaded NPs 
were then solidified and formed. Phospholipid was introduced as the amphiphilic 
molecule to decrease the interfacial tension between oil-water phase and thus attach on 




Figure 3.1 Schematic illustration of the structure of the paclitaxel loaded lipid shell 
(for instance, DLPC) PLGA core NPs. 
 
3.3.2 The influence of lipid type on the characteristics of the NPs 
Served as emulsifier in the nano-emulsification process to produce lipid shell polymer 
core NPs, the type of lipids has distinctive impact on the characteristics of the NPs 
resulting from the flexibility depended on the satruation of their carbon chains as well 
as the HLB determined by the length of their carbon chains (Feng and Huang, 2001). 
Table 3.1 illustrates the size, size distribution, surface charge and drug encapsulation 
efficiency of the paclitaxel loaded NPs of various saturated lipid shell and PLGA core 
with lipid amount of 0.05% (w/v). Overally, in terms of the size and polydispersity 
property, DLPC shell NPs showed smallest hydrodynamic diameter and most narrow 
size distribution. Additionally, the surface charge of such formulation was shown to be 
the lowest, which indicates the highest colloidal stability. For the EE results, all of the 
lipids except DSPC displayed acceptable drug loading capability. It can be concluded 
that shorter chain lipids, such as DLPC and DCPC could be better candidates to be 
employed as the agents to produce lipid shell polymer core NPs due to their higher 
HLB value (13 and 15, respectively).  
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Table 3.1 Characteristics of the paclitaxel loaded lipid shell and PLGA core NPs of 
various lipid used with 0.05% (w/v) as concentration in the nano-emulsification 
process: particle size, size distribution, zeta-potential and encapsulation efficiency. 
Data represent mean ± SE, n=6 (For EE results, n=3). 
lipid shell
 






DSPC > 1000 > 0.3 N.A. N.A. 
DPPC 578.3 ± 14.4 0.220 ± 0.030 -28.11 ± 2.25 45.5 ± 1.44 
DMPC
 
310.0 ± 7.3 0.269 ± 0.028 -34.85 ± 3.76 38.7 ± 0.20 
DLPC 243.0 ± 4.2 0.138 ± 0.043 -36.88 ± 1.30 43.8 ± 0.06 
DCPC
 
275.1 ± 8.9 0.153 ± 0.009 -29.95 ± 3.12 48.8 ± 1.90 
 
3.3.3 The influence of lipid quantity on the characteristics of the NPs 
We next used DPPC, DMPC, DLPC to formulate NPs and investigate the impact of 
lipid quantity on the NPs properties since DSPC failed to produce nanoscaled particles 
due to its low HLB value and DCPC is not stable at room temperature. Table 3.2 to 3.4 
summarize the properties of the paclitaxel loaded NPs of DPPC, DMPC, DLPC shell 
and PLGA core with various lipid amount, respectively. The trend of the size change 
with lipid quantity was shown to be that increase of lipid quantity would result in 
smaller NPs. Especially, when increasing the quantity of DPPC to 0.10% (w/v), 
particles with size smaller than 300 nm was able to be produced. This is 
understandable since the role of the emulsifier is to stay in the oil-water interface to 
lower the surface tension to facilitate the nanoparticle formulation. Too little amount of 
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lipid would not be enough to cover the entire surface of the NPs of small size (large 
surface area) to stabilize the oil droplets in the O/W emulsion, thus  leading to particles 
of large size. Too much amount of lipid, however, would cause particle adhesion in the 
aqueous phase. The zeta potential values also showed to be dependent on the lipid 
quantity. The more lipid used in the preparation process, the larger absolute value of 
the negative charge would be resulted. The negative charge of the NPs could be due to 
both of the polymer and the lipid. As for the drug EE of the NPs, it can be seen that the 
lipid amount is a decisive factor for EE. Too less lipid used could be failed to produce 
sufficient NPs, which results in less drug encapsulated. Rather, too much lipids used 
could also decrease EE in that the excess lipids would form free aggregators to 
compete with polymer matrix to engulf drugs. The optimized amount of lipids was 
thus able to be confirmed after the two abovementioned investigation (listed in Table 
3.5). 
Table 3.2 Characteristics of the paclitaxel loaded DPPC shell and PLGA core NPs of 
various DPPC amount used in the nano-emulsification process: particle size, size 













0.20 271.0 ± 4.2 0.287 ± 0.010 -41.43 ± 0.68 11.3 ± 0.11 
0.10 279.1 ± 8.5 0.178 ± 0.040 -38.16 ± 1.25 39.3 ± 0.81 




Table 3.3 Characteristics of the paclitaxel loaded DMPC shell and PLGA core NPs of 
various DMPC amount used in the nano-emulsification process: particle size, size 













0.10 239.6 ± 9.1 0.129 ± 0.052 -36.97 ± 2.60 76.8 ± 0.90 
0.05 310.0 ± 7.3 0.269 ± 0.028 -34.85 ± 3.76 38.7 ± 0.20 
0.03 401.5 ± 3.3 0.038 ± 0.033 -32.35 ± 0.90 54.2 ± 0.30 
 
Table 3.4 Characteristics of the paclitaxel loaded DLPC shell and PLGA core NPs of 
various DLPC amount used in the nano-emulsification process: particle size, size 













0.10 238.7 ± 4.1 0.239 ± 0.037 -44.75 ± 1.39 41.8 ± 0.07 




0.324 ± 0.013 -30.25 ± 1.03 15.1 ± 0.01 
 
Table 3.5 Characteristics of the optimized formulation of paclitaxel loaded lipid shell 
and PLGA core NPs (highlighted from the above 3 tables). Data represent mean ± SE, 











DPPC 0.10% 279.1 ± 8.5 0.178 ± 0.040 -38.16 ± 1.25 39.3 ± 0.81 
DMPC 0.10% 239.6 ± 9.1 0.129 ± 0.052 -36.97 ± 2.60 76.8 ± 0.90 
DLPC 0.05% 242.5 ± 4.2 0.138 ± 0.043 -36.88 ± 1.30 43.8 ± 0.06 
 
Next we fixed to use DLPC to formulate the drug loaded, lipid shell and polymer core 
NPs with a wider range of lipid concentrations, from 0.01 to 0.1% (w/v). The results 
were summarized in Table 3.6. 
Table 3.6 Characteristics of the paclitaxel loaded DLPC shell and PLGA core NPs of 
various DLPC amount used in the nano-emulsification process: particle size, size 













0.1 238.7 ± 4.1 0.239 ± 0.037 -44.75 ± 1.39 41.8 ± 0.07 
0.05 242.5 ± 4.2 0.138 ± 0.043 -36.88 ± 1.30 43.8 ± 0.06 
0.04 243.6 ± 8.6 0.139 ± 0.035 -36.12 ± 1.18 56.1 ± 0.07 
0.02 264.8 ± 4.2 0.174 ± 0.018 -35.07 ± 1.19 36.9 ± 4.17 




The trend of the size and surface charge change with lipid quantity was shown in 
Figure 3.2, i.e. increase of lipid quantity would result in smaller NPs and lower surface 
charge. The emulsifier amount used in the nano-emulsification process can be used to 
quantitatively control the nanoparticles size, which is a dominant factor to determine 
the key characters of the drug loaded nanoparticles. The surface charge test 
demonstrated that the more DLPC used in the preparation process, the larger absolute 
value of the negative charge would be resulted. The negative charge of the NPs could 
be due to both of the polymer and the emulsifier. Although DLPC is neutral, the DLPC 
coated NPs could still exhibit non-zero mobilities in an external electric field that may 
result in higher negative charge since some anions could bind to the neutral lipids, 
making the surface more negatively charged (Makino et al. 1991). We thus pursued an 
optimization by using 0.04% (w/v) DLPC in the nano-emulsification process in terms 
of the combined outstanding particle size, stability and encapsulation efficiency. 


























































To demonstrate the advantages of using phospholipids to formulate NPs, we shows a 
comparison of the characteristics of DLPC-emulsified and PVA-emulsified PLGA NPs 
(Table 3.7) at the same initial drug loading (5%), from which it can be seen that as 
emulsifier, DLPC has advantages over the traditional PVA (1) DLPC has much higher 
emulsification efficiency than PVA. To form the same amount NPs, the DLPC needed 
is only 1/50 of the PVA; (2) DLPC-emulsified NPs would result in higher drug 
encapsulation efficiency. Moreover, DLPC is a natural product and the PVA is a 
synthetic one. The former can thus cause fewer side effects than the latter. 
Table 3.7 Comparison of the characteristics of DLPC shell PLGA core NPs and PVA 
coated PLGA NPs under 5% initial drug loading: particle size, size distribution, zeta 














DLPC 0.04 243.6 ± 8.6 0.139 ± 0.035 -36.12 ± 1.18 56.1 ± 0.07 
PVA 2 293.9 ± 4.8 0.143 ± 0.023 -26.54 ± 1.54 43.1 ± 4.98 
 
3.3.4 Particle morphology 
Field emission scanning electron microscope was employed to image the morphology 
of the particles (Figure 3.3 and 3.4). It is revealed from the images that the lipid coated 
NPs are generally spherical in shape with narrow size distribution. The rough surface 
of the NPs might be due to the lipid layers coated on the PLGA cores. The particle size 
observed from the FESEM image is in good agreement with that determined above by 
LLS. There are a few larger spheres attached with each other, which might be 
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attributed to the low solubility of lipids in water, thereby the spare amount of which 
still surrounds the solid polymeric particles or simultaneously forms large vesicle-like 
aggregators.  
 
Figure 3.3 FESEM images of the paclitaxel loaded 0.10% (w/v) DPPC shell (A), 
0.10% (w/v) DMPC shell (B), and 0.05% (w/v) DLPC shell (C) PLGA core NPs 
 
Figure 3.4 FESEM image of the paclitaxel loaded 0.04% w/v DLPC shell and PLGA 
core NPs (left) and the zoom-in FESEM image of the left one (right). 
 
3.3.5 Surface chemistry 
The surface chemistry of the drug loaded NPs was analyzed by XPS. For proving the 
successful surface coating of lipids on PLGA cores, phosphorous was specifically 
scanned in that this element only exists in lipid molecules. From Figure 3.5, the 
distinct peak of signals from 2p orbital of phosphorous (P 2p) qualitatively verifies that 
lipid molecules embrace PLGA cores since only lipid molecules consist of 
 80 
 
phosphorous. Therefore, it can be confirmed that the lipid shell has been successfully 
coated on the PLGA core. Another method could also be applied to visualize the lipid 
shell on the top of polymer core thus confirm the coating which involves the 
counterstaining of nitrogen contained in lipid molecules by phosphotungstic acid. Our 
group is using this method in another study that is still ongoing.  






Figure 3.5 XPS spectrum of the paclitaxel loaded lipid shell PLGA core NPs with 
0.10% (w/v) DPPC shell (lower curve), 0.10% (w/v) DMPC shell (middle curve), and 
0.04% (w/v) DLPC shell (upper curve): P 2p spectrum 
 
3.3.6 In vitro drug release 
The in vitro drug release profile of the paclitaxel loaded DLPC shell PLGA NPs in 168 
hours was shown in Figure 3.6, from which it can be seen that there is an initial burst 
of 32.48% in the first 12 hours. Such a fast drug release may be due to the drug 
molecules on and near the surface of the NPs. The initial burst could be helpful to 
suppress the growth of cancer cells in short time. In the following 72 hours, the 
cumulative release percent reached 75.83%, and the release presents a sustained 
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manner, which provides the possibility to continually fight against cancer cells, 
resulting in the decreased cancer cell viability as shown in the section of in vitro 
cytotoxicity below. The cumulative release percent almost achieved 100% after 7 days, 
showing a full release ability of the NP formulation. The generally sustained and 
controlled release profile of paclitaxel facilitates the application of the NPs for the 
delivery of anticancer drugs. Rather, it can also be seen that the release rate of 
paclitaxel from PVA-emulsified PLGA NPs was much slower. The possible reason can 
be attributed to the much higher molecular weight of PVA (30,000-75,000) than DLPC 
resulting in denser coating on the PLGA core and thus slower diffusion of the drugs 
into water in the same time. 





























Figure 3.6 In vitro paclitaxel release profile from the PVA-emulsified PLGA NPs 
(square dot curve) and the paclitaxel loaded DLPC shell PLGA core NPs with 0.04% 
(w/v) DLPC (round dot curve). Data represent mean ± SE, n=3. 
 
3.3.7 In vitro cellular uptake  
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The cellular uptake of the coumarin-6 loaded NPs was examined qualitatively to 
visualize the internalization in the cells. The Figure 3.7 shows the CLSM images of the 
MCF7 human adenocarcinoma cells after 0.5 hr (row 1 and 2) and 2 hr (row 3 and 4) 
incubation with the coumarin-6 loaded 0.10% (w/v) DPPC shell (row 1 and 3) and 
0.04% (w/v) DLPC shell (row 2 and 4) PLGA NPs. The pictures in the left column 
show the green fluorescence in FTIC channel from the coumarin-6 loaded NPs which 
have been internalized in the MCF7 cells. The pictures in the middle column show the 
red fluorescence from the cell nuclei stained by PI. The pictures in the right column are 
the merged images of the corresponding left and middle pictures. It can be seen from 
this figure that the red fluorescence representing the nucleus stained by PI is 
circumvented by green fluorescence representing the coumarin-6 loaded NPs 
internalized in the cytoplasm. In addition, after incubating 2 hr, the fluorescent NPs 
taken up by the cells are more than those incubated for 0.5 hr, which was confirmed by 
the higher distribution of green fluorescence in cytoplasm of the cells with 2 hr 
incubation under the same exciting laser intensity. A quantitative investigation has also 
been conducted by measuring the fluorescence intensity of the CLSM images to 
demonstrate the possible advantages of the DLPC shell PLGA NPs versus the PVA-
emulsified PLGA NPs. The same concentration of well dispersed coumarin-6 loaded 
DLPC shell or PVA-emulsified PLGA NPs (250 μg/ml) was used for all four cases of 
the MCF7 cells after 0.5, 1, 2, 4 hour incubation at 37ºC, respectively. We can see 
from the Figure 3.8 that the fluorescence intensity (a.u.) from the DLPC shell PLGA 
NPs taken up by the cells was 9726 ± 424, 12478 ± 437, 21081 ± 1148, and 27340 ± 
1729 in comparison with 7712 ± 365, 9958 ± 354, 12529 ± 569, and 16404 ± 1643 for 
the PVA-emulsified PLGA NPs, respectively (student‟s t test, P <0.05). This means 
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that the former is 26.1%, 25.3%, 68.2%, and 66.7% more effective than the latter after 
0.5, 1, 2, and 4 hr incubation with the MCF7 cells, respectively, revealing the 
possibility of such nanoparticulate formulations to deliver anticancer drugs into 
cancerous cells.  
 
Figure 3.7 The confocal laser scanning microscopy images of MCF7 cancer cells 































Figure 3.8 Cellular uptake efficiency of the coumarin-6 loaded DLPC- or PVA-
emulsified PLGA NPs by MCF7 cells after 0.5, 1, 2, 4 hr incubation at 250 µg/ml NP 
concentration, respectively. Data represent mean ± SE, n=6. 
 
3.3.8 In vitro cell cytotoxicity 
Due to the overally distinctive characteristics of 0.04% (w/v) DLPC shell PLGA NPs, 
it was used to further evaluate the cytotoxicity performance. Figure 3.9 shows the  in 
vitro cell viability of MCF7 cancer cells after 24, 48, 72 hour incubation with Taxol
®
 
or the paclitaxel loaded DLPC shell PLGA NPs at the equivalent paclitaxel dose of  25, 
10, 2.5, 0.25 μg/ml, respectively (In all cases, P < 0.05 under the two-tailed student‟s t 
test). T25, T10, T2.5, T0.25 and NP25, NP10, NP2.5, NP0.25 denote the cases of 
Taxol
®
 and the NP formulation at 25 μg/ml, 10 μg/ml, 2.5 μg/ml, and 0.25 μg/ml dose 
respectively. From this figure, the effects of the drug dose and the incubation time can 
be clearly observed. It is straightforward to notice that the lower cell viability 
corresponds to the higher concentration of drugs and longer treating time. As for the 
NP formulation, the cell viability obviously decreased with the increase of drug 
concentration and the exposure time. It can be concluded from this finding that the NP 
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formulation presented controlled and sustained release property. Rather for Taxol
®
, 
although less living cells were counted at 48 and 72 hr time points, the concentration 
dependence of cell viability was virtually disappeared, which could be attributed to the 
toxic effect of the commercial drug formulation. Moreover, 25μg/ml far exceeds the 
toxic level of paclitaxel (8.540 μg/ml) (Zhang et al., 2008), resulting severe side effects 
to normal cells. A quantitative evaluation of the in vitro therapeutic effect of a dosage 
form is IC50, which is defined as the drug concentration needed to kill 50% of the 
incubated cells in a designated time period. It can be calculated from the above in vitro 
cell viability data that the IC50 for 24, 48, 72 hour treatment was 5.06, 0.0163, 0.00897 
μg/ml for Taxol® and 0.86, 0.00285, 1.23×10-6 μg/ml, for the NP formulation, 
respectively. This means that the DLPC shell PLGA core NP formulation of paclitaxel 
could be 5.88-, 5.72-, 7.29×10
3
- fold effective than the commercial formulation Taxol
®
 
after 24, 48, 72 hr treatment, respectively. 
                 
Figure 3.9 In vitro cell viability of MCF7 cancer cells after 24, 48, 72 hour incubation 
with Taxol
®
 or the paclitaxel loaded DLPC shell PLGA core NPs at the equivalent 
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paclitaxel dose of 25, 10, 2.5, and 0.25 μg/ml. T25, T10, T2.5, T0.25 and NP25, NP10, 
NP2.5, NP0.25 denote the cases of Taxol
®
 and the NP formulation at 25 μg/ml, 10 
μg/ml, 2.5 μg/ml, and 0.25 μg/ml dose, respectively. Data represent mean ± SE, n=6. 
 
3.4 Conclusions 
We have successfully developed a system of nanoparticles of lipid shell and PLGA 
core for sustained and controlled release of anticancer drugs with paclitaxel as a model 
drug. We continued our earlier work of using phospholipids as emulsifier in the 
nanoparticle formulation with the focus that the type and amount of lipids used in the 
nano-emulsification process would play a key role to determine the physicochemical 
properties and in vitro performance of the drug loaded NPs. Five types of 
phospholipids were selected to produce the nanoparticles and the properties were 
compared. Selective formulations with various lipids were completely characterized to 
demonstrate the possibility of being employed as drug delivery systems. We also 
presented great advantages of phospholipid versus traditional PVA as emulsifier with 
higher emulsification efficiency, higher drug encapsulation efficiency and better in 
vitro performance. We demonstrated that after incubation with MCF7 cells at 0.250 
mg/ml NP concentration, the coumarin-6 loaded PLGA NPs of DLPC shell showed 
effective in vitro cellular uptake performance.  The analysis of IC50 based on in vitro 
cytotoxicity evaluation demonstrated that the DLPC shell PLGA core NP formulation 
of paclitaxel could be 5.88-, 5.72-, 7.29×10
3
- fold effective than the commercial 
formulation Taxol
®
 after 24, 48, 72 hr treatment, respectively. Consistent evaluation 
and analysis on the novel formulations evolve a fascinating opportunity and promising 
prospect to develop these new drug delivery systems.   
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Chapter 4 : Folic Acid Conjugated Nanoparticles of Mixed Lipid 
Monolayer Shell and Biodegradable Polymer Core for Targeted 
Delivery of Docetaxel 
A system of nanoparticles of mixed lipid monolayer shell and biodegradable polymer 
core was developed for targeted delivery of anticancer drugs with docetaxel as a model 
drug, which provides targeting versatility with a quantitative control of the targeting 
effect by adjusting the lipid component ratio of the mixed lipid monolayer, and 
combine the advantages and avoid disadvantages of polymeric nanoparticles and 
liposomes in drug delivery. X-ray photoelectron spectroscopy confirmed the coating of 
the mixed lipid monolayer on the polymeric core. Fluorescent microscopy proved the 
targeting efficacy of the folic acid conjugated on the mixed lipid monolayer for the 
cancer cells of over expression of folate receptors. The folic acid conjugated 
nanoparticles of mixed lipid monolayer shell and biodegradable polymer core were 
proved to possess sustainable, controlled and targeted delivery of anticancer drugs with 
docetaxel as a model drug, which may provide  a novel drug delivery system of precise 
control of the targeting effect. 
 
4.1 Introduction 
Nanotechnology has been extensively exploited to improve conventional cancer 
therapy in the recent years (Ferrari, 2005; Sinha et al., 2006; Farokhzad and Langer, 
2006; Farokhzad and Langer, 2009; Zhang et al., 2008a). The designed nanocarriers 
for achieving precise drug delivery to cancer cells are expected to be non-toxic, 
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efficiently load the drugs, enhance the circulation time in bloodstream, and actively 
target the cancer cells (Cho et al., 2008). The nanocarries currently under intensive 
investigation can be divided into two categories in general, i.e. the lipid-based and the 
polymer-based with liposomes and polymeric nanoparticle as their typical 
representative, respectively. Liposomes have been widely used due to their high 
biocompatibility, favorable pharmacokinetic profile, high delivery efficiency and ease 
of surface modification. Limitations of liposomal drug delivery, however, include 
insufficient drug loading, fast drug release, and instability in storage (Rai et al., 2008). 
Nanoparticles of biodegradable polymers, featured by their small size, acceptable 
biocompatibility, high drug encapsulation efficiency especially for hydrophobic drugs, 
controlled drug release manner, high cellular internalization, desired pharmacokinetics 
and long circulation half-life, are another prospective platform for drug delivery 
(Zhang et al., 2008a; Cho et al., 2008; Tong and Cheng, 2007). It is thus ideal if any 
technology could be developed to combine the advantages and overcome the 
disadvantages of the two types of drug nanocarriers. One possibility is to synthesize 
lipid-shell and polymer-core nanoparticles (LPNPs) as a novel drug delivery system. 
The pioneering work of such a design can be back to 2001, when phospholipids were 
used as effective emulsifier, which stays between the oil-water interface to lower the 
interfacial tension and thus facilitate the formulation of colloidal nanoparticles (Feng 
and Huang, 2001). The LPNPs can be formulated via a single step, which combines 
the nanoprecipiation method and the self-assembly technique to produce the desired 
structured NPs of lipid shell and polymer core (Zhang et al., 2008b; Chan et al., 2009). 
The strategy meets the requirement to develop well-defined LPNPs with predictable 
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physicochemical and pharmaceutical properties as well as facilitates future scale-up, 
which thus deserves further development. 
Active targeting can then be further realized by conjugating molecular probes onto the 
LPNPs surface, which provides a promising approach for the drug delivery system to 
reach and penetrate into the malignant cells with overexpression of the corresponding 
receptors on their surface, and then release the encapsulated therapeutics in a 
controlled and sustained manner (Cho et al., 2008; Wang et al., 2008). Phospholipid 
molecules can provide their end functional groups to facilitate conjugation of the 
molecular probes, i.e. the targeting ligands on the LPNPs surface. For instance, the 
carboxylic group linked to the ligand can be employed to conjugate the active primary 
amine group of phosphoethanolamine or amino PEG attached with 
phosphoethanolamine (Torchilin, 2005; Allen et al., 1996; Yang et al., 2007). The 
targeted drug delivery by nanoparticles can thus be made feasible and the conjugation 
technology can be not as complicated.  
In this work, we synthesized a novel kind of nanoparticles of mixed lipid monolayer 
shell and biodegradable polymer core to provide targeting versatility with a 
quantitative control of the targeting effect by controlling the lipid component ratio of 
the mixed lipid monolayer shell. Docetaxel is used as a model hydrophobic anticancer 
drug, which is a potent anticancer drug effective to a wide spectrum of cancers (Engels 
et al., 2007). Folic acid is selected as the model molecular probe for targeted delivery 
of the drug to the cancer cells of folate overexpression such as certain breast cancer 
and ovarian cancer cells. PLGA, one of the most popular FDA approved polymers, is 
used to form the polymer core matrix, which is wrapped by the mixed lipid monolayer 
shells of three distinct functional components: (i) 1,2-dilauroylphosphatidylocholine 
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(DLPC), a phospholipid of an appropriate HLB value which is employed to stabilize 
the NPs in the aqueous phase; (ii) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2k), a PEGlyated DSPE to 
facilitate stealth NPs formulation to escaped from recognition by the RES and thus 
increase the systemic circulation time of the LPNPs (Yamamoto et al., 2001); and (iii) 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-5000] 
(DSPE-PEG5k-FOL), a PEGylated DSPE of longer PEG chains for the LPNPs to be 
functionalized by folic acid conjugation for targeted delivery purpose. From now on 
we use LPNPs to denote the docetaxel loaded nanoparticles of the mixed DLPC and 
DSPE-PEG2k shell and PLGA core, which have no targeting function, and TLPNPs to 
denote the docetaxel loaded nanoparticles of the mixed DLPC, DSPE-PEG2k and 
DSPE-PEG5k-FOL shell and PLGA core, which have targeting function to the cancer 
cells of folate receptors overexpression. Such kind of ligand conjugated nanoparticles 
of mixed lipid monolayer shell and biodegradable polymer core are expected to 
combine the desirable characteristics of liposomes and polymeric NPs while exclude 
some of their intrinsic limitations as well as to precisely control the targeting effect by 
adjusting the component lipid ratio, and thus to evolve a fascinating opportunity to 
develop new drug delivery systems. 
 
4.2 Materials and methods 
4.2.1 Materials 
Docetaxel (anhydrous, 99.56%) was purchased from Shanghai Jinhe Bio-Technology 
Co. Ltd, China. Taxotere
®
 was provided by National Cancer Center (Singapore). 
 91 
 
PLGA (75:25, Mw: 90,000-126,000), 1,2-didodecanoyl-sn-glycero-3-phosphocholine 
(synonyms: 1,2-dilauroyl-sn-glycero-3-phosphocholine or DLPC, C32H64NO8P), folic 
acid, sucrose, methanol, ethanol, DCM, ACN, DMSO, coumarin-6, PBS (pH 7.4), 
MTT, trypsin-EDTA solution and PI were all purchased from Sigma-Aldrich (St. 
Louise, MO, USA). DSPE-PEG2k was provided by Lipoid GmbH (Ludwigshafen, 
Germany). Poly [ethylene glycol]-5000 bis-amine (PEG5k bis-amine) was offered by 
Laysan Bio (Arab, AL, USA). DSPE-PEG5k-FOL was synthesized by carbodiimide 
chemistry as previously reported (Lee and Low, 1995; Wu et al., 2006). Tween-80 was 
from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was provided by USB 
Corporation (OH, USA). FBS was purchased from Gibco Life Technologies (AG, 
Switzerland). Penicillin-streptomycin solution was from Invitrogen. DMEM was from 
Sigma. All solvents used in this study were HPLC grade. MCF7 breast cancer cells and 
NIH/3T3 fibroblast cells were provided by American Type Culture Collection. The 
water used was pretreated with the Milli-Q
®
 Plus System (Millipore Corporation, 
Bedford, USA). 
4.2.2 Preparation of the NPs 
Weighed amount of PLGA and docetaxel were dissolved in DCM to form the oil phase. 
For TLPNPs, weighed amount of DLPC, DSPE-PEG2k, and DSPE-PEG5k-FOL (molar 
ratio = 85:10:5) were dispersed in ultrapure water by sonication to form the aqueous 
phase. For LPNPs, the aqueous phase consists of DLPC and DSPE-PEG2k as molar 
ratio of 85:15. The oil phase was then poured into the water phase and the mixture was 
sonicated by probe ultrasonicator under ice bath. DCM was evaporated from the 
emulsion by magnetic stirring. The suspension was centrifuged at 12,000 rpm for 15 
minutes at 4 
°
C to collect the nanoparticles. After washing three times, the 
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nanoparticles were resuspended in the water of designated volume with 3% w/w 
sucrose as cryoprotectant and freeze-dried to obtain the fine powder. The fluorescent 
LPNPs and TLPNPs were fabricated in a same way with drug replaced by coumarin-6. 
4.2.3 Characterization of the NPs 
Data were expressed as the means with 95% confidence intervals. Statistical tests were 
performed with the Student‟s t test. For all tests, P values less than 0.05 were 
considered to be statistically significant. All statistical tests were two-tailed. 
The particle size and size distribution of the drug loaded NPs were measured by 
dynamic light scattering (90Plus, Brookhaven Instruments Co. USA). The dispersion 
of NPs was diluted by ultrapure water according to the mass concentration and 
completely sonicated before measurement. 
The amount of docetaxel encapsulated in the NPs was measured by high performance 
liquid chromatography (Agilent LC1100). A reversed phase Inertsil
®
 ODS-3 column 
(250×4.6 mm, particle size 5 µm, GL Science Inc., Tokyo, Japan) was used. 3 mg 
freeze-dried NPs were dissolved in 1 ml DCM. After evaporating DCM, 3 ml mobile 
phase (50:50 v/v acetonitrile/water solution) was added to dissolve the drugs. The 
solution was then filtered by 0.45 μm PVDF syringe filter for HPLC analysis. The 
column effluent was detected at 230 nm with a UV/VIS detector. The EE is calculated 
as (actual amount of drug encapsulated in NPs) / (initial amount of drug used in the 
fabrication of NPs) × 100%. 
The surface charge of the the drug loaded NPs was determined by ZetaPlus zeta 
potential analyzer (Brookhaven Instruments Co. USA) at room temperature in water. 
 93 
 
The suspension of NPs was diluted by ultrapure water. The pH value and concentration 
of the NPs dispersion were fixed before measurement. 
The shape and surface morphology of the NPs were investigated by field emission 
scanning electron microscope (JSM-6700F, JEOL, Japan). The layer of the NP powder 
was obtained on copper tape for FESEM under reduced pressure from the particle 
dispersion. The dried particles were then coated by platinum carried out by the Auto 
Fine Coater (JEOL, Tokyo, Japan). 
The surface chemistry of the NPs was studied by X-ray photoelectron spectroscopy 
(AXIS His-165 Ultra, Kratos Analytical, Shimadzu Corporation, Japan) to confirm the 
existence of lipid coating on the surface of the NPs. The elements on the NP surface 
were identified according to the specific binding energy (eV), which was recorded 
from 0 to 1200 eV with pass energy of 80 eV under the fixed transmission mode. The 
data were processed by specific XPS softwares. 
4.2.4 In vitro evaluation 
For the controlled release study, the drug loaded NPs were dispersed in PBS (0.1 M, 
pH 7.4) containing 0.1% w/v Tween-80, which can improve the solubility of docetaxel 
in PBS. The dispersion was then put in an orbital shaker shaking at 120 rpm with water 
bath at 37°C. At designated time intervals, the suspension was centrifuged at 12,000 
rpm for 30 min. The pellet was resuspended in fresh medium to continue the release. 
The drug released in the supernatant was extracted by DCM and transferred in the 
same mobile phase. After the evaporation of DCM, docetaxel quantity was determined 




MCF7 breast cancer cells, which are of folate overexpression, and NIH/3T3 fibroblast 
cells, which lack folate overexpression, were employed in this work. The DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin was utilized as the cell 
culture medium. Cells were cultivated in humidified environment at 37°C with 5% 
CO2. Before experiment, the cells were pre-cultured until confluence was reached to 
75%.  
For quantitative cellular uptake analysis, MCF7 cells were seeded into 96-well black 
plates (Costar, IL, USA) at 5×10
3
 cells/well (0.1 ml) and after the cells reached 80% 
confluence, the medium was changed to the suspension of coumarin-6 loaded NPs at a 
NP concentration of 0.250 mg/ml for 0.5 and 2.0 h, respectively. After incubation, the 
NP suspension in the testing wells was removed and the wells were washed with 0.1 
ml PBS three times to remove the NPs outside the cells. After that, 50 μl of 0.5% 
Triton X-100 in 0.2 N NaOH solution was added to lyse the cells. Microplate reader 
(Genios, Tecan, Switzerland) was used to measure the fluorescence intensity from 
coumarin 6 loaded NPs in the desired wells with excitation wavelength at 430 nm and 
emission wavelength at 485 nm. The cellular uptake efficiency was expressed as the 
percentage of the fluorescence of the testing wells over that of the positive control 
wells. 
For fluorescent microscope study, MCF7 and NIH/3T3 cells were cultivated in the 8-
well coverglass chamber (LAB-TEK
®
, Nagle Nunc, IL) till 70% confluence. The 
fluorescent NPs dispersed in the cell culture medium at concentration of 0.250 mg/ml 
were added into the wells. Cells were washed three times after incubation for 0.5 and 2 
h and then fixed by 70% ethanol for 20 mins. The cells were further washed thrice by 
PBS and the nuclei were then counterstained by PI for 45 mins. The fixed cell 
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monolayer was finally washed thrice by PBS and observed by confocal laser scanning 
microscope (Olympus Fluoview FV1000). 
For cytotoxicity measurement, MCF7 cells were incubated in 96-well transparent 
plates (Costar, IL, USA) at 5×10
3
 cells/well (0.1 ml) and after 12 h, the old medium 
was removed and the cells were incubated for 24, 48 h and 72 h in the media 
containing Taxotere
®
 or docetaxel loaded NPs at the equivalent drug concentration of 
25, 10, 2.5, 0.25 μg/ml. The NPs were sterilized with UV irradiation for 1 day prior to 
use. MTT assay was used to measure the cell viability at given time intervals. The 
absorbance of the wells was measured by the microplate reader with wavelength at 570 
nm and reference wavelength at 620 nm. Cell viability is defined as the percentage of 
the absorbance of the wells containing the cells incubated with the drug contained 
dosage over that of the cells only.  
 
4.3 Results and discussion 
4.3.1 Fabrication of the NPs 
The schematic structure of such kind of LPNPs is represented in Figure 4.1. The 
LPNPs were produced by the oil-in-water single emulsion and solvent evaporation 
method with the mixed lipids as emulsifiers (Feng et al., 2007). After emulsification of 
the oil phase in the aqueous phase by applying ultrasonication, the amphiphilic lipids 
were adsorbed on the surface of oil droplets containing PLGA and docetaxel by 
hydrophobic interaction. Followed by the evaporation of DCM under continuous 
magnetic stirring, the drug loaded NPs can be collected. DLPC was introduced as the 
major stabilizer to facilitate formation of the solid PLGA cores. The HLB of DLPC is 
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calculated as around 13 by the equation: HLB value=∑ (Hydrophilic groups) + ∑ 
(Lipophilic groups) + 7, which is appropriate to stabilize oil-in-water emulsions, thus 
promoting to form solid polymeric cores. DSPE-PEG2k, the PEGlyated DSPE, was 
selected to facilitate stealth NPs formulation to be escaped from the recognition by the 
RES and thus increase the systemic circulation time of the LPNPs. DSPE-PEG5k-FOL, 
a PEGylated DSPE of longer PEG chains functionalized by folic acid conjugation was 
employed for providing the LPNPs for targeted delivery capability. PEG5k, the space 
linker with longer chain length was selected since it could ensure better recognition of 
the targeting moiety on the NPs surface by the receptors (Shiokawa et al., 2005).  
 
Figure 4.1 Schematic illustration of the formulation of TLPNPs. The NPs comprise a 
PLGA core, an amphiphilic lipid monolayer shell on the surface of the core, a stealth 
lipid shell, and a targeted lipid corona. 
 
4.3.2 Characterization of the NPs 
Table 4.1 illustrates the characteristics of the drug loaded LPNPs and TLPNPs. The 
general sizes of the two formulations measured by DLS are in the range of 200 to 300 
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nm with polydispersity of 0.130 to 0.160, which is not wide size distribution. It can be 
shown that the DLPC is helpful in stabilizing polymeric NPs in the aqueous phase. 
Including the DSPE-PEG5k-FOL in the lipid monolayer shell increased the 
hydrodynamic diameter of the LPNPs in that the longer chain length of PEG5k had 
more significant effect on the nanoparticle size than that of the PEG2k in DSPE-PEG2k. 
The drug encapsulation efficiency of the NPs is crucial to justify their clinical 
applications. Table 4.1 shows the EE of the two types of NP formulations. It can be 
attributed that the EE not as high as 100% to the interaction between the lipids and 
docetaxel (Feng and Huang, 2001). The excess lipids might either form lipid vesicles 
that entrap certain amount of drugs or absorb drugs via hydrogen bonding or 
hydrophobic-hydrophobic interaction. Subsequently, the vesicles or the complex of 
excess lipid molecules and drug molecules will be washed away in the washing 
process. However, after all, the reasonable EE values prove the effectiveness of the 
NPs of lipid monolayer shell and polymer core to load anticancer drugs. Obviously, 
such a novel formulation demonstrates the prospect for a practically useful drug 
delivery carrier with appropriate size, stability and drug loading capacity. 
Surface charge is an important indication for the stability of a colloidal system in 
medium. The repulsion among the nanoparticles with the same type of surface charge 
provides extra stability. The zeta-potential of the drug loaded LPNPs and TLPNPs also 
shown in Table 4.1 indicates the negative charges on the nanoparticle surface. It is due 
to the overall negative charges of the lipids and PLGA. The lower absolute value of the 
zeta potential of TLPNPs than that of the LPNPs results by the shield of longer PEG 
chains on DSPE-PEG5k-FOL. 
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Table 4.1 Characteristics of docetaxel loaded LPNPs and TLPNPs: particle size, size 
distribution, zeta-potential and drug encapsulation efficiency. Data represent mean ± 













203.8 ± 7.5 0.130 ± 0.030 -26.12 ± 1.16 60.46 ± 0.25 
TLPNPs
 
263.6 ± 8.7 0.160 ± 0.032 -20.74 ± 1.21 66.88 ± 0.67 
 
4.3.3 Surface morphology 
FESEM was used to image the morphology of the LPNPs and TLPNPs (Figure 4.2). It 
is revealed in FESEM image that the NPs are generally spherical in shape with narrow 
size distribution. The particle sizes observed from the FESEM image are in good 
agreement with that determined by the DLS. However, few larger spheres attached 
with each other might be attributed to the low solubility of DLPC in water, thereby the 
little excess amount of which still surrounds the solid polymeric particles or 
simultaneously forms large vesicle-like aggregators. 
 




4.3.4 Surface chemistry 
The existence of elements on the surface of samples was presented by specific binding 
energy (eV) on XPS spectrum. The elements on the NP surface were identified 
according to the specific binding energy (eV), which was recorded from 0 to 1200 eV 
with pass energy of 80 eV under the fixed transmission mode. The data were processed 
by specific XPS softwares. For proving the successful surface coating of lipids on 
PLGA cores, phosphorous was specifically scanned in that phosphorous only exists in 
lipid molecules. From Figure 4.3, the distinct peak of signals from 2p orbital of 
phosphorous (P 2p) qualitatively verifies that lipid molecules embrace PLGA cores 
since only lipid molecules consist of phosphorous. Meanwhile, the conjugation of folic 
acid on the NPs surface was proved via N 1s signals. Two peaks (left: folic acid, right: 
lipids) were detected from the TLPNPs, while only one peak was detected from the 
LPNPs. Therefore, it can be confirmed that lipid molecules coat polymer matrix as 
well as certain amount of folic acid conjugated lipids stay on the surface of TLPNPs, 
which could be assumed that the targeting ligands can be detected by corresponding 
receptors on cell membranes. 
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Figure 4.3 XPS peaks of the NPs. Wide scan spectra (bottom), P 2p signal spectra (left 
inset) and N 1s signal spectra (right inset) were shown in the figure. 
  
4.3.5 In vitro drug release 
The in vitro drug release profiles of the docetaxel loaded LPNPs and TLPNPS in 168 
hours are shown in Figure 4.4. From the data, for TLPNPs, an initial burst of 18.38% 
in the first 12 hours can be observed. This relatively speedy release formed by certain 
amount of docetaxel stayed on the surface of the NPs is helpful to suppress the growth 
of cancer cells in short time. In the following 72 hours, the cumulative release percent 
reached 60.94%, and the release presents a sustainably increased manner, which 
provides the possibility to continually fight against cancer cells, resulting in the 
decreased cancer cell viability (shown in the section of in vitro cytotoxicity below). 
The cumulative release percent almost achieved almost 90% after 7 days, showing a 
virtually full released ability of the NP formulation. It is known that in the short period 
of time, the release of hydrophobic drugs from PLGA NPs is dominantly due to 
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diffusion. Hence the reason of fast release of docetaxel is possibly due to the strong 
interaction between lipid molecules and drug molecules, therefore drugs are more 
likely to diffuse from PLGA matrix to lipid monolayers. Meanwhile, water molecules 
are attracted by the hydrophilic parts of lipid molecules and permeate into the lipid 
monolayers, thus leading to the fast diffusion of drugs. Comparatively, the drug release 
from the LPNPs shows similar behavior to that of TLPNPs apart from the little faster 
rate. It is highly due to the shorter chain length of PEG2k, resulting in the weaker 
shielding of lipid monolayers on polymer cores and easier permeation of water into 
lipid monolayers. All in all, the generally sustained and controlled release profile of 
docetaxel facilitates the application of the NPs of lipid shell and polymer core for the 
delivery of anticancer drugs. 


































Figure 4.4 In vitro docetaxel release profile from the LPNPs (upper curve) and 
TLPNPs (lower curve). Data represent mean ± SE, n=3.  
 
4.3.6 In vitro cellular uptake 
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The cellular uptake of the LPNPs and the TLPNPs was examined to demonstrate the 
penetration of the nanoparticles into the cells and the targeting effects of the 
nanoparticles conjugated with folic acid. The internalization of coumarin-6 loaded NPs 
incubated for 2 hours was visualized by CLSM. In Figure 4.5, the fluorescence from 
the NPs internalized in MCF7 human adenocarcinoma cells and NIH/3T3 murine 
fibroblast cells were shown in Row 1, 2 and 3, 4, respectively. Row 1 and 3 show the 
images of the cells incubated with the LPNPs of no targeting effect, and Row 2 and 4 
show the TLPNPs with targeting effect. The images obtained from the FITC channel 
which shows the green fluorescence of the coumarin-6 loaded LPNPs are shown in 
column A; the column B lists the images obtained from the PI channel which show the 
nuclei in red fluorescence stained by the propidium iodide; and column C lists the 
images obtained from the merge channels of FITC and PI, from which it can be seen 
that , the red fluorescence representing the nucleus stained by PI is circumvented by 
green fluorescence representing the coumarin-6 loaded NPs internalized in the 
cytoplasm. Hence, the qualitative cellular uptake can be visually verified by the CLSM 
images. In addition, the folate receptor (FR) targeted behavior of the TLPNPs can also 
be examined. Folic acid, an oxidized form of folate, is an attractive target ligand due to 
its high binding affinity for the folate receptors (Kd ~ 10
-10
 M). Folic acid is able to be 
efficiently internalized into the cells through the receptor-mediated endocytosis even 
when conjugated with a wide variety of molecules (Leamon and Low, 1991; Yoo and 
Park, 2004). Folic acid and its conjugate were widely used for selective delivery of 
anticancer agents to cells with folate receptors. In the condition of the same exciting 
laser intensity from the same confocal microscope, viewing row 1 and 2, after 
incubating 2 hours, the fluorescence of TLPNPs in the cytoplasm (row 2) is much 
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brighter than that of the LPNPs (row 1). It can be explained that RME facilitates and 
promotes the entry of NPs into cells when folate targeted NPs meet the overexpressed 
folate receptors (FR (+)) on MCF7 cells (Lee et al., 2003; Decuzzi and Ferrari, 2007). 
While for NIH/3T3 cells without overexpressed folate receptors (FR (-)) (Pan and 
Feng, 2009), the fluorescence in cytoplasm does not display distinct difference 
between the LPNPs and the TLPNPs.  
 
Figure 4.5 CLSM images show the internalization of fluorescent NPs in cells (2 hours 
incubation). Column A: FITC channels showing the green fluorescence from 
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coumarin-6 loaded NPs distributed in cytoplasm. Column B: PI channels showing the 
red fluorescence from propidium iodide stained nuclei. Column C: Merged channels of 
FITC and PI channels. Row 1 and 2: MCF7 cells were used. Row 3 and 4: NIH/3T3 
cells were used. In row 1 and 3, LPNPs were used while in row 2 and 4, TLPNPs were 
used.  
 
A quantitative analysis of cellular uptake efficiency was conducted by measuring 
percentage of the NPs used in incubation which have been entrapped in the cells. The 
same concentration of well dispersed NPs (250 μg/ml) as used in the previous CLSM 
was applied in this investigation. After 0.5 h and 2 h incubation, the cellular uptake 
efficiency of the LPNPs was measured to be 18.99 ± 0.75 % and 25.39 ± 0.54%, 
respectively. Instead, after 0.5h and 2h incubation, the cellular uptake efficiency of the 
TLPNPs was measured to be 26.24 ± 0.68 % and 39.09 ± 0.64 %, respectively. The 
targeting effect of folic acid conjugation is thus significant of 38.2% increment for 0.5 
h incubation and 54.0% increases for 2 h incubation, respectively (Figure 4.6, two-
tailed student‟s t test, P <0.05). The mechanism of the in vitro cellular uptake of the 
LPNPs can be assumed to be the carrier-mediated endocytosis and cell fusion (Ito et al., 
1991). Due to the existence of lipids on the NPs‟ surface, which are similar to the cell 
membrane conmponent, the uptake of the NPs is facilitated by the mutual interaction 
between the NPs and the cell membrane. For the TLPNPs, the RME can further 


































Figure 4.6 The diagram of in vitro cellular uptake efficiency at 0.5 h and 2 h 
incubation. TLPNPs show greater efficiency than LPNPs under the same incubation 
time. Data represent mean ± SE (shown as plus SE only), n=6. 
 
4.3.7 In vitro cytotoxicity 
The efficacy of the formulations to defeat cancer cells is reflected by their cytotoxicity. 
It is shown in Figure 4.7A-C that for the cancer cells incubated with Taxotere
®
 at 25, 
10, 2.5, and 0.25 μg/ml drug concentration, the cell viability shows the drug 
concentration and incubation time dependent trend.  For the cytotoxicity of the NP 
formulations, the same concentration 25, 10, 2.5, and 0.25 μg/ml of the drug, which is 
encapsulated in the NPs, were applied. The lowest cell viability, i.e. the highest cell 
mortality, appeared at the highest concentration of the various formulations after 
treatment for the longest time, which proves the controlled and sustained efficacy of 
the NP formulation (In all cases, P < 0.05 under the two-tailed student‟s t test). 
Furthermore, the NP formulations prevent the toxic effect of the drug applied at high 
concentration of drugs (25 μg/ml) and thus can increase the maximum tolerable dose. 
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Such a high concentration of drug instantly exposed in blood is presumed to be toxic 
not only for the cancer cells but also for the normal cells since it has exceeded the 
suggested maximum tolerable level of docetaxel (2,700 ng/ml) (Feng et al., 2009).  It 
is also clear that the TLPNPs formulation demonstrated higher cytotoxicity than the 
LPNPs formulation at the same drug concentration and exposure time resulting by the 
targeting effect, which means that for the same therapeutic effect, the drug needed for 
the TLPNPs formulation could be much less than that for the LPNPs formation and 
Taxotere
®
. The development of the TLPNPs formulation thus can enhance the 
therapeutic effect as well as to decrease the side effects of docetaxel.  
A quantitative evaluation of the in vitro therapeutic effect of a dosage form is IC50, 
which is defined as the drug concentration needed to kill 50% of the incubated cells in 
a designated time period. It can be calculated from the above in vitro cellular viability 
data that the IC50 after 24 h treatment is 0.0509 μg/ml for Taxotere
®
, 0.00658 μg/ml for 
the LPNPs formulation and 0.00323 μg/ml for the TLPNPs formulation, which means 
the TLPNPs formulation to be 50.91% more effective than the LPNPs formulation and 
93.65% more effective than Taxotere
®














































































Figure 4.7 The diagrams of cell viability at various concentrations of the drug under 24 
h (A), 48 h (B), and 72 h (C) treatment. Compared with LPNPs, TLPNPs show higher 






Two systems of the lipid shell polymer core NPs, i.e. the nanoparticles of mixed lipid 
monolayer shell and biodegradable polymer core and the ligand-conjugated 
nanoparticles of mixed lipid monolayer shell and biodegradable polymer core, were 
successfully developed in this research for sustainable, controlled and targeted delivery 
of anticancer drugs with docetaxel as a model drug. The mixed lipid monolayer shells 
provide the nanoparticles with the natural property, high stability, desired surface 
properties in favor of cellular uptake, stealth feature of long half life in the plasma, and 
most importantly, quantitative (exact) management of the targeting effect by adjusting 





Chapter 5 : Development of New TPGS Surfactants Coated 
Nanoparticles of Biodegradable Polymers for Targeted Anticancer 
Drug Delivery 
This research focused on engineering biodegradable nanoparticles by a series of new 
surfactants for new-concept chemotherapy aiming to achieve greater efficacy against 
cancer over traditional chemotherapy and the nanoparticles constructed by 
conventional surfactant. Synthesis of the new surfactant materials TPGS2k, TPGS5k 
and TPGS2kNH2 was conducted by carbodiimide chemistry. The surfactants were 
used for the fabrication of docetaxel loaded polymeric nanoparticles. Characterizations 
and in vitro evaluation of the new formulations were carried out to demonstrate the 
potential for chemotherapy. Analysis of the new nanoparticle formulations was 
fulfilled by comparison to the conventional surfactant TPGS1k coated particles and 
also to the particles without surfactant. Characteristics of the new nanoparticles in 
terms of size, size distribution, surface charge and surface morphology were similar. 
However, the new formulations were superior in terms of drug loading, cellular uptake 
efficiency and cytotoxicity. In addition, targeting effect by folic acid conjugation to the 
new surfactant coated nanoparticles was also evaluated. The targeted formulation to 
folate receptors was proved to be effective in increasing in vitro cellular uptake 
efficiency and cytotoxicity. Consistent evaluation and analysis on the novel 
formulations evolve a fascinating opportunity to continuously engineer the new drug 





Although chemotherapy is a complicated procedure and carries a high risk due to 
dosage form, drug toxicity, restricted pharmacokinetics and pharmacodynamics, severe 
side effects and drug resistance at various physiological levels (Feng, 2006), 
chemotherapy has still played important role in fighting against cancer due to the 
systemic property. With the emerging of nanotechnology to engineer chemotherapy, 
the problems could be readily solved by new-generation nanoscaled drug carriers. 
Among various types of nano-systems, nanoparticles of biodegradable polymers may 
provide an ideal solution for the problems encountered in current regimen of 
chemotherapy owing to their unique properties such as the small size, acceptable 
biocompatibility, high drug encapsulation efficiency especially for hydrophobic drugs, 
controlled and sustained drug release manner, high cellular uptake efficiency, desired 
pharmacokinetics, long circulation half-life, and highly tailored functions (Cho et al., 
2008; Tong and Cheng, 2007; Zhang et al., 2008a). With the aid of NPs, the problems 
of traditional chemotherapy, i.e. the dosage form, toxicity, severe side effects, and 
unfavorable pharmacokinetics could be settled with satisfaction. Furthermore, new-
concept chemotherapies can be progressively promoted which may include sustained, 
controlled and targeted delivery of chemotherapeutic drugs; personalized 
chemotherapy; delivery of therapeutic agents across physiological drug barriers; and 
eventually, chemotherapy at home (Feng, 2004).  
However, at present, NPs should be appropriately engineered to overcome several fun-
damental problems and technical barriers for anticancer drug delivery (Nie, 2010), 
such as escape from the recognition by RES, ability of long enough circulation lifetime, 
accumulation in the vicinity of solid tumors and targeting the cancerous cells (Dreher 
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et al., 2006; Minchinton and Tannock, 2006). The effective solution is to engineer NPs 
by tuning their size, shape, surface area, surface charge, as well as surface chemical 
property. Among those characteristics of NPs, surface property plays a key role in 
determining the performance on chemotherapy in the aspects of 1) enhancing the 
circulation time of the NPs, which results by avoiding the capture by phagocytic 
system and escaping from the adsorption of proteins in bloodstream; 2) prompting 
cellular uptake efficiency benefiting from higher interaction of the surface of NPs with 
the cell membrane; and 3) decorating NPs surface to achieve designed chemotherapy 
by coating with various functional materials and/or conjugating desired targeting 
ligands. It is highly anticipated to achieve the desired surface properties through 
introducing versatile materials to coat on the NPs. 
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS1k) surfactants are 
amphiphilic macromolecules comprising the hydrophilic PEG segment and 
hydrophobic tocopherol (vitamin E) segment (Sadoqi et al., 2009). TPGS1k was 
proved as a favorable material for nanoparticle formation for drug delivery (Win and 
Feng, 2006; Feng et al., 2007). Moreover, due to its bulky lipophilic segment, TPGS1k 
was thought to possess properties such as better drug solubilization, high 
emulsification effect, high drug encapsulation efficiency, high cellular adhesion and 
adsorption (Feng et al., 2009; Gao et al., 2009; Mu and Seow, 2006). TPGS1k was also 
proved to be able to effectively block P-glycoprotein efflux pump which is a major 
component in the multi-drug resistance system expressed on a lot of cancerous cells 
that removes the drug molecules from the cancerous cells, thus alleviating 
bioavailability of the drug (Dintaman and Silverman, 1999; Mu and Feng, 2002). 
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Inhibition of P- glycoprotein allows drugs to be retained within the pathological cells 
enabling drug concentration to keep effective doses to kill the cells.  
Nonetheless, the chain length of PEG in TPGS1k (Mw = 1,000) is not long enough to 
fulfill the requirement of avoiding RES scavenging and protein adsorption. It is widely 
believed that, however, only molecular weight of PEG not shorter than 2,000 could 
achieve those benefits (Kah et al., 2009; Owens and Peppas, 2006). In 2006, 
researchers synthesized a series of TPGS analogues with a variety of PEG chain length 
and indicated that the transportation of rhodamine 123 in Caco-2 cells was influenced 
by the chain length of PEG (Collnot et al., 2006). It is thus inspired that the 
performance of the materials is related to the types of PEG molecules. Therefore, we 
would expect to modify the currently used TPGS1k to be better surfactant materials to 
formulate NPs for chemotherapy by conjugating longer PEG molecules as well as 
other functional PEG on the hydrophobic segment vitamin E. 
In this work, we synthesized a series of TPGS surfactants using various PEG to 
demonstrate the effectiveness of those new materials as the additives to nanoparticle 
formation for drug delivery and broaden the application of TPGS molecules to be a 
family of candidates for engineering NPs. It is expected that the new materials are able 
to display better performance than the conventional one. Functional TPGS was also 
produced to provide the possibility of active targeting to folate receptors overexpressed 
on lots of cancer cells after conjugating with folic acid, the widely applied small 
molecules of targeting with high affinity with the receptor. PLGA NPs were prepared 
by the nanoprecipitation method with TPGS as surfactants for sustained and controlled 
chemotherapy by using docetaxel as a prototype drug, which is one of the best 
antineoplastic agents aiming to a wide spectrum of cancers. The chemotherapeutic 
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engineering technology developed in this article devoid of toxic additives by preparing 
novel TPGS macromolecules coated PLGA NPs, which showed a variety of 
advantages over the commercial formulation of docetaxel, Taxotere
®
 and supply a lot 
more choices for engineering versatile NPs by selecting different TPGS molecules in 
the family.  
 
5.2 Materials and methods 
5.2.1 Materials 
Docetaxel (anhydrous, 99.56%) was purchased from Shanghai Jinhe Bio-Technology 
Co. Ltd, China. Taxotere
®
 was provided by National Cancer Center, Singapore. 
TPGS1k, PLGA (75:25, Mw = 90,000-126,000), monomethoxy PEG (MPEG, Mw = 
2,000 and 5,000, from now on, simply MPEG2k and MPEG5k, respectively), 
tocopherol succinate (or vitamin E succinate, simply, VES), dicyclohexylcarbodiimide 
(DCC), 4-(Dimethylamino) pyridine (DMAP), N-Hydroxysuccinimide (NHS), 
triethylamine (TEA), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDAC), folic acid, sucrose, methanol, ethanol, dichloromethane, diethyl ether, 
acetone, acetonitrile, dimethyl sulfoxide, coumarin-6, PBS (pH 7.4), MTT, and PI 
were purchased from Sigma-Aldrich (St. Louise, MO, USA). Poly [ethylene glycol]-
2000 bis-amine (PEG2k bis-amine) was offered by Laysan Bio (Arab, AL, USA). 
Tween-80 was from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was provided by 
USB Corporation (OH, USA). FBS, trypsin-EDTA solution and penicillin-
streptomycin solution were purchased from Invitrogen. DMEM was from Sigma. All 
solvents used in this study were HPLC grade. MCF7 breast cancer cells were provided 
 113 
 
by American Type Culture Collection. The water used was pretreated with the Milli-
Q
®
 Plus System (Millipore Corporation, Bedford, USA). 
5.2.2 Synthesis of various surfactants 
The surfactants were synthesized by carbodiimide chemistry. Briefly, tocopherol 
succinate was weighed and dissolved in DCM. MPEG2k or MPEG5k was also 
weighed and dissolved in DCM. Both the tocopherol succinate and MPEG were then 
added together with DCC and DMAP with stoichiometric ratio of 1:1:2:0.1 
respectively and left to stir overnight in nitrogen environment at dark. The solution 
was then filtered to remove by-product and precipitated in cold diethyl ether. The 
precipitate obtained was then washed by diethyl ether again and dissolved in water and 
dialyzed against water. The milky dispersion was filtered again to remove impurities 
and the filtrate was collected. D-α-tocopheryl polyethylene glycol 2000 succinate 
(TPGS2k) and D-α-tocopheryl polyethylene glycol 5000 succinate (TPGS5k) powder 
was obtained after freeze drying of the filtrate. For amine terminated TPGS, tocopherol 
succinate, PEG2k bis-amine, DCC and NHS were weighed and dissolved in DCM 
separately with stoichiometric ratio of 1:1.2:2:2 respectively. The solution was mixed 
with 20 μl of TEA and left to stir in a nitrogen environment at dark for 2 days. The 
solution was then filtered to remove by-product and precipitated in cold diethyl ether. 
The precipitate obtained was then washed by diethyl ether again and dissolved in water 
and dialyzed against water. The milky dispersion was filtered again to remove 
impurities and the filtrate was collected. D-α-tocopheryl amino polyethylene glycol 
2000 succinate (TPGS2kNH2) powder was obtained after freeze drying the filtrate. The 
1
H NMR spectra were collected on a Bruker ACF300 (300MHz) spectrometer using 
d6-DMSO as solvent. 
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5.2.3 Fabrication of surfactant coated PLGA NPs 
Nanoparticles were fabricated using the nanoprecipitation method. The aqueous phase 
was first prepared by dispersing various surfactants in ultrapure water (as 
concentration of 0.08mg/ml). PLGA was weighed and dissolved in acetone forming a 
10mg/ml oil phase. The oil phase was then added dropwise into 10 times of the 
aqueous phase while continuously stirring. The particle suspension was left to stir until 
all the solvent was evaporated. The particle suspension was then filtered and 
centrifuged and washed 3 times at 8,000 rpm for 15 minutes at 4°C. The powder of the 
NPs was obtained by freeze drying. The docetaxel loaded NPs were fabricated using 
the same method with the drug contained oil phase. The fluorescent NPs were 
fabricated as the same procedure except using coumarin-6 contained oil phase. 
Formulations without surfactant were prepared using the same method but replacing 
the aqueous phase with only ultrapure water. From now on, PLGA NP, T1k NP, T2k 
NP, and T5k NP are assigned in abbreviation to PLGA nanoparticles without 
surfactant, TPGS1k coated PLGA nanoparticles, TPGS2k coated PLGA nanoparticles, 
and TPGS5k coated PLGA nanoparticles, respectively. 
5.2.4 Conjugation of folic acid onto the TPGS2kNH2 coated PLGA NPs 
Post-conjugation strategy to conjugate folic acid to TPGS2kNH2 coated NPs was 
applied. Suspended NPs were mixed with folic acid at a molar ratio of 20:1. EDAC 
and NHS were added in excess and the suspension was stirred overnight before 
filtering through a filter paper. Filtrate collected was dispersed in ultrapure water and 
washed three times. The particles were collected and freeze dried. Similarly, T2kN NP 
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and T2k NP-FOL infer TPGS2kNH2 coated PLGA nanoparticles and the PLGA 
nanoparticles coated by TPGS2kNH2 and further conjugated by folic acid, respectively.  
5.2.5 Characterization of the NPs 
Data were expressed as the means with 95% confidence intervals. Statistical tests were 
performed with the Student‟s t test. For all tests, P values less than 0.05 were 
considered to be statistically significant. All statistical tests were two-tailed.  
The average particle size and size distribution of the NPs were measured using laser 
light scattering (90Plus Particle Sizer, Brookhaven Instruments Corporation, 
Huntsville, NY, USA) at a laser angle of 90° at 25°C. The sample was prepared by 
diluting the nanoparticle suspension with ultrapure water and sonicating for 1 minute 
to ensure homogenous dispersion of the particles. The surface charge of the NPs in 
water was measured using a zeta-potential analyzer (Zeta Plus, Brookhaven 
Instruments Corporation, Huntsville, NY, USA) at 25°C. The sample was prepared by 
diluting the nanoparticle suspension with ultrapure water and sonicating for 1 minute 
to ensure homogenous dispersion of the particles. The zeta potential was measured 
under certain pH value and concentration of the dispersion. The drug loading 
efficiency of the NPs was determined in triplicates by high performance liquid 
chromatography (Agilent LC 1100 series, USA). A reversed phase Inertsil
®
 ODS-3 
column (250×4.6 mm, particle size 5 μm, GL Science Inc., Tokyo, Japan) was used. 3 
ml of nanoparticle suspension with known amount of NPs was freeze dried, re-
dissolved in 1ml of DCM and left overnight to evaporate. 4 ml of mobile phase (50:50, 
v/v acetonitrile/water solution) was added and the solution was filtered using a 0.45 
μm PVDF syringe filter before being transferred to a HPLC vial. The effluent was 
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detected at 230nm with a UV-VIS detector. The drug loading is defined as the ratio 
between the mass of drug encapsulated in the NPs and the mass of the drug loaded NPs 
presented. 
The surface morphology of the NPs was visualized using field-emission scanning 
electron microscope (JSM-6700F, JEOL, Japan) at an accelerating voltage of 5 kV. 
The samples were prepared by placing a drop of the nanoparticle suspension on copper 
tape placed on top of a sample stub and left under reduced pressure to dry. The sample 
was then coated with a platinum layer using Auto Fine Coater (JEOL, Tokyo, Japan) 
for 30s at 30 mA current. 
The surface composition of the NPs was analyzed using X-Ray photoelectron 
spectroscopy (AXIS His-165 Ultra, Kratos Analytical, Shimadzu Corporation, Japan). 
The samples were analyzed using a fixed transmission mode covering a range of 
binding energy from 0 to 1100 eV with pass energy of 80 eV. Spectrum generation 
was performed using software provided by the instrument manufacturer. 
5.2.6 In vitro evaluation 
Cell line experiments were carried out using MCF7 human breast adenocarcinoma 
cells cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin 
as the antibiotics in humidified environment of 5% CO2 at 37°C. Growth medium was 
replenished every other day and subculture was performed when cells reached 80% 
confluence. 
For quantitative cellular uptake study, MCF7 cells were seeded into 96-well black 
plates (Costar, IL, USA) at 5 × 10
3
 cells/well (0.1ml) and after the cells reached 80% 
confluence, the medium was changed to the suspension of coumarin-6 loaded NPs at a 
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NP concentration of 0.125 mg/ml for 2 h. After incubation, the NP suspension in the 
testing wells was removed and the wells were washed with 0.1 ml PBS three times to 
remove the NPs outside the cells. After that, 50 μl of 0.5% Triton X-100 in 0.2N 
NaOH solution was added to lyse the cells. The fluorescence intensity present in each 
well was then measured by microplate reader (Genios, Tecan, Switzerland) with 
excitation wavelength at 430 nm and emission wavelength at 485 nm.  
For qualitative cellular uptake studies, MCF7 cells were seeded in a chambered cover 
glass system (LAB-TEK
®
, Nagle Nunc International, Naperville, IL, USA) in 
humidified environment of 5% CO2 at 37°C. After incubation of 24 h, the medium was 
replaced by coumarin-6 loaded nanoparticle suspension at a concentration of 0.125 
mg/ml. Cells were incubated again for 2 h and washed thrice with PBS. Cells were 
then fixated by addition of 75% ethanol for 20 min. Cells were further washed twice 
with PBS and nuclei counterstaining was carried out with propidium iodide for 45 min. 
Washing of the cells was carried out twice with PBS. Finally, the cells were observed 
using confocal laser scanning microscope (Olympus Fluoview FV1000) using a PI and 
FITC channel. 
For cytotoxicity study, MCF7 cells were seeded in 96-well transparent plates (Costar, 
IL, USA) at 5×10
3
 cells/well (0.1 ml) and after 12 h, the old medium was removed and 
the cells were incubated for 24, 48 and 72 h in the medium containing Taxotere
®
 or 
docetaxel loaded nanoparticle suspension at an equivalent drug concentration of 0.5, 
0.25, 0.1 and 0.025 μg/ml. The NPs were sterilized with UV irradiation for 1 day prior 
to use. At given time intervals, the cultured cells were assayed for cell viability with 
MTT. The wells were washed twice with PBS and 10 μl of MTT supplemented with 
90 μl culture medium was added. After 3 hr incubation, the medium was removed and 
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the precipitate was dissolved in DMSO. The absorbance of the wells was measured by 
the microplate reader (Genios, Tecan, Switzerland) with wavelength at 570 nm and 
reference wavelength at 620 nm. Cell viability was calculated by the following 
equation: cell viability = Abss / Abscontrol × 100%, where Abss is the absorbance of the 
wells containing the cells incubated with the nanoparticle suspension and Abscontrol is 
the absorbance of the wells containing the cells incubated with the culture medium 
only (positive control). 
 
5.3 Results and discussion 
5.3.1 Synthesis of various surfactants 
The class of TPGS surfactants was synthesized using the carbodiimide reaction. 
1
H 
NMR was applied to confirm the successful conjugation of PEG molecules with VES. 
Typically, the results of TPGS2k from the NMR analysis were shown in the Figure 5.1. 
This figure showed a comparison between MPEG2k, VES and the product of the 
reaction. Most peaks that occur in the spectrum of MPEG2k and VES also occur in the 
spectrum of the product, albeit slightly shifted, showing a strong resemblance between 
the structures of the basic compounds and the product as well as the change of 
chemical environment in the product. TPGS5k was synthesized similarly except using 
MPEG5k instead of MPEG2k. The functionalized material, TPGS2kNH2 was also 
synthesized using the carbodiimide reaction in the presence of NHS. The reaction 
resulted in the formation of a yellowish solid. Figure 5.2 showed a comparison 
between PEG2k bis-amine, VES and the product. All peaks that occur in the spectrum 
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of PEG and VES also occur in the spectrum of the product with slight shift, pointing to 
a successful synthesis of TPGS2kNH2. 








H NMR Spectra of MPEG2k, VES and TPGS2k.  












5.3.2 Fabrication of the NPs and conjugation of folic acid to the NPs 
The NPs were fabricated using the nanoprecipitation method. The surfactants dispersed 
in aqueous phase were subsequently adsorbed onto the surface of the nanoparticles due 
to hydrophobic interaction. Surface coating of nanoparticles was thus able to be 
achieved by using various desired surfactants. The surfactants used during the 
fabrication included TPGS1k, TPGS2k, and TPGS5k. TPGS1k is the conventional 
surfactant currently used which was used as a comparison to benchmark the 
effectiveness of the new surfactants introduced. 
The conjugation was proposed to fulfill the targeted delivery purpose aiming to target 
folate receptors overexpressed on cancerous cells by folic acid on the top of the NPs. 
Post-conjugation strategy was employed which was achieved via the aqueous phase 
carbodiimide reaction between folic acid and the free amine groups on TPGS2kNH2 
coated NPs using EDAC and NHS. The schematic diagram of the structure of the NPs 
and the reaction was illustrated in Figure 5.3. The merit of post-conjugation for 
attaching the targeting ligands onto nanoparticles is that it ensures the ligands to stay 
on the top of the particles but not buried inside the spheres. 
 
Figure 5.3 Schematic illustration of the structure of the nanoparticles and the post-




5.3.3 Characterization of the NPs 
The size and size distribution of the NPs with different surfactants was compared in 
Table 5.1. It can be seen that the particle size measured using LLS is between 200 to 
250 nm. The size of the NPs coated by the new surfactants, namely TPGS2k and 
TPGS5k falls close to that of TPGS1k coated NPs. The particles conjugated with folic 
acid are slightly larger in size due to the extra folic acid tail attached to the surface. 
The size distribution is quite narrow indicating that the NPs are quite uniform in size. 
A low variation would allow for better control of the properties of the NPs. 
The surface charge of the NPs indicates the stability of the particle dispersion. Surface 
charge that is highly negative or positive points to a stable colloidal suspension due to 
the high repulsion force between the particles of the same charge. Yet nanoparticles 
that are too negatively charged are believed to be hindered from crossing the cell 
membrane due to the negative nature of the membrane which might repel the 
nanoparticles. The NPs fabricated all have a negative surface charge below -19 mV. 
The negative surface charge of the NPs could be due to the ionized oxygen contained 
groups of PLGA. Surfactants stabilized NPs are less negative possibly because of 
shielding of the negative charge by the surfactants. The formulations with surfactants 
have a zeta potential close to -20 mV indicating that the NPs are stable in its 
suspension. Furthermore, the charges of the NPs are not too negative thus allowing the 
possibility of passage through the cell membrane. 
Drug loading is defined as the amount of drug encapsulated in a certain amount of 
nanoparticles and is represented by the units of μg drug per mg nanoparticles.  The 
 122 
 
drug loading of T2k NP and T5k NP are higher in comparison to other nanoparticle 
formulations, which suggests that new surfactants are more effective in ensuring more 
drugs entrapped within PLGA matrix.  
Table 5.1 Characteristics of the docetaxel loaded PLGA NPs with various surfactants: 
particle size, size distribution, zeta-potential and encapsulation efficiency. Data 









Drug loading (μg 
/ mg NP) 
NP 206.7 ± 2.9 0.065 ± 0.027 -42.57 ± 0.60 8.23 ± 0.026 
T1k NP 215.8 ± 2.7 0.035 ± 0.014 -21.48 ± 1.14 5.60 ± 0.040 
T2k NP 202.3 ± 6.1 0.069 ± 0.049 -22.21 ± 0.98 28.48 ± 0.110 
T5k NP 249.2 ± 16.6 0.225 ± 0.028 -24.91 ± 0.80 36.90 ± 4.170 
T2k NP-FOL 241.5 ± 4.3 0.150 ± 0.023 -19.00 ± 0.82 3.79 ± 0.054 
 
5.3.4 Particle morphology 
High-resolution images to study the surface morphology of the NPs were obtained 
using FESEM (Figure 5.4). Particles with different surfactants were shown to be about 
200-300 nm, consistent with the results obtained from LLS. In addition, the particles 
were revealed to be generally spherical in shape and uniform in size. The particles 
were also quite similar in visualization under using different surfactants. The surface of 
the NPs was also revealed to be smooth on the images. However, T2k NP-FOL 
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formulation was seen to be more adhesive than others which could be attributed to the 
bulky condition of the surface causing entanglement between particles after drying.  
 
Figure 5.4 FESEM images of (A) PLGA NP, (B) T1k NP, (C) T2k NP, (D) T5k NP, (E) 
T2kN NP, and (F) T2k NP-FOL. 
 
5.3.5 Surface chemistry 
In order to confirm the existence of the primary amine groups as well as the folic acid 
on the NPs‟ surface, surface chemical composition of the NPs was elucidated from the 
specific binding energy on the XPS spectrum. Figure 5.5 showed the wide scan 
comparison between TPGS2kNH2, T2kN NP and T2k NP-FOL. To prove the 
successful synthesis of TPGS2kNH2, nitrogen was specifically scanned. From the inset 
of Figure 5.5, a peak for nitrogen at a binding energy of 396 eV was observed in the 
XPS spectrum, indicating the successful conjugation of amino PEG onto VES resulting 
in the product. In addition, the nitrogen peak can be observed in the spectrum of both 
the T2kN NP and T2k NP-FOL, demonstrating the presence of the surfactant on the 
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surface of the NPs. The slight shift of the position of the nitrogen peak from the two 
NPs is possibly due to the change of the chemical environment in the vicinity of the 
surfactants, i.e. the presence of PLGA. The higher signal intensity from the nitrogen on 
T2k NP-FOL can be attributed to the presence of more nitrogen atoms in the chemical 
structure of folic acid (seven nitrogen atoms in one folic acid molecule). 
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Figure 5.5 XPS widescan spectra of the synthesized product TPGS2kNH2 (lower 
curve), T2kN NP (middle curve) and T2k NP-FOL (upper curve). The inset graph 
shows the N 1s spectra of those three with the same sequence. 
 
5.3.6 In vitro cellular uptake  
The ability of the particles to penetrate into the cells and be internalized and retained 
within the cell is important to achieve the objective of delivering drugs. Targeting 
effects of folic acid conjugation can also be examined. The qualitative cellular uptake 
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analysis was conducted by visualization of the internalized coumarin-6 loaded NPs 
using confocal laser scanning microscope. Figure 5.6 showed the images of the 
fluorescent nanoparticles internalized in MCF7 human adenocarcinoma cells. The 
images in Row A to E are of various nanoparticle formulations in the following order: 
NPs without surfactant, T1k NPs, T2k NPs, T5k NPs, and T2k NP-FOL. The images 
in column 1 were obtained using the FITC channel which reveals the green 
fluorescence of coumarin-6 loaded nanoparticles. Column 2 contains images obtained 
using the PI channel that highlights the nuclei stained by PI in red fluorescence. 
Column 3 lists the images that were overlaid by the FITC and PI channels. The images 
in column 3 show the nucleus of the cells surrounded by green fluorescence from the 
coumarin-6 loaded nanoparticles distributed in cytoplasm. The particles coated by the 
new surfactants were also successfully internalized with noticeably higher 
concentrations within the cell as can be seen from the brighter green fluorescence in 
the images. The comparison of the particles retained in the cells between folic acid 
conjugated NPs (T2k NP-FOL) with non-ligand attached NPs (T2k NP) demonstrated 
the folate receptor targeted behavior from the ligand conjugated NPs. In the condition 
of the same exciting laser intensity from the same confocal microscope, after 
incubating 2 h, the fluorescence distribution of T2k NP-FOL internalized in the 
cytoplasm (row E) is greater than that of T2k NP (row C). It can be explained that 
receptor-mediated endocytosis facilitates and promotes the entry of the NPs into cells 
when folate targeted NPs contact the overexpressed folate receptors on MCF7 cells 
(Yoo and Park, 2004). Apart from that, quantitative measurement also evidently 
displayed the higher cellular uptake efficiency of folic acid conjugated NPs. The 
efficiency is 42.8%, 14.3%, 23.1%, and 45.4% higher than the uptake of PLGA NPs, 
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T1k NPs, T2k NPs, and T5k NPs, respectively (two-tailed student‟s t test, P < 0.05). 
This suggests that the targeting effect of folic acid conjugation is significant after 
sufficient incubation time. The finding supports the hypothesis that the new surfactant 





Figure 5.6 CLSM images of the particles internalized in MCF7 cells. Row A to E 
shows PLGA NP, T1k NP, T2k NP, T5k NP, and T2k NP-FOL used, respectively.  
 
5.3.7 In vitro cytotoxicity 
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The efficacy of the drug delivery system was demonstrated in the cytotoxicity 
measurement (Figure 5.7). Lower cell viability or survival rate would translate to 
higher cytotoxicity. A general decreasing cell viability trend was observed with 
increasing incubation times for the different formulations tested. Longer incubation 
times would mean longer exposure of the cells to the nanoparticles carrying the drug 
allowing more time for the nanoparticles to internalize into the cells and release the 
loaded drugs in the cytoplasm, resulting in higher cell mortality. It was also observed 
that higher drug concentrations lead in lower cell viability, which is quite 
straightforward to understand. The highest cell mortality appeared at the highest 
concentration of the nanoparticle formulation after the longest treatment time 
suggesting that the drugs were released controllably and sustainably from the particles 
over a period of time, which is consistent with our previous study on nanoparticles 
(Feng et al., 2007). From this figure, the cell viabilities from the groups treated by 
nanoparticle formulations were found to be generally lower than that treated by 
Taxotere
®
, especially in the lower drug concentration groups, which infers the close 
even better capability of the nanoparticle formulations to defeat cancer cells. When 
compared the viability results of nanoparticles coated with the new surfactants with the 
traditional TPGS1k, most of the performance of T2k NPs and T5k NPs were clearly 
better, than T1k NPs, showing the value of those new materials to be further 
investigated.  
In addition, we notice that cell viability is lower with the use of T2k NP-FOL as 
compared to all of the other formulations in all of the drug concentration cases. This 
situation was also repeated at all treatment times. As the concentration of the drugs is 
the same, the lower viability of cells implies that the result could be due to the 
 129 
 
targeting effect of folic acid. As there was a propensity for nanoparticles conjugated 
with folic acid to accumulate within cancer cells, a higher concentration of the drug 
would be presented leading to higher cell mortality. The results also act in coordination 





























































































Figure 5.7 MCF7 cell viability measurement after 24 hr (A), 48 hr (B), 72 hr (C) 
treated by formulations of Taxotere
®
, T1k NP, T2k NP, T5k NP, and T2k NP-FOL at 
various drug concentrations.  
 
Quantitative analysis of the dosage form for in vitro therapeutic effect was carried out 
from the in vitro cell viability data. The IC50, defined as the drug concentration needed 
to kill 50% of the incubated cells in a designated time period, was calculated from the 
evaluation (Table 5.2). The IC50 value after 24 h treatment is 0.026 μg/ml for T2k NP 
and 0.0025 μg/ml for T2k NP-FOL. The results connote that the folic acid decorated 
nanoparticle formulation is 90.4% more effective than TPGS2k coated nanoparticle 
formulation after 24 h treatment and suggest that conjugation with folic acid to 






Table 5.2 IC50 values (μg/ml) of various formulations after different treatment times. 
 Taxotere
® 
T1k NP T2k NP
 
T5k NP T2k NP-FOL 
24 h 0.98 2.13 0.026 1.44 0.0025 
48 h 0.53 0.15 0.0068 0.014 0.0026 






A series of new TPGS analogues, TPGS2k, TPGS5k and TPGS2kNH2 were 
successfully synthesized in this study. Docetaxel loaded PLGA NPs using the new 
compounds as surfactant were also fabricated using the nanoprecipitation method. The 
NPs were characterized and the in vitro performance evaluated. Folic acid was 
conjugated as targeting ligand onto TPGS2kNH2 coated PLGA NPs for targeted 
chemotherapy. Comparison of the characteristics of PLGA NPs using new TPGS as 
surfactants to conventional TPGS1k shows similar properties in terms of size, size 
distribution, surface charge and surface morphology. The new surfactant coated NPs 
were shown to have higher drug loading and in vitro evaluation revealed that the new 
materials were able to grant the particles greater cellular uptake efficiency and 
cytotoxicity. The conjugation of folic acid on the nanoparticles significantly increased 
the ability of targeted NPs to penetrate into cancer cells and inhibit the growth of the 
cells, as revealed in the higher cellular uptake efficiency and cytotoxicity results, 
indicating the potential of such engineered nanocarriers to achieve targeted 
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chemotherapy. Therefore, the major contribution of this project is that new surfactants 
have been successfully developed for fabrication of PLGA NPs as nanocarriers for 
chemotherapy with even better characteristics. Meanwhile, the strategy provides the 
space using potent TPGS analogues for conjugation of versatile targeting ligands on 




Chapter 6 : A Strategy for Precision Engineering of Nanoparticles of 
Biodegradable Copolymers for Quantitative Control of Targeted 
Drug Delivery 
Research on quantitative control of targeting effect for the drug delivery system of 
ligand-conjugated nanoparticles of biodegradable polymers is at the cutting edge in the 
design of drug delivery device. In this work, we developed a post-conjugation strategy, 
which makes the ligand conjugation after the preparation of the drug loaded 
nanoparticles of two copolymers blend. We synthesized the PLGA-PEG copolymer 
with PEG functioning as the linker molecule needed for herceptin conjugation. 
Docetaxel loaded nanoparticles of the PLGA-PEG/PLGA copolymer blend were 
prepared by the nanoprecipitation method. Anti-HER2 antibody (heceptin), which 
targets the breast cancer cells of HER2 receptor overexpression, was conjugated on the 
drug loaded PLGA-PEG/PLGA nanoparticles for sustained, controlled and targeted 
delivery of docetaxel. We demonstrated that the targeting effect can be quantitatively 
controlled by two ways, i.e. (1) adjusting the copolymer blend ratio of the nanoparticle 
matrix, and (2) adjusting the herceptin feed molar ratio to NH2 in the linker molecules 
appearing on the nanoparticle surface. Compared with the pre-conjugation strategy, the 
post conjugation strategy provides more efficient use of the ligand and protects its 
bioactivity in the nanoparticle preparation process, thus resulting in better performance 
in drug targeting, which was assessed in vitro with SK-BR-3 breast cancer cells of 
HER2 receptor overexpression and MCF7 breast cancer cells of HER2 receptors 





Drug delivery device of controlled and targeted function can ideally deliver high dose 
of the therapeutic agent specifically to the diseased cells with the healthy cells less 
interfered, thus resulting in desired pharmacokinetics and biodistribution for higher 
therapeutic effect and fewer side effect. It has been arousing continuous interest in 
developing various advanced targeting strategies, among which ligand-conjugated 
nanocarriers may be the most prospective (Vetvicka et al., 2009; Ferrari, 2005; Sinha 
et al., 2006; Farokhzad and Langer, 2006; Farokhzad and Langer, 2009; Zhang et al., 
2008a). Polymeric nanoparticles are able to dissolve hydrophobic drugs in polymeric 
matrix, solving the drug solubility problem as well as possess the advantages such as 
high stability, efficient drug load, sustained drug release, enhanced circulation time in 
bloodstream and active targeting space for cancer cells (Cho et al., 2008; Feng et al., 
2007). A good example is the polymeric nanoparticle formulation of docetaxel, a 
potent anticancer drug approved by FDA for the treatment on a wide spectrum of 
cancers (Engels et al., 2007), which has aroused high attraction recently (Esmaeili et 
al., 2010; Zheng et al., 2010; Mei et al., 2009).  
Targeted drug delivery is of necessary importance to achieve “on-site” delivery. 
Passive targeting can be realized by the enhanced permeation and retention effect of 
the leaky vessels of tumors which allows the drug carrier of appropriate size and 
surface properties accumulated in the tumor. Active targeting presents a more 
promising approach, which can be realized by conjugating molecular probes or ligands 
onto the surface of the nanocarriers, providing drug delivery systems for reaching and 
penetrating into the malignant cells which are of overexpression of the corresponding 
receptors on their membrane, and then releasing the encapsulated therapeutics in the 
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diseased cells in a controlled and sustained manner (Wang et al., 2008). Among 
various targeting ligands, herceptin (or Herceptin
®
, the clinical formulation of 
Trastuzumab invented by Genentech), the first humanized antibody approved by FDA 
for the treatment of HER2-positive metastatic breast cancers, has widely appeared in 
recent studies (Smith, 2001; Vogel et al., 2002). It is known that HER2 overexpresses 
in 25-30% invasive breast cancers. Herceptin is managed to efficiently internalize into 
the cells through the receptor-mediated endocytosis even when conjugated with a wide 
variety of molecules (Muller et al., 2009; Senter, 2009). Herceptin and its conjugates 
with toxins or nanoparticle formulations were widely used for selective delivery of 
anticancer agents to cells with positive HER2 receptors (Tsai et al., 2009; Sun et al., 
2008; Sun and Feng, 2009; Phillips et al., 2008). 
Tailoring of the functional nanocarriers depends on the selection of matrix materials as 
well as functionalization of surface property. A good example in the literature is to use 
PLGA as the core of the NPs and PEG to facilitate functionalization of the 
nanoparticle surface by antibody conjugation. The PEG layer coated over the PLGA 
core makes the NPs stealth property which is basic to achieve passive targeting 
purpose. In addition, the functional PEG chains provide the reaction site for antibody 
decoration on the NPs (Duncan, 2003; Yamamoto et al., 2001). The results showed the 
qualitative targeting effects of the nanoparticles of the copolymer blend for cancer 
treatment while there have been only a few reports that demonstrate a quantitative 
effect for drug targeting. 
Precision engineering of the nanoparticles for targeted drug delivery means to develop 
a practical strategy that can control the quantity, i.e. the surface density, of the 
targeting ligand on the NP surface. Although little of such work could be found so far 
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from the literature, this task represents an important aspect at the cutting edge in the 
design of drug delivery systems for drug targeting. To certain extent, the ligand density 
on the surface of drug delivery systems is believed as one of the essential 
biophysicochemical properties as important as size, shape, charge, and surface 
hydrophilicity of the nanoparticle drug delivery system (Farokhzad and Langer, 2009). 
The control of the ligand density on the NPs surface exerts the carriers in a more 
precise manner as well as facilitates the balance between tissue penetration and cellular 
uptake, resulting in optimal therapeutic efficacy (Farokhzad and Langer, 2009). 
Recently, there are two strategies developed for quantitative control of the targeting 
effects by adjusting the ligand density on the nanoparticle surface. The first trial is 
through conjugation of ligand on the particle forming polymers before the nanoparticle 
formation, which we call the pre-conjugation method. The other is so-called the post-
conjugation method, i.e. to conjugate the ligand to the particles after the nanoparticle 
formation. For the pre-conjugation strategy, one copolymer such as PLGA-PEG of the 
nanoparticle matrix was firstly conjugated with targeting ligand, the NPs was then 
prepared by nanoprecipitation method (Gu et al., 2008). The disadvantage of such a 
strategy is clear. Only part of the ligand would appear on the nanoparticle surface with 
some of the ligand wasted within the polymeric matrix, leading to insufficient quantity 
of the targeting moieties on the nanoparticle surface. Moreover, the ligand distribution 
on the surface of each NP would not be uniform since the polymeric macromolecules 
with the ligand would not be evenly distributed in each NP. Furthermore, the ligand 
molecules are usually fragile biomolecules of complex conformation that may be 
inactivated in the organic solvent used in the NP preparation process, thus weakening 
the targeting effects. This strategy, therefore, is not as desired to precisely control the 
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targeting effect. For the post-conjugation strategy, instead, it used the ligand more 
efficiently and protects its bioactivity.  
In this study, we intend to show the feasibility of the post-conjugation strategy for 
quantitative control of the targeting effect by controlling the ligand density on the 
nanoparticle surface and to demonstrate its impact on the cellular uptake efficiency and 
cytotoxicity. To our knowledge, there is no report so far in the literature on the 
formulation of docetaxel by herceptin-conjugated nanoparticles of the PLGA-
PEG/PLGA copolymer blend. We demonstrate that the surface density of the ligand 
molecules can be precisely controlled by adjusting the ratio of the copolymers and the 
antibody. In fact, a linear relation between these two parameters can be achieved 
within certain range of the copolymer blend ratio. We synthesized PLGA-PEG block 
copolymer, which was then mixed with PLGA at a designated blend ratio to prepare 
the docetaxel loaded NPs of the copolymer blend. The distal primary amine groups on 
the PEG chain were utilized to conjugate the carboxylic groups on anti-HER2 antibody 
as the ligand to target HER2 receptors on breast cancer cells. The control on the ligand 
density on the NP surface was achieved by 1) using various designated ratio of PLGA-
PEG over PLGA, thus controlling the percentage of the amine groups on the surface; 
and 2) providing different initial amount of the antibody in the herceptin-nanoparticle 
conjugation process with a fixed blend ratio between the PLGA-PEG and the PLGA 
copolymers. The amount of the antibody conjugated on the NPs was measured by the 
Bradford assay. For the formulation of a designated ligand density, the ligand-
conjugated, drug loaded nanoparticles were characterized for their various 
physicochemical properties. The in vitro experiment was conducted by using SK-BR-3 
breast cancer cells of HER2 receptor overexpression and MCF7 breast cancer cells of 
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HER2 receptors moderate expression. The in vitro cellular uptake of the corresponding 
fluorescent dye loaded nanoparticles was investigated qualitatively by the confocal cell 
laser scanning microscope and quantitatively by the microplate reader. The in vitro 
viability was assessed by the MTT assay. The overall performance of the designed 
drug delivery carrier was evaluated by the whole results in consistency. 
 
6.2 Materials and methods 
6.2.1 Materials 
Docetaxel (anhydrous, 99.56%) was purchased from Shanghai Jinhe Bio-Technology 
Co. Ltd, China. Taxotere
®
 was provided by National Cancer Center (Singapore). 
Herceptin (20 mg in 0.95 ml) was offered by Singapore General Hospital. PLGA 
(50:50, Mw: 40,000-75,000), acetone, ethanol, dichloromethane, acetonitrile, dimethyl 
sulfoxide, coumarin-6, sucrose, PBS (pH 7.4), sodium borate, Bradford reagent (for 1-
1,400 μg/ml protein), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDAC), N-Hydroxysulfosuccinimide (Sulfo-NHS), MTT, trypsin-EDTA solution and 
PI were all purchased from Sigma-Aldrich (St. Louise, MO, USA). PLGA acid 
terminated (PLGA-COOH, 50:50, IV=0.4 dl/g) was provided by PURAC Biomaterials 
(Lincolnshire, IL, USA). Poly(ethylene glycol)-2000 bis-amine (PEG2k bis-amine) was 
offered by Laysan Bio (Arab, AL, USA). PLGA-PEG block copolymer was 
synthesized using PLGA-COOH and PEG bis-amine by carbodiimide chemistry as 
previously reported (Esmaeili et al., 2008; Murugesan et al., 2008). Tween-80 was 
from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was provided by USB 
Corporation (OH, USA). FBS and penicillin-streptomycin solution was purchased 
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from Invitrogen. DMEM was from Sigma. All solvents used in this study were HPLC 
grade. SK-BR-3 and MCF7 breast cancer cells were provided by American Type 
Culture Collection. The water used was pretreated with the Milli-Q
®
 Plus System 
(Millipore Corporation, Bedford, USA). 
6.2.2 Preparation of the NPs 
The NPs were prepared by the nanoprecipitation method with modification as reported 
in earlier publication (Cheng et al., 2007). Briefly, a weighed amount of PLGA with 
designated ratio between PLGA-PEG and docetaxel were dissolved in acetone to reach 
at 10 mg/ml concentration. 5 ml of such solution were subsequently added dropwise 
into 5 ml ultrapure water under vigorous stirring. The acetone was then evaporated 
under reduced pressure. The particle suspension was centrifuged at 8,000 rpm for 15 
minutes at 4 
°
C to collect the NPs. After washing twice, the NPs were resuspended in 
the water of designated volume with 3% w/w sucrose as cryoprotectant and freeze-
dried to obtain the fine powder. For blank (without drug load) NPs, only the polymers 
were dissolved in acetone. The fluorescent NPs were prepared in a same way with 
docetaxel replaced by coumarin-6. 
6.2.3 Herceptin conjugation and ligand surface density control 
Herceptin was diluted in borate buffer (pH 8.4) to acquire 1 mg/ml concentration as 
stock solution. Desired amount of various freeze-dried NPs powder was resuspended 
in borate buffer with designated volume of herceptin stock solution in the presence of 
EDAC and Sulfo-NHS to conjugate the free primary amine groups on the NPs surface 
with the carboxylic groups on the antibody molecules. After overnight reaction under 
room temperature with gentle end-to-end mixing, the NPs were collected by 
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centrifugation and further washed twice by borate buffer. The pellets were resuspended 
in ultrapure water for further characterization, while the supernatant after each 
centrifugation was collected and accumulated for measurement of the antibody 
concentration. Standard protocol of Bradford assay was employed for quantifying the 
concentration of the protein in the supernatant. The ligand amount on the NPs surface 
was thus obtained via reduction of the amount in the supernatant from the initial 
amount.  
6.2.4 Surface chemistry analysis 
The existence of herceptin on the NPs surface was confirmed by X-ray photoelectron 
spectroscopy (AXIS His-165 Ultra, Kratos Analytical, Shimadzu Corporation, Kyoto, 
Japan). The elements on the NPs surface were identified according to the specific 
binding energy (eV), which was recorded from 0 to 1200 eV with pass energy of 80 eV 
under the fixed transmission mode. The nitrogen element was particularly tested under 
fine mode with 0.5 eV as step. The data were processed by specific XPS software. 
6.2.5 Characterization of the NPs 
Data were expressed as the means with 95% confidence intervals. Statistical tests were 
performed with the Student‟s t test. For all tests, P values less than 0.05 were 
considered to be statistically significant. All statistical tests were two-tailed. 
The particle size and size distribution of the NPs were measured by dynamic light 
scattering (90Plus, Brookhaven Instruments Co., TX, USA). The dispersion of NPs 
was diluted by ultrapure water according to the mass concentration and completely 
sonicated before measurement. The surface charge of the NPs was determined by 
ZetaPlus zeta potential analyzer (Brookhaven Instruments Co., TX, USA) at room 
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temperature in ultrapure water. The pH value and concentration of the NPs dispersion 
were determined before measurement. The amount of docetaxel encapsulated in the 
NPs was measured by high performance liquid chromatography (Agilent LC1100). A 
reversed phase Inertsil
®
 ODS-3 column (250×4.6 mm, particle size 5 µm, GL Science 
Inc., Tokyo, Japan) was used. 3 mg freeze-dried NPs were dissolved in 1 ml DCM to 
break polymer matrix. After evaporating DCM, 3 ml mobile phase (50% ACN in water 
in volume ratio) was added to dissolve the extracted drugs. The solution was then 
filtered by 0.45 µm PVDF membrane for HPLC analysis. The column effluent was 
detected at 230 nm with a UV/VIS detector. The drug load is calculated as the weight 
of the drug encapsulated in the NPs divided the total weight of the NPs. The unit of 
drug load is mg drug per mg NPs. 
6.2.6 Particle morphology 
The shape and surface morphology of the NPs were investigated by field emission 
scanning electron microscope (JSM-6700F, JEOL, Tokyo, Japan). Samples were 
completely sonicated before dribbling onto copper tape. The thin layer of the NPs 
powder was obtained on copper tape for FESEM by evaporating water under reduced 
pressure. The dried particles were then coated by fine platinum carried out on the Auto 
Fine Coater (JEOL, Tokyo, Japan). 
6.2.7 In vitro drug release 
The drug loaded NPs were dispersed in PBS (0.1 M, pH 7.4) containing 0.1% (v/v) 
Tween-80, which improves the solubility of docetaxel in PBS to simulate the sink 
condition. The dispersion in tubes was then put in an orbital shaker shaking at 120 rpm 
in a water bath at 37°C. At designated time intervals, the tube of the suspension was 
 141 
 
centrifuged at 10,000 rpm for 20 min. The pellet was drained and resuspended in fresh 
medium to continue the drug release process. The drug released in the supernatant was 
extracted by DCM and transferred in the same mobile phase as used in measuring drug 
load. After the evaporation of DCM, docetaxel quantity was determined by the same 
HPLC procedure as mentioned above. The error bars were obtained from triplicate 
samples. 
6.2.8 In vitro evaluation 
SK-BR-3 and MCF7 breast cancer cells, which are of moderate HER2 expression, 
were employed in this study. The Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FBS and 1% penicillin-streptomycin solution was utilized as 
the cell culture medium. Cells were cultivated in humidified environment at 37°C with 
5% CO2. Before experiment, the cells were pre-cultured until confluence was reached 
to 75%.  
For quantitative cellular uptake analysis, cells were seeded into 96-well black plates 
(Costar, IL, USA) at 5×10
3
 cells/well (0.1 ml). After the cells reached 70% confluence, 
the culture medium was changed to the suspension of coumarin-6 loaded NPs at a NPs 
concentration of 0.125 mg/ml for 0.5 and 2 hr incubation. After incubation, the NPs 
suspension in the testing wells was removed and the wells were washed by 0.1 ml PBS 
thrice to wash away the NPs outside the cells. After that, 50 μl of 0.5% Triton X-100 
in 0.2 N NaOH solution was added to lyse the cells. Microplate reader (Genios, Tecan, 
Basel, Switzerland) was used to measure the fluorescence intensity from coumarin-6 
loaded NPs in the desired wells with excitation wavelength at 430 nm and emission 
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wavelength at 485 nm. The cellular uptake efficiency was expressed as the percentage 
of the fluorescence of the testing wells over that of the positive control wells. 
For fluorescent microscope study, cells were cultivated in the 4-well coverglass 
chamber (LAB-TEK
®
, Nagle Nunc, IL, USA) for 1 day. The fluorescent NPs dispersed 
in the cell culture medium at concentration of 0.125 mg/ml were added into the wells. 
Cells were washed three times after incubation for 2 hrs and then fixed by 70% ethanol 
for 20 mins. The cells were further washed thrice by PBS and the nuclei were then 
counterstained by PI for 45 mins. The fixed cell monolayer was finally washed thrice 
by PBS and observed by confocal laser scanning microscope (Olympus Fluoview 
FV1000).  
For cytotoxicity measurement, cells were incubated in 96-well transparent plates 
(Costar, IL, USA) at 5×10
3
 cells/well (0.1 ml) and after 12 hrs, the old medium was 
removed and the cells were incubated with prepared doses for 24, 48 and 72 hrs. The 
NPs were sterilized with UV irradiation for 1 day prior to using. MTT assay was used 
to measure the cell viability at given time intervals. The absorbance of the wells was 
measured by the microplate reader with wavelength at 570 nm and reference 
wavelength at 620 nm. Cell viability is defined as the percentage of the absorbance of 




6.3.1 Preparation and size characterization of the NPs 
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The nanoprecipitation method was applied for the NPs preparation with the target to 
make the surfactant-free system with particle size around 200 nm. We used various 
mass ratio of PLGA-PEG over the total mass of PLGA-PEG and PLGA from 0% to 
20% to achieve different density of amine groups on the NPs surface for quantitative 
control of the surface density of the antibody. With the condition of 10 mg/ml polymer 
concentration in acetone as the oil phase and the mixing ratio of oil phase to aqueous 
phase (without surfactant) as 1 to 1, the particle sizes could be obtained of a size close 
to 200 nm in general, which has been shown in the literature for high cellular uptake 
efficiency (Win and Feng, 2005). Table 6.1 illustrates the particle size and size 
distribution of five formulations of the NPs. The general sizes of the formulations are 
in the range of 150 to 250 nm with polydispersity of 0.065 to 0.244, which is regarded 
as acceptable narrow size distribution. It can be found that the presence of various 
amounts of PEG chains on the NPs has little effect on the particle size while bare 
PLGA NPs have smallest size due to lack of PEG long chains that could enlarge the 
hydrodynamic diameter in water. The structure of the NPs produced in this study is a 
core-shell system in which PLGA chains possess the core matrix while PEG chains 
from PLGA-PEG copolymers stretch on the PLGA core as the shielding shell layer, 
which can enhance the hydrophilicity and assist to escape from the phagocytosis and 
opsonization. It is widely accepted that NPs of PLGA-PEG are even more 





Table 6.1 Particle size and size distribution of the PLGA-PEG/PLGA blend 
nanoparticles of various PLGA-PEG amounts used in the nanoprecipitation process. 
Data represent mean ± SE, n=3. 
ratio of PLGA-PEG
 
Particle Size (nm) Polydispersity
 
0 162.7 ± 2.9 0.065 ± 0.027 
5 190.7 ± 7.6 0.191 ± 0.009 
10 225.4 ± 21.9 0.244 ± 0.013 
15 202.5 ± 8.7 0.141 ± 0.017 
20 192.7 ± 6.0 0.119 ± 0.071 
 
6.3.2 Herceptin conjugation and surface chemistry analysis 
The conjugation of herceptin on the NPs was fulfilled by one-step carbodiimide 
coupling method with EDAC and Sulfo-NHS in aqueous phase (Figure 6.1) based on 
the abovementioned five formulations. The carboxylic groups on the antibody 
molecules were activated first and then reacted with the primary amine groups on the 
PLGA-PEG chains to form amide bonds which link the antibody molecules on the NPs 
surface. In order to confirm the successful conjugation, the surface chemistry of the 
antibody conjugated NPs was analyzed by XPS to identify the change of nitrogen 
signal according to the specific binding energy in that one. Herceptin molecule 
contains 1726 nitrogen atoms, which should respond stronger signal than that from 
amine groups in the PLGA-PEG molecules. A typical NPs formulation of 20% PLGA-
PEG copolymer was taken as the example, which is shown in Figure 6.2. The more 
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distinct peak of signals from the orbital of nitrogen (N 1s) qualitatively verifies after 
the antibody molecules embrace the polymeric matrix cores although the non-
conjugated NPs also present slight nitrogen existence due to the amine groups on the 
surface yet the signal intensity is much lower. Therefore, it can be confirmed that the 
antibody molecules have been successfully conjugated on the polymer matrix. It is 
quite well known that the molecular weight of herceptin is large (145 kDa) as well as 
the molecule size is bulky. Therefore, in conjugation process, the activated antibody 
molecules will scramble for the opportunity to react with the amine groups. Yet the 
bulky size causes steric hindrance effect to hurdle further reaction, resulting the 
inefficient conjugation and free antibody molecules more than stoic molar ratio. As 
such, we cannot control the surface density of herceptin practically. Consequently, we 
mixed PLGA-PEG with PLGA to lower the surface density of amine groups, making 
paucity for penetration of antibody molecules into PEG layer, which can enhance the 
reaction efficiency of amine groups and control the conjugated antibodies more 
precisely.  
 
Figure 6.1 Schematic illustration of the fabrication of herceptin conjugated 
nanoparticles: the nanoparticles comprise a PLGA core with docetaxel loaded, a 
hydrophilic and stealth PEG layer shell on the surface of the core and a herceptin 
ligand coating.  
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Figure 6.2 Representative XPS spectrum of widescan spectrum and N 1s peaks (the 
inset) from the 20% PLGA-PEG / PLGA nanoparticles before (lower curve) and after 
antibody conjugation (upper curve).  
 
6.3.3 Control of ligand surface density on NPs surface 
We investigated firstly the correlation of the surface quantity of the antibody 
conjugated on the NPs surface with the ratio of PLGA-PEG in the PLGA-PEG/PLGA 
copolymer blend, which has been found to have a linear proportionality and thus 
shows the feasibility of quantitative control of the targeting effects of the ligand-
conjugated NPs. A series of PLGA-PEG/PLGA NPs of 0%, 5%, 10%, 15% and 20% 
PLGA-PEG in the copolymer blend were fabricated and then conjugated with 
herceptin of excess supply. The final amount of the antibody conjugated on the NPs 
surface was measured to be 0, 0.110, 0.250, 0.340, and 0.450 mg per mg of the NPs 
after deducting the background amount using 0% NPs as control (Figure 6.3). The 
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linear fit of the data points (R
2
 = 0.996) reveals that it is a simple way to control the 
amount of the ligand conjugated on the NPs by proportional change of the ratio of the 
PLGA-PEG in the copolymer blend. This strategy is understandable and can be 
supported by the free amine groups on the NPs surface to provide the linkers for the 
ligand molecules in the presence of EDAC as the typical protein coupling method. 
With the increase of amine groups brought from the PLGA-PEG molecules, or in other 
words, the ratio of PLGA-PEG in the copolymer blend, more ligand molecules could 
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Figure 6.3 Correlation of various ratio of PLGA-PEG in the polymer blend (0, 5, 10, 
15, and 20%) with the amount of the antibody conjugated on the nanoparticle surface. 
The black line represents the linear fitting of the five data points with R
2
 = 0.996. 
 
To confirm the feasibility of such a simple strategy for precision engineering of the 
nanoparticles, we chose the 20% PLGA-PEG NPs as example, which provide 
maximum number of the linker molecules (the free amine groups) for the ligand 
conjugation within our designated experimental scope, to investigate the feasibility to 
control the surface density of the ligand (thus the targeting effects) by changing the 
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feeding ratio of the ligand in the conjugation process. The results are expressed in 
Figure 6.4, in which, the amount of the ligand added in the conjugation process with 
marks at 0.0, 0.1, 0.2, 0.3, 0.4, 0.5 mg expressed in the upper horizontal axis can be 
converted to the molar ratio of the ligand to the NH2 group with marks at 0.000, 0.209, 
0.418, 0.627, 0.836, 1.046. Accordingly, the amount of the antibody conjugated on the 
NPs with marks at 0.000, 0.034, 0.084, 0.118, 0.146, 0.180 mg per mg of NPs, which 
is expressed in the left vertical axis, can be easily converted to the antibody density on 
the NPs surface in micromole (µmol) per mg NPs with marks at 0.000, 0.232, 0.581, 
0.814, 1.007, 1.240 umol per mg NPs, which are expressed on the right vertical axis. It 
can be seen that the quantity of the ligand conjugated on the NPs surface indeed is 
proportionally increased with augment of the ratio of the antibody in feed to the amine 
groups. Supportively, it also shows a linear manner with R
2
 = 0.997, which 
demonstrates the feasibility of the suggested copolymer blend strategy for precision 
engineering of the nanoparticles of biodegradable copolymer blend for targeted drug 
delivery as well as for targeted molecular imaging if the encapsulated drug is replaced 
by a designated imaging agent. In our opinion, this strategy is feasible, practical and 
convenient. It is a simpler and more economic method since only one type of NPs 
formulation, for example the 20% PLGA-PEG NPs, needs to be prepared for various 
designated targeting effects. The method suggested in this work is also more precise to 
control since the theoretical quantity of the free amine groups was fixed for the various 
antibody feed ratio with a designated PLGA-PEG portion say 20%, which can be 
easily measured by facile fluorescent method to guide the addition of the ligand 
amount in feed. By using this strategy, desired surface density of antibody on the NPs 
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surface can be conveniently obtained and precision engineering of the nanoparticles for 
targeted drug delivery and molecular imaging can thus be practically realized.  
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Figure 6.4 Control of the amount of the antibody conjugated or surface density of the 
antibody on 20% PLGA-PEG / PLGA nanoparticles through adjusting different 
amount of the antibody added for reaction. Data represent mean ± SE, n=3. The red 
line represents the linear fitting of the six data points with R
2
 = 0.997. 
 
6.3.4 Characterization of the docetaxel loaded NPs 
The docetaxel loaded NPs of PLGA-PEG/PLGA copolymer blend of 20% PLGA-PEG 
which were conjugated with 1.046-fold (in stoichiometric ratio) herceptin were 
selected as the illustrative formulation to demonstrate the properties of so-designed 
nanocarrier to deliver docetaxel in the following sections. From now on, we define this 
formulation as HNPs (herceptin-conjugated NPs) and those with no herceptin 
conjugated on their surface as BNPs (bare NPs). Table 6.2 illustrates the size and size 
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distribution of such docetaxel loaded NPs before and after herceptin conjugation, 
which were obtained from DLS measurement. The general sizes of the NPs are smaller 
than 250 nm in diameter with polydispersity less than 0.25. The size of the conjugated 
NPs is in general slightly larger than the bare NPs. This could be due to the high 
molecular weight of herceptin (145 kDa) and thus bulky volume domain. The zeta-
potential of the NPs shown in the table indicates the negative charges on the bare NPs 
surface, which is due to the overall negative charges of functional groups on PLGA in 
ultrapure water. The high negative surface charge (below -20 mV) is an important 
indication for the stability of a colloidal system in medium. After antibody conjugation, 
the zeta-potential became less negatively charged since the antibody molecules are 
positively charged in ultrapure water environment (pH~5.5) due to its isoelectric point 
of 8.45. The value of drug load of the NPs was also shown in the table. Obviously, 
such a formulation system demonstrates the prospect for a practically useful drug 
delivery carrier with appropriate size, stability and drug load capacity. 
Table 6.2 Comparison of the characteristics of HNPs and BNPs: particle size, size 
distribution, zeta potential and drug load. Data represent mean ± SE, n=6 (For drug 
load results, n=3). 
Formulation Particle Size (nm) Polydispersity
 
Zeta Potential (mV) Drug load (%) 
BNPs 200.7 ± 1.2 0.164 ± 0.031 -37.34 ± 2.41 34.1 ± 0.005 
HNPs 243.6 ± 7.2 0.205 ± 0.029 -25.81 ± 3.01 34.1 ± 0.005 
 
6.3.5 Surface morphology 
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FESEM was employed to image the morphology of the NPs (Figure 6.5). It is revealed 
from the images that the NPs are generally spherical in shape with narrow size 
distribution. Moreover, the particle size observed from these FESEM images is in good 
agreement with that determined by DLS. After ligand conjugation, the particles (C and 
D) become much more adhesive compared with the simple PLGA NPs (A) as well as 
the 20% PLGA-PEG NPs (B), which is possibly due to the attachment of the protein 
layer.  
 
Figure 6.5 Representative FESEM images of PLGA NPs (A), BNPs (B), 0.209-fold 
herceptin conjugated NPs (C) and HNPs (D). 
 
6.3.6 In vitro drug release 
The in vitro drug release profile of the BNPs and HNPs in ten days was shown in 
Figure 6.6, from which it can be seen that there is an initial burst of 23.8% for the NPs 
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with no herceptin conjugation and 10.8% for the herceptin-conjugated NPs in the first 
12 hours. Such the burst release may be due to the dissolution and diffusion of the drug 
molecules located near the surface in the NPs. The moderate initial burst could be 
helpful to suppress the growth of cancer cells at the beginning of the treatment. In the 
following 72 hours, the cumulative drug release reached 57.4% and 40.6% for the NPs 
without and with herceptin conjugation, respectively, and the release presents a first-
order increasing manner, which can provide a sustainable treatment. The cumulative 
drug release approached 73% after ten days for the NPs with no herceptin conjugation, 
which is attributed to the diffusion of the drug localized in the PLGA core of the NPs. 
Comparatively, the drug release from the herceptin-conjugated NPs shows a similar 
manner except for the slightly slower release rate. This is due to the antibody molecule 
layer coated on the surface, resulting in a barrier on the polymeric cores, which lower 
permeation of water into the polymeric core as well as diffusion of drug outwards. 
Such a controlled release profile of docetaxel facilitates the NPs for the delivery of 
anticancer drugs.  


































Figure 6.6 In vitro docetaxel release profile from the BNPs (square dots) and HNPs 




6.3.7 In vitro cellular uptake: quantitative study 
A quantitative investigation has been conducted by measuring the percentage of the 
coumarin-6 loaded NPs which have been entrapped in SK-BR-3 and MCF7 cells to 
demonstrate the possible advantages of the NPs to penetrate into the cells. The same 
concentration of well dispersed fluorescent PLGA-PEG/PLGA NPs (125 μg/ml) 
without or with herceptin conjugated on the NPs surface was used for all the cases, 
which was applied for incubation with the SK-BR-3 and MCF7 cells for 0.5 and 2 hr at 
37ºC. The results are summarized in Figure 6.7. It can be seen from this figure that for 
both of the SK-BR-3 and MCF7 cells, the intensity of the fluorescence from the NPs 
which has been taken up by the cells increases with the incubation time. Moreover, to 
demonstrate the effect of the surface density of the ligand on the NPs surface against 
the cellular uptake efficiency, we produced a series of the NP samples with various 
antibody amount coated on the surface which were described in Section 6.3.3. All 
antibody-conjugated NPs, regardless of the herceptin surface densities, consistently 
demonstrated stable internalization of the coumarin-6 loaded NPs by the MCF7 cells 
that moderately express HER2 receptors. Interestingly, the cells also endocytosed more 
NPs with the highest surface density of the ligand, indicating that even for such kind of 
cells of less HER2 receptors, ligand conjugation can still improve the cellular uptake 
of the NPs by the ligand conjugation as long as the quantity of the ligand on the NPs 
surface is high enough. In contrast, the amount of NPs endocytosed by SK-BR-3 cells 
that overexpress HER2 receptors can be controlled by adjusting the surface density of 
the conjugated ligand. The NPs of no antibody conjugation had virtually no uptake by 
the SK-BR-3 cells. On the contrary, significantly increased cellular uptake efficiency 
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can be observed for the NPs conjugated with herceptin. By increasing the surface 
density of the ligand by 104.6% of the amine groups, there was a 1.6-fold increase in 
the amount of the fluorescent NPs taken up by the cells compared to the bare 
fluorescent NPs. Furthermore, the percentage of the NPs endocytosed by the cells was 
almost proportionally increased to the surface density of the ligand. This shows indeed 
a preliminary proof-of-concept experimental result for the proposed copolymer blend 
strategy for precision engineering of the nanoparticles of biodegradable copolymer 
blend for quantitative control of targeted drug delivery. It is obvious to understand that 
insufficient ligand conjugation takes negative effect on efficient cellular uptake or 
targeted drug delivery. It is the very motivation to investigate such correlation and 
control the quantity of the conjugated ligands. The results of the effect of surface 
density of the ligand on cellular uptake efficiency demonstrate that increased surface 
density of the ligand promotes the cellular uptake efficiency of the targeted NPs in 
receptor overexpressed cancer cells. Rather, any further increase in surface density of 
the ligand resulted in a rare increase in the uptake. We hypothesize that it is a layer-by-
layer conjugation when further increases the antibody amount in feed. The outmost 
layer of the ligand shields the inner molecules, resulting equivalent one layer of 































































Figure 6.7 Cellular uptake efficiency of the coumarin-6 loaded 20% PLGA-PEG / 
PLGA nanoparticles with various molar ratio of the antibody added for conjugation to 
amine groups on the nanoparticles on MCF7 (A) and SK-BR-3 cells (B) after 0.5 and 2 
hrs incubation at 125 µg/ml nanoparticle concentration, respectively. Data represent 
mean ± SE, n=6. 
 
6.3.8 In vitro cellular uptake: confocal microscopy study 
The cellular uptake of the BNPs and the HNPs after 2 hr incubation with the MCF7 
and SK-BR-3 was further investigated by CLSM to visualize the penetration of the 
NPs into the cells and the targeting effects of the NPs conjugated with herceptin. The 
results are shown in Figure 6.8. Row A, B and C, D, respectively. Row A and C show 
the images of the cells incubated with the BNPs of no targeting effect, and Row B and 
D show the HNPs of herceptin conjugation. The images obtained from FITC channel 
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which shows the green fluorescence of the coumarin-6 loaded NPs are shown in 
column 1; column 2 lists the images obtained from the PI channel which show the 
nuclei in red fluorescence stained by the propidium iodide; and column 3 lists the 
images obtained from the merged channels of FITC and PI, from which it can be seen 
that, the red fluorescence representing the nucleus stained by PI is circumvented by 
green fluorescence representing the coumarin-6 loaded NPs internalized in the 
cytoplasm. Hence, the qualitative cellular uptake can be visually verified by the CLSM 
images. In addition, the HER2 receptor targeted behavior of the HNPs can also be 
observed. Under the same exciting laser intensity from the same confocal microscope, 
it can be seen from row C and D that the fluorescence from the HNPs in the cytoplasm 
(row D) is much brighter and greater than that from the BNPs (row C). It can thus be 
concluded that the receptor-mediated endocytosis does facilitate and promote the entry 
of NPs into cells when the herceptin conjugated NPs meet the overexpressed HER2 
receptors on the SK-BR-3 cell surface. As for MCF7 cells with moderately expressed 
HER2 receptors, the fluorescence in cytoplasm does not display distinct difference 




Figure 6.8 Representative CLSM images show the internalization of fluorescent 
nanoparticles in cells (2 hours incubation). Row A and B: MCF7 cells were used. Row 
C and D: SK-BR-3 cells were used. In row A and C, BNPs were incubated while in 
row B and D, HNPs were incubated. Scale bars were labelled on the figures. 
 
6.3.9 In vitro cytotoxicity 
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The efficacy of the NPs formulations of docetaxel to defeat cancer cells is reflected by 
their cytotoxicity for the cancer cells. Figure 6.9 illustrated the quantitative analysis on 
the cytotoxicity of docetaxel formulated in the nanoparticles of PLGA-PEG/PLGA 
copolymer blend, which are of various level of surface density of herceptin as 
described in Section 6.3.3. Under the same antibody surface density, higher drug 
concentration would result in lower cell viability, or equivalently higher cell mortality. 
Noteworthily, the cell viability indeed decreases with increase of the surface density of 
the antibody, indicating the great potential to achieve the designated cytotoxicity via 
controlling the ligand surface densities. The 3D plot clearly presents the effects of the 
antibody surface density and the dose of the drug on the cytotoxicity, i.e. the in vitro 
therapeutic effects. The explanation is straightforward since the NPs formulation with 
more antibody conjugated on their surface can be more efficiently taken up by the 
cancer cells of the corresponding antigen overexpression. The other cause could be due 




Figure 6.9 The diagram presents the cell viability of the docetaxel loaded 20% PLGA-
PEG/PLGA nanoparticles with various molar ratio of the antibody added for 
conjugation to amine groups on the nanoparticles on SK-BR-3 cells at various 
concentrations of the drug under 24 hrs treatment. Data shown were taken average 
from six repeats. 
 
A quantitative evaluation of the in vitro therapeutic effect of a dosage form is IC50, 
which is defined as the drug concentration needed to kill 50% of the incubated cells in 
a designated time period. Table 6.3 summarizes the IC50 values of docetaxel 
formulated in the various nanoparticles as described in Section 6.3.3 after 24 hr 
treatment on SK-BR-3 cells. From this table, a consistent decrease in IC50 can be 
observed with increase of the surface density of the conjugated antibody on the NPs 
surface, which again demonstrates the feasibility of the proposed copolymer blend 
strategy for precision engineering of nanoparticles of biodegradable copolymers for 
quantitative control of targeted drug delivery.   
Table 6.3 IC50 values of SK-BR-3 cells treated by various formulations after 24 hrs. 
The first row represents various molar ratio of the antibody in feed to NH2 group on 
the NPs, and the last column shows the value of Taxotere
®
, which is the commercial 
formulation of docetaxel. 
Formulation 0 0.209 0.418 0.628 0.837 1.046 Taxotere
® 
IC50 (µg/ml) 1.01 0.54 0.48 0.45 0.27 0.23 2.94 
 
Figure 6.10 highlighted a thorough investigation on SK-BR-3 cytotoxicity of BNPs 
and HNPs over 24, 48 and 72 hrs period respectively. The equivalent drug 
concentration of 2.5, 1.0, 0.25, and 0.025 μg/ml was applied. In all cases, P is lower 
than 0.05 under the two-tailed student‟s t test. It is straightforward to understand that 
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higher drug concentration and longer incubation time will cause lower cell viability, or 
equivalently higher mortality of the cells.  The lowest cell viability, i.e. the highest cell 
mortality, appeared at the highest drug concentration of the various formulations after 
treatment for the longest time, which proves the controlled and sustained efficacy of 
the NP formulations. Furthermore, it is clear that the HNP formulation demonstrated 
higher cytotoxicity than the BNP formulation at the same drug concentration and 
exposure time, showing the targeting effect, which means that for the same therapeutic 
effect, the dose needed for the HNP formulation could be less than that for the BNP 
formulation. It can also be calculated from the in vitro cell viability data that the IC50 
for 24 hr treatment is 1.53 μg/ml using BNPs and 0.31 μg/ml using HNPs, which 
means the HNP formulation is 79.7% more effective than the BNP formulation in the 
24 hr treatment. The more effective treatment of the HNPs formulation could be 
attributed to the targeting ability of the herceptin conjugation, which can thus be taken 
up into the cancer cells more effectively; hence the development of the HNPs 
formulation can enhance the therapeutic effect. The side effects can also be minimized 
since fewer drugs would be needed and the drug would be mainly delivered to the 
cancer cells with the healthy cells ignored. It is highly meaningful that the same 
amount of the cancer cells can be killed by using less dose of anticancer agent, thus 
causing fewer side effects like cardio-toxicity (Albini et al., 2010). Herceptin, the 
formulation intensively applied in clinical cases, is a well tolerated agent and there is 
minimal additional toxicity (Chan, 2007). Through the investigation, the addition of 
the antibody on the NP formulation of docetaxel makes the necessary amount of drug 
reduce to a much less toxic level, which is a very helpful solution for anticancer 
efficacy as well as reducing the side effects. Moreover, not only HER2 overexpressed 
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breast cancer cells, but also HER2 moderately expressed breast cancer cells can be 





























Figure 6.10 The diagram presents the cell viability at various concentrations of the 




Synthesized PLGA-PEG block copolymer was mixed with PLGA as a biodegradable 
copolymer blend to produce NPs which were successfully developed in this research 
for sustainable, controlled and targeted delivery of docetaxel as a model drug. The 
anti-HER2 antibody, herceptin was used as the ligand to conjugate on the NPs to target 
HER2 receptors on breast cancer cells. The surface density of the ligand on the NPs 
was quantitatively controlled by using various ratio of PLGA-PEG over PLGA and 
different initial amount of the antibody while fixing the ratio of PLGA-PEG over 
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PLGA. A representative formulation with certain amount of ligand conjugated was 
selected for further and thorough evaluation. The formulation was found to be in favor 
of stealth feature and cellular uptake efficiency owning to the PEG layer and ligand 
attached on the surface, respectively. The targeted delivery system was also proved to 
be more cytotoxic to HER2 receptor overexpressed cancer cells. The overall 
performance of the drug delivery carrier shows significant potential and suggests that 
further investigation would be appropriate. Excitingly, it was shown that the surface 
density of the ligand on NPs positively impacts on in vitro performance. We thus hope 
that the reporting of this preliminary study demonstrates the necessity to quantify the 
ligand amount on nanocarriers in researches on targeted drug delivery systems as a 




Chapter 7 : CONCLUSIONS 
Throughout the thesis, the dedication of research is on the development of better 
performed nanotechnology based formulations for anticancer purpose. Nanoparticles 
of biodegradable polymers have been employed as the platform to achieve cancer 
nanomedicine. Multifunctional nanoparticles with the functions of therapeutics 
delivery, molecular imaging, and cancer cell targeting are the final target of the 
research toward cancer diagnosis and treatment in a targeted manner. The specific 
work in this project is focused on the development of novel nanoparticles through 
tailoring the surface properties of the nanoparticles thus obtain modified and improved 
overall performance for cancer nanomedicine. The lipid shell polymer core 
nanoparticles integrates the merits from both lipids and polymers. Particularly, the 
effective interaction of lipids with cell membranes was utilized for the system to 
achieve better cellular uptake efficiency. Moreover, space for further modification on 
lipids is another important feature for producing targeted nanoparticles. While for 
TPGS coated nanoparticles, it was designed for improving circulation life of the 
systems in future clinical applications. The controlling on targeting effects is more 
advanced, targeting to future optimal and personal therapies. Therefore the objective of 
developing those systems is various and the systems open up more chances to be 
selected for clinical trials based on their advantages. 
A system of nanoparticles of lipid shell and PLGA core for sustained and controlled 
release of anticancer drugs was firstly developed in the work. We revisited our earlier 
work of using phospholipids as emulsifier for nanoparticle formation. Phospholipids, 
at present, has been regarded as not only efficient emulsifiers to produce colloidal 
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particles but also important components to provide merits for polymeric nanoparticles 
in terms of desired surface properties, space for conjugation of functional molecules 
and better cellular interaction. At beginning, the focus was on the type and amount of 
lipids used in the nanoparticle formation process that were believed to play a key role 
to determine the physicochemical properties and in vitro performance of the drug 
loaded NPs. Upon optimization, it was found that DLPC is an ideal lipid molecule to 
formulate the NPs with certain amount. Selective formulations were thus completely 
characterized to demonstrate the possibility of being employed as drug delivery 
systems. We also presented great advantages of phospholipid versus traditional PVA 
as emulsifier with higher emulsification efficiency, higher drug encapsulation 
efficiency and better in vitro performance. We demonstrated that the coumarin-6 
loaded PLGA NPs of DLPC shell showed effective in vitro cellular uptake 
performance on MCF7 cells.  The analysis of IC50 based on in vitro cytotoxicity 
evaluation demonstrated that the DLPC shell PLGA core NP formulation of paclitaxel 
could be 5.88-, 5.72-, 7.29×10
3
- fold effective than the commercial formulation Taxol
®
 
after 24, 48, 72 hr treatment, respectively. Subsequently, the nanoparticles of mixed 
lipid shell and biodegradable polymer core was developed as a novel platform to 
construct potential multifunctional nanoparticles for cancer nanomedicine due to the 
versatility of attaching desired functional molecules. Ligand-conjugated nanoparticles 
of mixed lipid shell and PLGA core was formulated for sustainable, controlled and 
targeted delivery of anticancer drugs. The mixed lipid shells, DLPC, DSPE-PEG2k, and 
functional DSPE-PEG5k provide the nanoparticles with the natural property, high 
stability, desired surface properties in favor of cellular uptake, stealth feature of long 
half life in the plasma, targeted delivery property, and most importantly, possibility of 
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quantitative management of the targeting effect by adjusting the component ratio of the 
mixed lipids to provide the moieties for ligand conjugation. The IC50 results calculated 
from in vitro cell viability data showed that the after 24 h treatment the targeted lipid 
shell polymer core formulation was 50.91% more effective than the non-targeted 
formulation and 93.65% more effective than the commercial formulation of docetaxel, 
Taxotere
®
, respectively. Consistent evaluation and analysis on the novel formulations 
evolve a fascinating opportunity and promising prospect to develop these new drug 
delivery systems although it should be pointed out that in vivo investigation should be 
followed to collect sufficient data for the application for clinical trials.   
Another type of improved materials was applied for producing polymeric nanoparticles 
in the followed chapter. TPGS1k, the traditional PEGylated vitamin E has been widely 
used to fabricate desired drug carriers; nonetheless the chain length of PEG is not 
sufficient for stealth property. Therefore a series of new TPGS analogues, TPGS2k, 
TPGS5k and TPGS2kNH2 were synthesized in the study to fabricate drug loaded 
PLGA NPs. The characterization and in vitro evaluation demonstrated that by 
comparison of the PLGA NPs using new TPGS as surfactants with those using 
conventional TPGS1k, the former shows similar properties in terms of size, size 
distribution, surface charge and surface morphology. The new surfactant coated NPs 
were proved to have higher drug loading and greater cellular uptake efficiency and 
cytotoxicity. Molecular ligands are also able to be conjugated on the new TPGS coated 
PLGA NPs by using, for instance, TPGS2kNH2 for targeted chemotherapy, which 
compensates the lack of reactive sites of TPGS1k and broadens the application of the 
new materials for various objectives as long as attaching desired molecules on 
selective TPGS analogues. The conjugation of folic acid on the nanoparticles 
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significantly increased the ability of the targeted NPs to penetrate into cancer cells and 
inhibit the growth of the cells, as revealed in the higher cellular uptake efficiency and 
cytotoxicity results, indicating the potential of such engineered nanocarriers to achieve 
targeted chemotherapy. Therefore, the major contribution of this project is that new 
surfactants have been successfully developed for fabrication of PLGA NPs as 
nanocarriers for chemotherapy with even better characteristics. Meanwhile, the 
strategy provides the space using potent TPGS analogues for conjugation of versatile 
targeting ligands on the nanocarriers to realize more effective chemotherapy. However, 
it is worthwhile to point out that this is only a preliminary investigation for such a 
novel design of the new materials coated nanoparticles. In vivo investigation should be 
followed to collect sufficient data to prove the stability and circulation time of those 
nanoparticles for the application for clinical trials.  
The last part covers the investigation on the relationship of targeting effects with the 
quantity of targeting ligands on nanocarriers. A biodegradable copolymer blend of 
PLGA-PEG with PLGA was used to produce NPs for sustainable, controlled and 
targeted delivery of docetaxel. The surface density of anti-HER2 antibody, herceptin 
conjugated on the NPs was quantitatively controlled by using various ratio of PLGA-
PEG over PLGA and different initial amount of the antibody while fixing the ratio of 
PLGA-PEG over PLGA. The targeted delivery system was proved to be more 
cytotoxic to HER2 receptor overexpressed cancer cells. The overall performance of the 
drug delivery carrier shows significant potential and suggests that further investigation 
would be appropriate. Interestingly, it was shown that the surface density of the ligand 
on NPs positively impacts on in vitro performance of the NPs. We thus hope that the 
reporting of this preliminary study demonstrates the necessity to quantify the ligand 
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amount on nanocarriers, as an important step to precisely engineering nanocarriers, in 
researches on targeted drug delivery systems as a property equally as important as, for 
instance, size and surface charge. It should be pointed out, however, that this is only a 
proof-of-concept investigation for such a novel design of the NPs. In vivo investigation 




Chapter 8 : RECOMMENDATIONS 
The preliminary results shown above evidently prove that the nanoparticles of 
biodegradable polymers are promising platforms for cancer treatment. However, 
further studies on animals are indispensible toward real clinical application. Besides, 
molecular imaging of tumor and cancer cells is another necessary component of 
multifunctional nanoparticles. Therefore in this section, in vivo studies and diagnosis 
of cancer will be proposed on the basis of the developed systems. 
The blood-brain barrier (BBB) represents an insurmountable obstacle for a large 
number of drugs, including antibiotics, antineoplastic agents, and a variety of central 
nervous system (CNS)-active drugs, especially neuropeptides (Xie et al., 2010). The 
barrier is crucial to protect brain from the invasion of toxins in blood while it hinders 
the transportation of therapeutic agents into brain to cure the diseases in brain. There 
are several approaches to overcome the barrier and deliver drugs into brain: to modify 
drugs to more readily cross the barrier, to utilize the native carriers expressed at the 
BBB, to inject drugs directly into the brain, and to use nanoparticles as drug carriers 
(Tamargo and Brem, 1992; Lockman et al., 2002; Ambikanadan et al., 2003; Kreuter, 
2001). Among those, nanoparticles offer a promising solution for this obstacle due to 
some advantages such as ease of drug encapsulation, protection of drug integrity, high 
drug delivery efficiency, sustained drug release in the brain, low stimulation and 
inflammation, and decreased peripheral toxicity (Lockman et al., 2002). One of the 
most widely exploited nanoparticulate formulations is probably Tween-80 coated 
PBCA NPs, which was shown to enhance brain uptake in vitro and in vivo (Kreuter, 
2001; Kreuter, 2003; Alyaudtin et al., 2001; Sun et al., 2004). However, PBCA NPs 
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have potential toxicity, BBB permeabilization, and short duration of delivery and 
hence, PLGA NPs was regarded as a promising alternative (Olivier, 2005). And 
Tween-80 has also been found to be associated with severe side effects including 
hypersensitivity reactions, cumulative fluid retention, nausea, mouth sores, hair loss, 
peripheral neuropathy, fatigue and anemia (Gelderblom et al., 2001; Immordino et al., 
2003; Baker et al., 2004). Therefore alternative materials have to be developed to 
formulate more potent PLGA NPs across BBB with higher safety. Phospholipids could 
be one of the candidates. The natural property could ensure the safety use for clinical 
trials and the high fusion with cell membranes could enhance cellular uptake efficiency, 
leading high interaction with the cells on BBB thus increasing the transportation 
efficiency. By using the NPs of lipid shell and PLGA core, it can be expected to be an 
effective nanocarrier across BBB with the merits of both lipids and PLGA. 
Furthermore, the end functional groups on certain types of lipids provide wide space 
for bioconjugation application to introduce molecular ligands which assist to cross 
BBB, such as transferring and OX-26 antibody, as reported similarly by using 
molecular ligands conjugated nanocariers for across BBB (Soni et al., 2008; Pang et al., 
2008; Gan and Feng, 2010). It needs to conduct thorough investigation in vivo to 
confirm the ability of targeted NPs of lipid shell and PLGA core to cross BBB and 
deliver drugs inside the brain.  
Although in vitro results prove the potential of the NPs of lipid shell and polymer core 
for cancer treatment, further in vivo studies should be conducted to more deeply 
confirm the practical applications in clinical trials. The stability of the particles in real 
human plasma should be firstly investigated and the release profile of the encapsulated 
drugs in such condition should also be studied. After that, pharmacokinetics of the 
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drugs loaded in the particles should be investigated to confirm the controlled and 
sustained release in rats. The therapeutic window of the released drug should be within 
the range of maximum tolerable dose and minimum effective dose of the anticancer 
drug. The biodistribution of such type of particles is also suggested to study. The 
results will demonstrate the long circulating property and possibility of accumulation 
of the particles in tumor. Histology study could prove the safety on the tissue level. 
Lastly, the ability of the particles to suppress tumor growth in rats can be tested by 
xenograft model study, which is the most direct evidence to show the anticancer effect.  
Moreover, the advantages of using PEG with longer chain length should also be 
demonstrated in animals by biodistribution study. If the concentration of the particles 
in blood is higher over long period, the merits could be proved.  
We have demonstrated the impact of ligand surface density on the anticancer effect in 
vitro and the necessity of quantitatively control the ligand amount. It thus deserves 
further investigation in vivo, though the work would be as huge as decades. If we could 
establish the charts indicating the relationship between targeting effect and tumor 
inhibition performance, optimal formulation could be given to the patients of different 
conditions, making the personalized therapy come true.  
Cancer diagnosis by molecular imaging of tumors and cancer cells is one of the most 
effective ways for cancer treatment. Identifying tumors or spread cancerous cells 
earlier will provide much more opportunity and higher probability to cure the disease. 
Hence some imaging agents will also be proposed to be encapsulated into the 
nanoparticulate systems to fulfill molecular imaging function.  
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QDs are verified powerful tools for imaging. There have been large numbers of work 
using QDs for tumor imaging recently. Our group has also accumulated certain 
experience of using QDs. Based on those findings, QDs will be selected to be loaded 
in the NPs. QDs with different emission wavelengths will be used to adapt different 
imaging signals called fluorescence spectrum to show different types of cancerous 
cells. The cancer cells detection and differentiation can be achieved by loading of QDs 
with different emission wavelengths in the particles anchored with different molecular 
ligands which are specific to certain type of cells. However, QDs still have some 
disadvantages. They cannot be excited repeatedly due to photo-bleaching. The safety 
issue still concerns due to the heavy metals. Accordingly, the imaging agents will be 
encapsulated into non-toxic nanoparticles or substituted by IOs, which is an MRI agent 
providing great contrast and spatial resolution among different soft tissues of the body. 
Yet, single imaging technique inevitably possesses limitations in practical applications. 
The idea that bridges more than one approach in an integrated system is thus inspired 
to compensate and complement the drawbacks, which thus provides more precise and 
complete information for cancer diagnosis. It is called multimodal imaging. Recently 
our group reported a co-encapsulation system of QDs and IOs in NPs of biodegradable 
polymers for tumor diagnosis (Tan et al., 2011). Similar strategy would be applied to 
produce multimodal imaging NPs on the platform of lipid shell and polymer core 
particles and evaluated in vivo.  
After the thorough investigation and proven successful results collected from the 
works above, the function of drug delivery, molecular imaging and cell targeting will 
be combined in one nanoparticulate system to produce multifunctional nanoparticles. 
Since the body is a very complicated system, it is hard to predict any unexpected 
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disasters when using such complex systems. Several problems need also to be 
addressed prior to clinical application of multifunctional particles, including the batch-
to-batch variation when manufacturing the particles, circulation time of the system in 
body, the release behavior of drugs and imaging agents, the harmful interaction 
between drugs and imaging agents, the accumulation of the particles in normal cells 
and healthy organs, fast clearance by the immune systems, resolution of the tumor 
detection signals, etc. To provide a more complete picture on the therapeutic effects of 
the fabricated particles, in vivo experiments such as pharmacokinetic studies, 
biodistribution and xenograft models should also be conducted to evaluate the practical 
performance of the multifunctional nanoparticles for cancer nanomedicine and 





Abra, R.M. The next generation of liposome delivery systems: recent experience with 
tumor-targeted, sterically stabilized immunoliposomes and active-loading gradients, J. 
Liposome Res., 12, pp.1-3. 2002. 
Adams, G.P. and L.M. Weiner. Monoclonal antibody therapy of cancer, Nat. 
Biotechnol. 23, pp.1147-57. 2005. 
Agarwal, A., Y. Lvov, R. Sawant and V. Torchilin. Stable nanocolloids of poorly 
soluble drugs with high drug content prepared using the combination of sonication and 
layer-by-layer technology, J. Control. Release, 128, pp.255-260. 2008. 
Ahlgren, S., H. Wallberg, T.A. Tran, C. Widstrom, M. Hjertman, L. Abrahmsen, D. 
Berndorff, L.M. Dinkelborg, J.E. Cyr, J. Feldwisch, A. Orlova and V. Tolmachev. 
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled 
recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. 
J. Nucl. Med., 50, pp.781-789. 2009. 
Ahmed, F. and D.E. Discher. Self-porating polymersomes of PEG-PLA and PEG-PCL: 
hydrolysis-triggered controlled release vesicles, J. Control. Release, 96, pp.37-53. 
2004. 
Albini, A., G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora and D.M. Noonan. 
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-
oncological prevention, J. Natl. Cancer Inst., 120, pp.14-25. 2010. 
Alexis, F. Factors affecting the degradation and drug-release mechanism of poly(lactic 
acid) and poly[(lactic acid)-co-(glycolic acid)], Polym. Int., 54, pp.36-46. 2005. 
Alexis, F., E. Pridgen, L.K. Molnar and O.C. Farokhzad. Factors affecting the 
clearance and biodistribution of polymeric nanoparticles, Mol. Pharm., 5, pp.505-515. 
2008. 
Allen, T.M. and C. Hansen. Pharmacokinetics of stealth versus conventional liposomes: 
effect of dose, Biochim. Biophys. Acta, 1068, pp.133-141. 1991. 
Allen, T.M. and E.H. Moase. Therapeutic opportunities for targeted liposomal drug 
delivery, Adv. Drug Deliv. Rev., 21, pp.117-133. 1996. 
Alyaudtin, R.N., A. Reichel, R. Löbenberg, P. Ramge, J. Kreuter and D.J. Begley. 
Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in 
vivo and in vitro, J. Drug Target., 9, pp.209-221. 2001. 
Ambikanadan, M., S. Ganesh and S. Aliasgar. Drug delivery to the central nervous 
system: a review, J. Pharm. Pharmaceut. Sci., 6, pp.252-273. 2003. 
Anderson, J.M. and M.S. Shive. Biodegradation and biocompatibility of PLA and 
PLGA microspheres, Adv. Drug Delive. Rev., 28, pp.5-24. 1997. 
 174 
 
Astete, C.E. and C.M. Sabliov. Synthesis and characterization of PLGA nanoparticles. 
J. Biomater. Sci. Polym. Ed., 17, pp.247-89. 2006. 
Avgoustakis, K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: 
preparation, properties and possible application in drug delivery, Curr. Drug Deliv., 1, 
pp.321-333. 2004. 
Bae, Y., S. Fukushima, A. Harada and K. Kataoka. Design of environment-sensitive 
supramolecular assemblies for intracellular drug delivery: polymeric micelles that are 
responsive to intracellular pH change, Angew. Chem. Int. Ed., 42, pp.4640-4643. 2003. 
Bae, Y., N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro and K. Kataoka. 
Preparation and biological characterization of polymeric micelle drug carriers with 
intracellular pH-triggered drug release property: tumor permeability, controlled 
subcellular drug distribution, and enhanced in vivo antitumor efficacy, Bioconjug. 
Chem., 16, pp.122-130. 2005.  
Baker, S.D., M. Zhao, P. He, M.A. Carducci, J. Verweij and A. Sparreboom. 
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in 
human plasma by liquid chromatography/tandem mass spectrometry, Anal. Biochem., 
324, pp.276-284. 2004. 
Bakker-Woudenberg, I.A. Long-circulating sterically stabilized liposomes as carriers 
of agents for treatment of infection or for imaging infectious foci, Int. J. Antimicrob. 
Agents, 19, pp.299-311. 2002. 
Bangham, A.D., M.M. Standish and J.C. Watkins. Diffusion of univalent ions across 
the lamellae of swollen phospholipids, J. Mol. Biol., 13, pp.238-252. 1965. 
Barbe, C., J. Bartlett, L.G. Kong, K. Finnie, Lin H.Q., M. Larkin, S. Calleja, A. Bush 
and G. Calleja. Silica particles: A novel drug delivery system, Adv. Mater., 16, 
pp.1959-1966. 2004, 
Bardhan, R., N.K. Grady and N.J. Halas. Nanoscale control of near-infrared 
fluorescence enhancement using Au nanoshells, Small, 4, pp.1716-1722. 2008. 
Barenholz, Y. Liposome application: problems and prospects, Curr. Opin. Colloid 
Interface Sci., 6, pp.66-77. 2001. 
Beletsi, A., P. Klepetsanis, D.S. Ithakissios, S. Kounias, A. Stavropoulos and K. 
Avgoustakis. Simultaneous optimization of cisplatin-loaded PLGA-mPEG 
nanoparticles with regard to their size and drug encapsulation, Curr. Nanosci., 4, 
pp.173-178. 2008. 
Bianco, A., J. Hoebeke, K. Kostarelos, M. Prato and C.D. Partidos. Carbon nanotubes: 
On the road to deliver, Curr. Drug Deliv., 2, pp.253-259. 2005. 
Bianco, A., K. Kostarelos, C.D. Partidos and M. Prato. Biomedical applications of 
functionalised carbon nanotubes, Chem. Commun., pp.571-577. 2005a. 
Bianco, A., K. Kostarelos and M. Prato. Applications of carbon nanotubes in drug 
delivery, Curr. Opin. Chem. Biol., 9, 674-679. 2005b. 
 175 
 
Bilati U., E. Allémann and E. Doelker. Development of a nanoprecipitation method 
intended for the entrapment of hydrophilic drugs into nanoparticles, Eur. J. Pharm. Sci., 
24, pp.67-75. 2005. 
Blackburn, E.H. Telomeres and telomerase: their mechanisms of action and the effects 
of altering their functions, FEBS Lett., 579, pp.859-862. 2005. 
Blume, G. and G. Cevc. Molecular mechanism of the lipid vesicle longevity in vivo, 
Biochim. Biophys. Acta, 1146, pp.157-168. 1993. 
Brigger, I. C. Dubernet and P. Couvreur. Nanoparticles in cancer therapy and diagnosis, 
Adv. Drug Deliv. Rev., 54, pp.631-651. 2002, 
Brown, K.C. Peptidic tumor targeting agents: The road from phage display peptide 
selections to clinical applications, Curr. Pharm. Design., 16, pp.1040-1054. 2010. 
Brunsvig, P.F., A. Anderson, S. Aamdal, V. Kristensen and H. Olsen. Pharmacokinetic 
analysis of two different docetaxel dose levels in patients with non-small cell lung 
cancer treated with docetaxel as monotherapy or with concurrent radiotherapy, BMC 
Cancer, 7, pp.197. 2007. 
Bullock, K. and K, Blackwell. Clinical efficacy of taxane-trastuzumab combination 
regimens for HER-2-positive metastatic breast cancer, Oncologist, 13, pp.515-525. 
2008. 
Carmeliet, P. and R.K. Jain. Angiogenesis in cancer and other diseases, Nature, 407, 
pp.249-257. 2000. 
Cattel, L., M. Ceruti and F. Dosio. From conventional to stealth liposomes a new 
frontier in cancer chemotherapy, Tumori, 89, pp.237-249. 2003, 
Chan, A. A review of the use of trastuzumab (Herceptin
®
) plus vinorelbine in 
metastatic breast cancer, Ann. Oncol., 18, pp.1152-1158. 2007. 
Chan, J.M., L.F. Zhang, K.P. Yuet, G. Liao, J.-W. Rhee, R. Langer and O.C. 
Farokhzad. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery, 
Biomaterials, 30, pp.1627-1634. 2009. 
Cheng, J., B.A. Teply, I. Sherifi, J. Sung, G. Luther, F.X. Gu, E. Levy-Nissenbaum, 
A.F. Radovic-Moreno, R. Langer and O.C. Farokhzad. Formulation of functionalized 
PLGA-PEG nanoparticles for in vivo targeted drug delivery, Biomaterials, 28, pp.869-
876. 2007. 
Cho, K., X. Wang, S. Nie, Z.(G.) Chen and D.M. Shin. Therapeutic nanoparticles for 
drug delivery in cancer, Clin. Cancer Res., 14, pp.1310-1316. 2008. 
Cirstoiu-Hapca, A., L. Bossy-Nobs, F. Buchegger, R. Gurny and F. Delie. Differential 
tumor cell targeting of anti-HER2 (Herceptin
®
) and anti-CD20 (Mabthera
®
) coupled 
nanoparticles, Int. J. Pharm., 331, pp.190-196. 2007. 
Cirstoiu-Hapca, A., F. Buchegger, L. Bossy, M. Kosinski, R. Gurny and F. Delie. 
Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-
 176 
 
loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells, 
Eur. J. Pharm. Sci., 38, pp.230-237. 2009. 
Collnot, E.M., C. Baldes, M.F. Wempe, J. Hyatt, L. Navarro, K.J. Edgar, U.F. 
Schaefer and C.M. Lehr. Influence of vitamin E TPGS poly(ethylene glycol) chain 
length on apical efflux transporters in Caco-2 cell monolayers, J. Control. Release, 111, 
pp.35-40. 2006. 
Danhier, F., N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, O. Feron 
and V. Préat. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in 
vivo evaluation, J. Control. Release, 133, pp.11-17. 2009. 
de la Zerda, A. and S.S. Gambhir. Drug delivery: Keeping tabs on nanocarriers, Nat. 
Nanotechnol., 2, pp.745-746. 2007. 
De Miguel, I., L. Imbertie, V. Rieumajou, M. Major, R. Kravtzoff and D. Betbeder. 
Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers, 
Pharm. Res., 17, pp.817-824. 2000. 
Debbage, P. and W. Jaschke. Molecular imaging with nanoparticles: giant roles for 
dwarf actors, Histochem. Cell Biol., 130, pp.845-875. 2008. 
Decuzzi, P. and M. Ferrari. The role of specific and non-specific interactions in 
receptor-mediated endocytosis of nanoparticles, Biomaterials, 28, pp.2915-2922. 2007. 
Dintaman, J.M. and J.A. Silverman. Inhibition of P-Glycoprotein by D-α-Tocopheryl 
Polyethylene Glycol 1000 Succinate (TPGS), Pharm. Res., 16, pp.1550-1556. 1999. 
Discher, D.E. and A. Eisenberg. Polymer vesicles, Science, 297, pp.967-973. 2002. 
Discher, D.E. and F. Ahmed. Polymersomes, Annu. Rev. Biomed. Eng., 8, pp.323-341. 
2006. 
Donehower, R.C., E.K. Rowinsky, L.B. Grochow, S.M. Longnecker and D.S. Ettinger. 
Phase I trial of Taxol in patients with advanced cancer, Cancer Treat. Rep., 71, 
pp.1171-1177. 1987. 
Dreher, M.R., W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan and A. Chilkoti. 
Tumor vascular permeability, accumulation, and penetration of macromolecular drug 
carriers, J. Natl. Cancer Inst., 98, pp.335-344. 2006. 
Duncan, R., L.W. Seymour, K.B. O'Hare, P.A. Flanagan, S. Wedge, I.C. Hume, K. 
Ulbrich, J. Strohalm, V. Subr, F. Spreafico, M. Grandi, M. Ripamonti, M. Farao and A. 
Suarato. Preclinical evaluation of polymer-bound doxorubicin, J. Control. Release, 19, 
pp.331-346. 1992. 
Duncan, R. The dawning era of polymer therapeutics, Nat. Rev. Drug Discov., 2, 
pp.347-360. 2003. 




Dusinska, M., M Dusinska, L.M. Fjellsbø, Z. Magdolenova, A. Rinna, E. Runden Pran, 
A. Bartonova, E. Heimstad, M. Harju, L. Tran, B. Ross, L. Juillerat, B. Halamoda 
Kenzaui, F .Marano, S. Boland, R. Guadaginini, M. Saunders, L. Cartwright, S. 
Carreira, M. Whelan, Ch. Kelin, A. Worth, T. Palosaari, E. Burello, C. Housiadas, M. 
Pilou, K. Volkovova, J. Tulinska, A. Kazimirova, M. Barancokova, K. Sebekova, M. 
Hurbankova, Z. Kovacikova, L. Knudsen, M. Poulsen, T. Mose, M. Vilà, L. Gombau, 
B. Fernandez, J. Castell, A. Marcomini, G. Pojana, D. Bilanicova and D. Vallotto. 
Testing strategies for the safety of nanoparticles used in medical applications, 
Nanomedicine, 4, pp.605-607. 2009. 
Engels, F.K., R.A.A. Mathot and J. Verweij. Alternative drug formulations of 
docetaxel: a review, Anticancer Drugs, 18, pp.95-103. 2007. 
Esfand, R. and D.A. Tomalia. Poly(amidoamine) (PAMAM) dendrimers: from 
biomimicry to drug delivery and biomedical applications, Drug Discov. Today, 6, 
pp.427-436. 2001. 
Esmaeili, F., M.H. Ghahremani, S.N. Ostad, F. Atyabi, M. Seyedabadi, M.R. 
Malekshahi, M. Amini and R. Dinarvand. Folate-receptor-targeted delivery of 
docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate, J. Drug Target., 16, 
pp.415-423. 2008. 
Esmaeili, F., R. Dinarvand, M.H. Ghahremani, S.N. Ostad, H. Esmaily and F. Atyabi. 
Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) 
nanoparticles, Anticancer Drugs, 21, pp.43-52. 2010. 
Evora, C., I. Soriano, R.A. Rogers, K.M. Shakesheff, J.Hanes and R. Langer. Relating 
the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the 
effect of 1,2-dipalmitoylphosphatidylcholine, J. Control. Release, 51, pp.143-152. 
1998. 
Farokhzad, O.C. and R. Langer. Nanomedicine: Developing smarter therapeutic and 
diagnostic modalities, Adv. Drug Deliv. Rev., 58, pp.1456-1459. 2006. 
Farokhzad, O.C., J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie and 
R. Langer. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in 
vivo, Proc. Natl. Acad. Sci., 103, pp.6315-6320. 2006a. 
Farokhzad, O.C. and R. Langer. Impact of Nanotechnology on Drug Delivery, ACS 
Nano, 3, pp.16-20. 2009. 
Feng, S.S. and G. Huang. Effects of emulsifiers on the controlled release of paclitaxel 
(Taxol
®
) from nanospheres of biodegradable polymers, J. Control. Release, 71, pp.53-
69. 2001. 
Feng, S.S., L. Mu, B.H. Chen and D. Pack. Polymeric nanospheres fabricated with 
natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol
®
), 
Mater. Sci. Eng. C, 20, pp.85-92. 2002. 
 178 
 
Feng, S.S. and S. Chien. Chemotherapeutic engineering: Application and further 
development of chemical engineering principles for chemotherapy of cancer and other 
diseases, Chem. Eng. Sci., 58, pp.4087-4114. 2003. 
Feng, S.S. Nanoparticles of biodegradable polymers for new-concept chemotherapy, 
Expert Rev. Med. Dev., 1, pp.115-125. 2004. 
Feng, S.S., L. Mu, K.Y. Win and G. Huang, Nanoparticles of biodegradable polymers 
for clinical administration of paclitaxel, Curr. Med. Chem., 11, pp.413-424. 2004. 
Feng, S.S. New-concept chemotherapy by nanoparticles of biodegradable polymers: 
where are we now? Nanomedicine, 1, pp. 297-309. 2006. 
Feng, S.S., L. Zhao, Z. Zhang, G. Bhakta, K.Y. Win, Y.Dong and S. Chien. 
Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of 
biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo, 
Chem. Eng. Sci., 62, pp.6641-6648. 2007. 
Feng, S.S., L. Mei, P. Anitha, C.W. Gan and W.Y. Zhou. Poly(lactide)-vitamin E 
derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel, 
Biomaterials, 30, 3297-3306. 2009. 
Ferrari, M. Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer, 5, 
pp.161-171. 2005. 
Fessi, H., F. Puisieux, J.P. Devissaguet, N. Ammoury and S. Benita. Nanocapsule 
formation by interfacial polymer deposition following solvent displacement, Int. J. 
Pharm., 55, pp.R1-R4. 1989. 
Fjallskog, M. L., L. Frii and J. Bergh. Is cremophor, solvent for paclitaxel, cytotoxic? 
Lancet, 342, pp.876. 1993. 
Fonseca, C., S. Simões and R. Gaspar. Paclitaxel-loaded PLGA nanoparticles: 
preparation, physicochemical characterization and in vitro anti-tumoral activity, J. 
Control. Release, 83, pp.273-286. 2002. 
Gabizon, A. Emerging role of liposomal drug carrier systems in cancer chemotherapy, 
J. Liposome Res., 13, pp.17-20. 2003. 
Gabizon, A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a 
new form of chemotherapy, Cancer Invest., 19, pp.424-436. 2001. 
Galindo-Rodriguez, S., E. Allémann, H. Fessi and E. Doelker. Physicochemical 
parameters associated with nanoparticle formation in the salting-out, emulsification-
diffusion, and nanoprecipitation methods, Pharm. Res., 21, pp.1428-1439. 2004. 
Gan, C.W. and S.S. Feng. Transferrin-conjugated nanoparticles of Poly(lactide)-D-a-
Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug 
delivery across the bloodebrain barrier, Biomaterials, 31, pp.7748-7757. 2010. 
 179 
 
Gan, C.W., S. Chien and S.S. Feng. Nanomedicine: Enhancement of 
chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle 
formulation, Curr. Pharm. Design, 16, pp.2308-2320. 2010. 
Gao, X.H., Y.Y. Cui, R.M. Levenson, L.W.K. Chung and  S.M. Nie. In vivo cancer 
targeting and imaging with semiconductor quantum dots, Nat. Biotechnol., 22, pp.969-
976. 2004. 
Gao, Y., L.B. Li and G. Zhai. Preparation and characterization of Pluronic/TPGS 
mixed micelles for solubilization of camptothecin, Colloid Surf., 64, pp.194-199. 2009. 
Garti, N. What can nature offer from an emulsifier point of view: trends and progress? 
Colloids Surf., 152, pp.125-146. 1999. 
Gelderblom, H., J. Verweij, K. Nooter and A. Sparreboom. Cremophor EL: the 
drawbacks and advantages of vehicle selection for drug formulation, Eur. J. Cancer, 37, 
pp.1590-1598. 2001. 
Gelmon, K. The taxoids: paclitaxel and docetaxel, Lancet, 344, pp.1267-1272. 1994. 
Geng, Y., P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, T. Minko and D.E. Discher. Shape 
effects of filaments versus spherical particles in flow and drug delivery, Nat. 
Nanotechnol., 2, pp.249-255. 2007. 
Govender, T., S. Stolnik, M.C. Garnett, L. Illum and S.S. Davis. PLGA nanoparticles 
prepared by nanoprecipitation: drug loading and release studies of a water soluble drug, 
J. Control. Release, 57, pp.171-185. 1999. 
Greenwald, R.B., Y.H. Choe, J. McGuire and C.D. Conover. Effective drug delivery 
by PEGylated drug conjugates, Adv. Drug Deliv. Rev. 55, pp.217-250. 2003. 
Gref, R., Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin and R. Langer. 
Biodegradable long-circulating polymeric nanospheres, Science, 263, pp.1600-1603. 
1994. 
Gros, L., H. Ringsdorf and H. Schupp. Polymeric anti-tumor agents on a molecular 
and on a cellular-level, Angew. Chem. Int. Ed., 20, pp.305-325. 1981. 
Gu, F., L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer 
and O.C. Farokhzad. Precise engineering of targeted nanoparticles by using self-
assembled biointegrated block copolymers, Proc. Natl. Acad. Sci. USA, 105, pp.2586-
2591. 2008. 
Hagan, S.A., A.G.A. Coombes, M.C. Garnett, S.E. Dunn, M.C. Davis, L. Illum, S.S. 
Davis, S.E. Harding, S. Purkiss and P.R. Gellert. Polylactide-poly(ethylene glycol) 
copolymers as drug delivery systems. 1. Characterization of water dispersible micelle-
forming systems, Langmuir, 12, pp.2153-2161. 1996. 
Hanauske, A.-R., H. Depenbrock, D. Shirvani and J. Rastetter. Effects of the 
microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on 
epidermal growth factor-receptor binding of human breast cancer cell lines in vitro, 
Eur. J. Cancer, 30, pp.1688-1694. 1994. 
 180 
 
Hans, M.L. and A.M. Lowman. Biodegradable nanoparticles for drug delivery and 
targeting, Curr. Opin. Solid St. M., 6, pp.319-327. 2002. 
Hatakeyama, H., A. Kikuchi, M. Yamato and T. Okano. Bio-functionalized 
thermoresponsive interfaces facilitating cell adhesion and proliferation, Biomaterials, 
27, pp.5069-5078. 2006. 
Hennenfent, K.L. and R. Govindan. Novel formulations of taxanes: a review. Old wine 
in a new bottle? Ann. of Oncol., 17, pp.735-749. 2006. 
Hoare, T.R. and D.S. Kohane. Hydrogels in drug delivery: Progress and challenges, 
Polymer, 49, pp.1993-2007. 2008. 
Holowka, E.P., V.Z. Sun, D.T. Kamei and T.J. Deming. Polyarginine segments in 
block copolypeptides drive both vesicular assembly and intracellular delivery, Nat. 
Mater., 6, pp.52-57. 2006. 
Huang, H.Y., E.E. Remsen, T. Kowalewski and K.L. Wooley. Nanocages derived from 
shell cross-linked micelle templates, J. Am. Chem. Soc., 121, pp.3805-3806. 1999. 
Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice, N. Engl. J. 
Med., 357, pp.39-51 (2007). 
Huh, Y.M., Y.W. Jun, H.T. Song, S. Kim, J.S. Choi, J.H. Lee, S. Yoon, K.S. Kim, J.S. 
Shin, J.S. Suh and J. Cheon. In vivo magnetic resonance detection of cancer by using 
multifunctional magnetic nanocrystals, J. Am. Chem. Soc., 127, pp.12387-12391. 2005. 
Immordino, M.L., P. Brusa, S. Arpicco, B. Stella, F. Dosio and L. Cattel. Preparation, 
characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel, 
J. Control. Release, 91, pp.417-429. 2003. 
Ito, J.-I., T. Kato, Y. Kamio, H. Kato, T. Kishikawa, T. Toda, S. Sasaki and R. Tanaka. 
A cellular uptake of cis-Platinum encapsulating liposome through endocytosis by 
human neuroblastoma cell, Neurochem. Int., 18, pp.257-264. 1991. 
Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other 
macromolecules in tumors, Cancer Res., 50, pp.814-819. 1990. 
Jain, R.K. Delivery of molecular and cellular medicine to solid tumors, Adv. Drug 
Deliv. Rev., 46, pp.149-168. 2001. 
Jalil, R. and J. Nixon. Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) 
microcapsules: Problems associated with preparative techniques and release properties, 
J. Microencapsul., 7, pp.297-325. 1990. 
Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun. Cancer statistics, 2009, 
CA Cancer J. Clin., 59, pp.225-249. 2009. 
Jemal, A., R. Siegel, J. Xu and E. Ward. Cancer statistics, 2010, CA Cancer J. Clin., 
60, pp.277-300. 2010. 
 181 
 
Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward and D. Forman. Global cancer 
statistics, CA Cancer J. Clin., 61, pp.69-90. 2011. 
Jiang, J., X. Tong and Y. Zhao. A new design for light-breakable polymer micelles, J. 
Am. Chem. Soc., 127, pp.8290-8291. 2005. 
Jones, S. Head-to-head: docetaxel challenges paclitaxel, Eur. J. Cancer, Supp 4, pp.4-8. 
2006. 
Jones, S.E., J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. 
Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers 
and P.M. Ravdin. Randomized phase III study of docetaxel compared with paclitaxel 
in metastatic breast cancer, J. Clin. Oncol., 23, pp.5542-5551. 2005. 
Kabanov, A.V., E.V. Batrakova and V.Y. Alakhov. Pluronic
®
 block copolymers as 
novel polymer therapeutics for drug and gene delivery, J. Control. Release, 82, pp.189-
212. 2002. 
Kah, J.C.Y., K.Y. Wong, K.G. Neoh, J.H. Song, J.W. Fu, S. Mhaisalkar, M. Olive and 
C.J. Sheppard. Critical parameters in the pegylation of gold nanoshells for biomedical 
applications: an in vitro macrophage study, J. Drug Target., 17, pp.181-193. 2009. 
Kakizawa, Y. and K. Kataoka. Block copolymer micelles for delivery of gene and 
related compounds, Adv. Drug Deliv. Rev., 54, pp.203-222. 2002. 
Kataoka, K., A. Harada and Y. Nagasaki. Block copolymer micelles for drug delivery: 
Design, characterization and biological significance, Adv. Drug Deliv. Rev., 47, 
pp.113-131. 2001. 
Kirpotin, D.B., D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. 
Marks, C.C. Benz and J.W. Park. Antibody targeting of long-circulating lipidic 
nanoparticles does not increase tumor localization but does increase internalization in 
animal models, Cancer Res., 66, pp.6732-6740. 2006. 
Klein, C.A. Cancer: The metastasis cascade, Science, 321, pp.1785-1787. 2008. 
Klibanov, A.L., K. Maruyama, V.P. Torchilin and L. Huang. Amphipatic 
polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 
268, pp.235-237. 1990. 
Klouda, L. and A.G. Mikos. Thermoresponsive hydrogels in biomedical applications, 
Eur. J. Pharm. Biopharm., 68, pp.34-45. 2008. 
Koo, Y.E.L., G.R. Reddy, M. Bhojani, R. Schneider, M.A. Philbert, A. Rehemtulla, 
B.D. Ross and R. Kopelman. Brain cancer diagnosis and therapy with nanoplatforms, 
Adv. Drug Deliv. Rev., 58, pp.1556-1577. 2006. 
Kopecek, J. and J. Yang. Hydrogels as smart materials, Polym. Int., 56, pp.1078-1098. 
2007. 




Kopelman, R., Y.E.K. Lee, M. Philbert, B.A. Moffat, G.R. Reddy, P. McConville, D.E. 
Hall, T.L. Chenevert, M.S. Bhojani, S.M. Buck, A. Rehemtulla and B.D. Ross. 
Multifunctional nanoparticle platforms for in vivo MRI enhancement and 
photodynamic therapy of a rat brain cancer, J. Magn. Magn. Mater., 293, pp.404-410. 
2005. 
Kostarelos, K. The long and short of carbon nanotube toxicity, Nat. Biothechnol., 26, 
pp.774-776. 2008. 
Kreuter, J. Nanoparticulate systems for brain delivery for drugs, Adv. Drug Deliv. 
Rev., 47, pp.65-81. 2001. 
Kreuter, J., P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. 
Alyautdin, H. von Briesen and D.J. Begley. Direct evidence that polysorbate-80-coated 
poly (butylcyanoacylate) nanoparticles deliver drugs to the CNS via specific 
mechanisms requiring prior binding of drugs to the nanoparticles, Pharm. Res., 20, 
pp.409-416. 2003. 
Krishna, R., and L.D. Mayer. Multidrug resistance (MDR) in cancer - Mechanisms, 
reversal using modulators of MDR and the role of MDR modulators in influencing the 
pharmacokinetics of anticancer drugs, Eur. J. Pharm. Sci., 11, pp.265-83. 2000. 
Kukowska-Latallo, J.F., K.A. Candido, Z.Y. Cao, S.S. Nigavekar, I.J. Majoros, T.P. 
Thomas, L.P. Balogh, M.K. Khan and J.R. Baker, Nanoparticle targeting of anticancer 
drug improves therapeutic response in animal model of human epithelial cancer, 
Cancer Res., 65, pp.5317-5324. 2005. 
Langer, R. Drug delivery and targeting, Nature, 392, pp.5-10. 1998. 
Langer, R. Drug delivery: Drugs on target, Science, 293, pp.58-59. 2001. 
Lasic, D.D. Liposomes: from physics to applications, Elsevier. 1993. 
Lavasanifar, A., J. Samuel, G.S. Kwon. Poly(ethylene oxide)-block-poly(L-amino acid) 
micelles for drug delivery, Adv. Drug Deliv. Rev., 54, pp.169-190. 2002. 
Lavelle, F., M.C. Bissery and C. Combeau. Preclinical evaluation of docetaxel 
(Taxotere), Semin. Oncol., 22, pp.3-16. 1995. 
Leamon, C.P. and P.S. Low. Delivery of macromolecules into living cells: a method 
that exploits folate receptor endocytosis, Proc. Natl. Acad. Sci., 88, pp.5572-5576. 
1991. 
Lee, C.C., J.A. MacKay, J.M.J. Frechet and F.C. Szoka. Designing dendrimers for 
biological applications, Nat. Biotechnol., 23, pp.1517-1526. 2005, 
Lee, C.C., E.R. Gillies, M.E. Fox, S.J. Guillaudeu, J.M.J. Frechet, E.E. Dy and F.C. 
Szoka. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice 
bearing C-26 colon carcinomas, Proc. Natl. Acad. Sci., 103, pp.16649-16654. 2006. 
Lee, E., K. Na, Y.H. Bae. Polymeric micelle for tumor pH and folate-mediated 
targeting, J. Control. Release, 91, pp.103-113. 2003. 
 183 
 
Lee, R.J. and P.S. Low. Folate-mediated tumor cell targeting of liposome-entrapped 
doxorubicin in vitro, Biochim. Biophys. Acta, 1233, pp.134-144. 1995. 
Lee, S.H., Z. Zhang and S.S. Feng. Nanoparticles of poly(lactide)-tocopheryl 
polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery, 
Biomaterials, 28, pp.2041-2050. 2007. 
Li, C., D.F. Yu, R.A. Newman, F. Cabral, L.C. Stephens, N. Hunter, L. Milas and S. 
Wallace. Complete regression of well-established tumors using a novel water-soluble 
poly(L-glutamic acid)-paclitaxel conjugate, Cancer Res., 58, pp.2404-2409. 1998. 
Li, Y.Q., H.L. Wong, A.J. Shuhendler, A.M. Rauth and X.Y. Wu. Molecular 
interactions, internal structure and drug release kinetics of rationally developed 
polymer-lipid hybrid nanoparticles, J. Control. Release, 128, pp.60-70. 2008. 
Liu, Y.Y., Y.H. Shao and J. Lu. Preparation, properties and controlled release 
behaviors of pH-induced thermosensitive amphiphilic gels, Biomaterials, 27, pp.4016-
4024. 2006. 
Liu, Z., C. Davis, W. Cai, L. He, X. Chen and H. Dai. Circulation and long-term fate 
of functionalized, biocompatible single-walled carbon nanotubes in mice probed by 
Raman spectroscopy, P. Natl. Acad. Sci., 105, pp.1410-1415. 2008. 
Lockman, P.R., R.J. Mumper, M.A. Khan and D.D. Allen. Nanoparticle technology for 
drug delivery across the blood-brain barrier, Drug Dev. Ind. Pharm., 28, pp.1-13. 2002. 
Longo, R., F. Torino and G. Gasparini. Targeted therapy of breast cancer, Curr. 
Pharma. Design, 13, pp.497-517. 2007. 
Lopes, N.M., E.G. Adams, T.W. Pitts and B.K. Bhuyan. Cell kill kinetics and cell 
cycle effects of Taxol on human and hamster ovarian cell lines, Cancer Chemoth. 
Pharm., 32, pp.235-242. 1993. 
Lukyanov, A.N. and V.P. Torchilin. Micelles from lipid derivatives of water-soluble 
polymers as delivery systems for poorly soluble drugs, Adv. Drug Deliv. Rev., 56, 
pp.1273-1289. 2004. 
Müller, R.H., C. Jacobs and O. Kayser. Nanosuspensions as particulate drug 
formulations in therapy: Rationale for development and what we can expect for the 
future, Adv. Drug Deliv. Rev., 47, pp.3-19. 2001. 
Maeda, H., J. Wu, T. Sawa, Y. Matsumura and K. Hori. Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 
pp.271-284. 2000. 
Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: 
the key role of tumor-selective macromolecular drug targeting, Adv. Enzyme Regul., 
41, pp.189-207. 2001. 
Makino, K., T. Yamada, M. Kimura, T. Oka, H. Ohshima and T. Kondo. Temperature- 
and ionic strength-induced conformational changes in the lipid head group region of 
liposomes as suggested by zeta potential data, Biophys. Chem., 41, pp.175-183. 1991. 
 184 
 
Malik, N., E. G. Evagorou and R. Duncan. Dendrimer-platinate: A novel approach to 
cancer chemotherapy, Anticancer Drugs, 10, pp.767-776. 1999. 
Manske, R. and H. Holmes. The Alkaloids: Chemistry and Physiology. The American 
Journal of Medical Sciences. 1952. 
Marty, J.J., R.C. Oppenheim and P. Speiser. Nanoparticles: New colloidal drug 
delivery system, Pharm. Acta Helv., 53, pp.17-23. 1978. 
Matsumura, Y. and H. Maeda. A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the 
antitumor agent smancs, Cancer Res., 46, 6387-6392. 1986. 
Mbeunkui, F. and D.J. Johann. Cancer and the tumor microenvironment: a review of 
an essential relationship, Cancer Chemother. Pharmacol., 63, pp.571-582. 2009. 
Meerum Terwogt, J. M., W.W. ten Bokkel Huinink, J.H. Schellens, M. Schot, I.A. 
Mandjes, M.G. Zurlo, M. Rocchetti, H. Rosing, F.J. Koopman and J.H. Beijnen. Phase 
I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-
conjugated prodrug of paclitaxel, Anticancer Drugs, 12, pp.315-323. 2001. 
Mei, L., Y.Q. Zhang, Y. Zheng, G. Tian, C.X. Song, D.Y. Yang, H. Chen, H. Sun, Y. 
Tian, K. Liu, Z. Li and L. Huang. A novel docetaxel-loaded poly (epsilon-
caprolactone)/Pluronic F68 nanoparticle overcoming multidrug resistance for breast 
cancer treatment, Nanoscale Res. Lett., 4, pp.1530-1539. 2009. 
Miller, C.A. Spontaneous emulsification produced by diffusion: A review, Colloids 
Surf., 29, pp.89-102. 1988. 
Minchinton, A.l. and I.F. Tannock. Drug penetration in solid tumours, Nat. Rev. 
Cancer, 6, pp.583-592. 2006. 
Moghimi, S.M., A.C. Hunter and J.C. Murray. Nanomedicine: Current status and 
future prospects, FASEB J., 19, pp.311-330. 2005. 
Mu, L. and S.S. Feng. Vitamin E TPGS used as emulsifier in the solvent 
evaporation/extraction technique for fabrication of polymeric nanospheres for 
controlled release of paclitaxel, J. Control. Release, 80, pp.129-144. 2002. 
Mu, L. and S.S. Feng. A novel controlled release formulation for the anticancer drug 
Paclitaxel (Taxol
®
): PLGA nanoparticles containing vitamin E TPGS, J. Control. 
Release, 86, pp.33-48. 2003. 
Mu, L., P.H. Seow, S.N. Ang and S.S. Feng. Study on surfactant coating of polymeric 
nanoparticles for controlled delivery of anticancer drug, Colloid Polym. Sci., 283, 
pp.58-65. 2004. 
Mu, L., T.A. Elbayoumi and V.P. Torchilin. Mixed micelles made of poly(ethylene 
glycol)-phosphatidylethanolamine conjugate and D-α-tocopherol succinate 
polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin, 
Int. J. Pharm., 306, pp.142-149. 2005. 
 185 
 
Mu, L. and P.H. Seow. Application of TPGS in polymeric nanoparticulate drug 
delivery system, Colloid Surf., 47, pp.90-97. 2006. 
Muller, V., I. Witzel and E. Stickeler. Immunological approaches in the treatment of 
metastasized breast cancer, Breast Care, 4, pp.358-366. 2009. 
Murugesan, S., P. Mishra and N.K. Jain. Development of folate-conjugated PEGylated 
poly (d, l-lactide-co-glycolide) nanoparticulate carrier for docetaxel, Curr. Nanosci., 4, 
pp.402-408. 2008. 
Musumeci, T., C.A. Ventura, I. Giannone, B. Ruozi, L. Montenegro, R. Pignatello and 
G. Puglisi. PLA/PLGA nanoparticles for sustained release of docetaxel, Int. J. Pharm., 
325, pp.172-179. 2006. 
Na, K., J.H. Park, S.W. Kim, B.K. Sun, D.G. Woo, H.M. Chung and K.H. Park. 
Delivery of dexamethasone, ascorbate, and growth factor (TGF beta-3) in thermo-
reversible hydrogel constructs embedded with rabbit chondrocytes, Biomaterials, 27, 
pp.5951-5957. 2006. 
Nahta, R. and F.J. Esteva. Herceptin: mechanisms of action and resistance, Cancer 
Lett., 232, pp.123-138. 2006. 
Neradovic, D., O. Soga, C.F. van Nostrum and W.E. Hennink. The effect of the 
processing and formulation parameters on the size of nanoparticles based on block 
copolymers of poly(ethylene glycol) and poly(N-isopropylacrylamide) with and 
without hydrolytically sensitive groups, Biomaterials, 25, pp.2409-2418. 2004. 
New, R.R.C. Liposomes a practical approach, Oxford University Press. 1990. 
Nie, S. Understanding and overcoming major barriers in cancer nanomedicine. 
Nanomedicine 5, pp.523-528. 2010. 
Nishiyama, N. and K. Kataoka. Current state, achievements, and future prospects of 
polymeric micelles as nanocarriers for drug and gene delivery, Pharmacol. Ther., 112, 
pp.630-648. 2006. 
Noble, C.O., D.B. Kirpotin, M.E. Hayes, C. Mamot, K. Hong, J.W. Park, C.C. Benz, 
J.D. Marks and D.C. Drummond. Development of ligand-targeted liposomes for 
cancer therapy, Expert Opin. Ther. Targets, 8, pp.335-353. 2004. 
Ochoa, L., A. Tolcher, J. Rizzo, G. Schwartz, A. Patnaik, L. Hammond, H. McCreery, 
L. Denis, M. Hidalgo, J. Kwiatek, J. McGuire and E. Rowinsky. A Phase I study of 
PEG-camptothecin (PEG-CPT) in patients with advanced solid tumours: A novel 
formulation for an insoluble but active agent, Proc. Am. Soc. Clin. Oncol., 19, pp.700. 
2000. 
Olivier, J. Drug transport to brain with targeted nanoparticles, NeuroRx, 2, pp.108-119. 
2005. 
Owens, D.E. and N.A. Peppas. Opsonization, biodistribution, and pharmacokinetics of 
polymeric nanoparticles. Int. J. Pharm., 307, pp.93-102. 2006. 
 186 
 
Pan, J. and S.S. Feng. Folate-decorated poly (lactide)-vitamin E TPGS nanoparticles 
for targeted delivery of paclitaxel, Biomaterials, 29, pp.2663-2672. 2008. 
Pan, J. and S.S. Feng. Targeting and imaging cancer cells by Folate-decorated, 
quantum dots (QDs) - loaded nanoparticles of biodegradable polymers, Biomaterials, 
30, pp.1176-1183. 2009. 
Pang, Z., W. Lu, H. Gao, K. Hu, J. Chen, C. Zhang, X. Gao, X. Jiang and C. Zhu. 
Preparation and brain delivery property of biodegradable polymersomes conjugated 
with OX26, J. Control. Release, 128, pp.120-127. 2008. 
Park, J. W., C.C. Benz. and F.J. Martin. Future directions of liposome and 
immunoliposome based cancer therapeutics, Semin. Oncol., 31, pp.196-205. 2004. 
Park, K., S. Lee, E. Kang, K. Kim, K. Choi and I.C. Kwon. New generation of 
multifunctional nanoparticles for cancer imaging and therapy, Adv. Func. Mater., 19, 
pp.1553-1566. 2009. 
Parveen, S. and S.K. Sahoo. Polymeric nanoparticles for cancer therapy, J. Drug 
Target., 16, pp.108-123. 2008. 
Pasut, G. and F.M. Veronese. Polymer-drug conjugation, recent achievements and 
general strategies, Prog. Polym. Sci., 32, pp.933-961. 2007. 
Patel, G. B. and G.D. Sprott. Archaeobacterial ether lipid liposomes (archaeosomes) as 
novel vaccine and drug delivery systems, Crit. Rev. Biotechnol., 19, pp.317-357. 1999. 
Patil, A., I.M. Shaikh, V.J. Kadam and K.R. Jadhav. Nanotechnology in therapeutics - 
Current technologies and applications, Curr. Nanosci., 5, pp.141-153. 2009. 
Pelicano, H., D.S. Martin, R.H. Xu and P. Huang. Glycolysis inhibition for anticancer 
treatment, Oncogene, 25, pp.4633-4646. 2006. 
Phillips, G.D.L., G.M. Li, D.L. Dugger, L.M. Crocker, K.L. Parsons, E. Mai, W.A. 
Blättler, J.M. Lambert, R.V. Chari, R.J. Lutz, W.L. Wong, F.S. Jacobson, H. Koeppen, 
R.H. Schwall, S.R. Kenkare-Mitra, S.D. Spencer and M.X. Sliwkowski. Targeting 
HER2-positive breast cancer with Trastuzumab-DM1, an antibody-cytotoxic drug 
conjugate, Cancer Res., 68, pp.9280-9290. 2008. 
Pratten, M., J. Lloyd, G. Horpel, H. Ringsdorf. Micelle forming block copolymers: 
Pinocytosis by macrophages and interaction with model membranes, Makromol. Chem. 
Macromol. Chem. Phys., 186, pp.725-733. 1985. 
Qiu, L.Y. and Y.H. Bae. Polymer architecture and drug delivery, Pharm. Res., 23, 
pp.1-30. 2006. 
Rai, S., R. Paliwal, P.N. Gupta, K. Khatri, A.K. Goyal, B. Vaidya and S.P. Vyas. Solid 
lipid nanoparticles (SLNs) as a rising tool in drug delivery science: one step up in 
nanotechnology, Curr. Nanosci., 4, pp.30-44. 2008. 
Rapoport, N. Physical stimuli-responsive polymeric micelles for anti-cancer drug 
delivery, Prog. Polym. Sci., 32, pp.962-990. 2007. 
 187 
 
Rijcken, C.J., C.J. Snel, R.M. Schiffelers, C.F. van Nostrum and W.E. Hennink. 
Hydrolysable core-crosslinked thermosensitive polymeric micelles: Synthesis, 
characterisation and in vivo studies, Biomaterials, 28, pp.5581-5593. 2007. 
Riou, J.F., A. Naudin and E. Lavelle. Effects of Taxotere on murine and human tumor 
cell lines, Biochem. Biophys. Res. Commun., 187, pp.164-170. 1992. 
Riou, J.F., O. Petitgenet, C. Combeau and F. Lavelle. Cellular uptake and efflux of 
Docetaxel (Taxotere
®
) and Paclitaxel (Taxol
®
) in P388 cell line, Proc. Am. Assoc. 
Cancer Res., 35, pp.385. 1994. 
Ross, J.S., J.A. Fletcher, K.J. Bloom, G.P. Linette, J .Stec, W.F. Symmans, L. Pusztai 
and G.N. Hortobagyi. Targeted therapy in breast cancer: the HER-2/neu gene and 
protein, Mol. Cell Proteomics, 3, pp.379-98. 2004. 
Rowinsky, E.K., L.A. Cazenave and R.C. Donehower. Taxol: a novel investigational 
antimicrotubule agent, J. Natl. Cancer Inst., 82, pp.1247-1259. 1990. 
Rowinsky, E.K., N. Onetto, R.M. Canetta and S.G. Arguck. Taxol - the 1st of the 
taxanes, an important new class of antitumor agents, Semin. Oncol., 6, pp.646-662. 
1992. 
Sadoqi, M., C.A. Lau-Cam and S.H. Wu. Investigation of the micellar properties of the 
tocopheryl polyethylene glycol succinate surfactants TPGS 400 and TPGS 1000 by 
steady state fluorometry, J. Colloid Interface Sci., 333, pp.585-589. 2009. 
Scholes, P.D., A.G.A. Coombes, L. Illum, S.S. Daviz, M. Vert and M.C. Davies. The 
preparation of sub-200 nm poly (lactide-co-glycolide) microspheres for site specific 
drug delivery, J. Control. Release, 25, pp.145-153. 1993. 
Seidman, A.D., M.N. Fornier, F.J. Esteva, L. Tan, S. Kaptain, A. Bach, K.S. Panageas, 
C. Arroyo, V. Valero, V. Currie, T. Gilewski, M. Theodoulou, M.E. Moynahan, M. 
Moasser, N. Sklarin, M. Dickler, G. D'Andrea, M. Cristofanilli, E. Rivera, G.N. 
Hortobagyi, L. Norton and C.A. Hudis. Weekly trastuzumab and paclitaxel therapy for 
metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and 
gene amplification, J. Clin. Oncol., 19, pp.2587-2595. 2001. 
Senter, P.D. Potent antibody drug conjugates for cancer therapy, Curr. Opin. Chem. 
Biol., 13, pp.235-244. 2009. 
Senthilkumar, M., P. Mishra and N.K. Jain. Long circulating PEGylated poly(d,l-
lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors, J. Drug 
Target., 16, pp.424-435. 2008. 
Sethuraman, V.A. and Y.H. Bae. Tat peptide-based micelle system for potential active 
targeting of anti-cancer agents to acidic solid tumors, J. Control. Release, 118, pp.216-
224. 2007. 
Seymour, L.W. for the Cancer Research Campaign Phase I/II Clinical Trials 
Committee. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin, 
J. Clin. Oncol., 20, pp.1668-1676. 2002. 
 188 
 
Shi, G., Q. Cai, C. Wang, N. Lu, S. Wang and J. Bei. Fabrication and biocompatibility 
of cell scaffolds of poly(L-lactic acid) and poly(L-lactic-co-glycolic acid), Polymer 
Adv. Tech., 13, pp.227-232. 2002. 
Shiokawa, T., Y. Hattori, K. Kawano, Y. Ohguchi, H. Kawakami, K. Toma and Y. 
Maitani. Effect of polyethylene glycol linker chain length of folate-linked 
microemulsions loading aclacinomycin A on targeting ability and antitumor effect in 
vitro and in vivo, Clin. Cancer Res., 11, pp.2018-2025. 2005. 
Sinha, R., G.J. Kim, S. Nie and D.M. Shin. Nanotechnology in cancer therapeutics: 
bioconjugated nanoparticles for drug delivery, Mol. Cancer Ther., 5, pp.1909-1917. 
2006. 
Smart, S.K., A.I. Cassady, G.Q. Lu and D.J. Martin. The biocompatibility of carbon 
nanotubes, Carbon, 44, pp.1034-1047. 2006. 
Smith, I.E. Efficacy and safety of Herceptin in women with metastatic breast cancer: 
results from pivotal clinical studies, Anticancer Drugs, 12, pp.S3-S10. 2001. 
Soni, V., D.V. Kohli and S.K. Jain. Transferrin-conjugated liposomal system for 
improved delivery of 5-fluorouracil to brain, J. Drug Target., 16, pp.73-78. 2008. 
Soppimath, K., T. Aminabhavi, A. Kulkarni and W. Rudzinski. Biodegradable 
polymeric nanoparticles as drug delivery devices, J. Control. Release, 70, pp.1-20. 
2001. 
Stohrer, M., Y. Boucher, M. Stangassinger and R.K. Jain. Oncotic pressure in solid 
tumors is elevated, Cancer Res., 60, pp.4251-4255. 2000. 
Strebhardt, K. and A. Ullrich. Paul Ehrlich's magic bullet concept: 100 years of 
progress, Nat. Rev. Cancer, 8, pp.473-480. 2008, 
Sun, B., B. Ranganathan and S.S. Feng. Multifunctional poly(D,L-lactide-co-
glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for 
targeted chemotherapy of breast cancer, Biomaterials, 29, pp.475-486. 2008. 
Sun, B. and S.S. Feng. Trastuzumab-functionalized nanoparticles of biodegradable 
copolymers for targeted delivery of docetaxel,  Nanomedicine, 4, pp.431-445. 2009. 
Sun, W., C. Xie, H. Wang and Y. Hu. Specific role of polysorbate 80 coating on the 
targeting of nanoparticles to the brain, Biomaterials, 25, pp.3065-3071. 2004. 
Svenson, S., D.A. Tomalia. Dendrimers in biomedical applications-reflections on the 
field, Adv. Drug Deliv. Rev., 57, pp.2106-2129. 2005. 
Tamargo, R.J. and H. Brem. Drug delivery to the central nervous system: a review, 
Neurosurg. Quat. 2, pp.259-279. 1992. 
Tan, Y.F., P. Chandrasekharan, D. Maity, C.X. Yong, K.H. Chuang, Y. Zhao, S. Wang, 
J. Ding and S.S. Feng. Multimodal tumor imaging by iron oxides and quantum dots 
formulated in poly (lactic acid)-d-alpha-tocopheryl polyethylene glycol 1000 succinate 
nanoparticles, Biomaterials, 32, pp.2969-2978. 2011. 
 189 
 
Tang, N., G. Du, N. Wang, C. Liu, H. Hang and W. Liang. Improving Penetration in 
Tumors With Nanoassemblies of Phospholipids and Doxorubicin, J. Natl. Cancer Inst., 
99, pp.1004-1015. 2007. 
Thevenot, J., A.L. Troutier, L. David, T. Delair and C. Ladaviere. Steric stabilization 
of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids, 
Biomacromolecules, 8, pp.3651-3660. 2007. 
Tong, R. and J. Cheng. Anticancer polymeric nanomedicines, Polym. Rev., 47, 
pp.345-381. 2007. 
Torchilin, V.P. and V.S. Trubetskoy. Which polymers can make nanoparticulate drug 
carriers long-circulating? Adv. Drug Deliv. Rev., 16, pp.141-155. 1995. 
Torchilin, V.P. Block copolymer micelles as a solution for drug delivery problems, 
Expert Opin. Ther. Patents, 15, pp.63-75. 2005. 
Torchilin, V.P. Recent Advances with liposomes as pharmaceutical carriers, Nat. Rev. 
Drug Discov, 4, pp.145-160. 2005a.  
Tsai, C.P., C.Y. Chen, Y. Hung, F.H. Chang and C.Y. Mou. Monoclonal antibody-
functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast 
cancer cells, J. Mater. Chem., 19, pp.5737-5743. 2009. 
van Vlerken, L.E., T.K. Vyas and M.M. Amiji. Poly(ethylene glycol)-modified 
nanocarriers for tumor-targeted and intracellular delivery, Pharm. Res., 24, pp.1405-
1414. 2007. 
Vasey, P. and on behalf of the Cancer Research Campaign Phase I/II Committee. 
Phase I clinical and pharmacokinetic study of PK1 [N-(2-
hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class 
of chemotherapeutic agents-drug-polymer conjugates, Clin. Cancer Res., 5, pp.83-94. 
1999. 
Veronese, F.M. and A. Mero. The impact of PEGylation on biological therapies, 
Biodrugs, 22, pp.315-329. 2008. 
Vetvicka, D., M. Hruby, O. Hovorka, T. Etrych, M. Vetrik, L. Kovar, M. Kovar, K. 
Ulbrich and B. Rihova. Biological evaluation of polymeric micelles with covalently 
bound doxorubicin, Bioconjug. Chem., 20, pp.2090-2097. 2009. 
Vogel, C.L., M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, 
D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart and M. 
Press. Efficacy and safety of trastuzumab as a single agent in first-line treatment of 
HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, pp.719-726. 2002. 
Wang, X., L. Yang, Z. Chen and D.M. Shin. Application of nanotechnology in cancer 
therapy and imaging, CA Cancer J. Clin., 58, pp.97-110. 2008. 
Webster, L., M. Linsenmeyer, M. Millward, C. Morton, J. Bishop, and D. Woodcock. 
Measurement of cremopnor EL following taxol: Plasma levels sufficient to reverse 
 190 
 
drug exclusion mediated by the multidrug-resistant phenotype, J. Natl. Cancer Inst., 85, 
pp.1685-1690. 1993. 
Wichterle, O. and D. Lím. Hydrophilic gels for biological use, Nature, 185, pp.117-
118. 1960. 
Win, K.Y. and S.S. Feng. Effects of particle size and surface coating on cellular uptake 
of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26, 
pp.2713-2722. 2005. 
Win, K.Y. and S.S. Feng. In vitro and in vivo studies on vitamin E TPGS-emulsified 
poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation, 
Biomaterials, 27, pp.2285-2291. 2006. 
Wong, H.L., R. Bendayan, A.M. Rauth and X.Y. Wu. Simultaneous delivery of 
doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) 
for enhanced treatment of multidrug-resistant breast cancer, J. Control. Release, 116, 
pp.275-284. 2006. 
Wong, H.L., R. Bendayan, A.M. Rauth, H.Y. Xue, K. Babakhanian and X.Y. Wu. A 
mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant 
breastcancer cells using a polymer-lipid hybrid nanoparticle system, J. Pharmacol. Exp. 
Ther., 317, pp.1372-1381. 2006a. 
Wong, H.L., A.M. Rauth, R. Bendayan and X.Y. Wu. In vivo evaluation of a new 
polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid 
tumor model, Eur. J. Pharm. Biopharm., 65, pp.300-308. 2007. 
Wu, J., Q. Liu and R.J. Lee. A folate receptor-targeted liposomal formulation for 
paclitaxel, Int. J. Pharm., 316, pp.148-153. 2006. 
Xie, J., C. Lei, Y. Hu, G.K. Gay, N.H.B. Jamali and C.H. Wang. Nanoparticulate 
formulations for paclitaxel delivery across MDCK cell monolayer, Curr. Pharm. 
Design, 16, pp.2331-2340. 2010. 
Xu, C. and J. Kopecek. Self-assembling hydrogels, Polymer Bulletin, 58, pp.53-63. 
2007. 
Yamamoto, Y., Y. Nagasaki, Y. Kato, Y. Sugiyama and K. Kataoka. Long-circulating 
poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated 
surface charge, J. Control. Release, 77, pp.27-38. 2001. 
Yang, K., S. Zhang, G. Zhang, X. Sun, S.T. Lee and Z. Liu. Graphene in mice: 
Ultrahigh in vivo tumor uptake and efficient photothermal therapy, Nano Lett., 10, 
pp.3318-3323. 2010. 
Yang, S.T., K.A. Fernando, J.H. Liu, J. Wang, H.F. Sun, Y. Liu, M. Chen, Y. Huang, 
X. Wang, H. Wang and Y.P. Sun. Covalently PEGylated carbon nanotubes with stealth 
character in vivo, Small, 4, pp.940-944. 2008. 
 191 
 
Yang, T., M.K. Choi, F.D. Cui, S.J. Lee, S.J. Chung, C.K. Shim and D.D. Kim. 
Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human 
breast cancer cells, Pharm. Res., 24, pp.2402-2411. 2007. 
Yarden, Y. The EGFR family and its ligands in human cancer: signalling mechanisms 
and therapeutic opportunities, Eur. J. Cancer, 37, pp.S3-S8. 2001. 
Yatvin, M.B., W. Kreutz, B.A. Horwitz and M. Shinitzky. pH-sensitive liposomes: 
possible clinical implications, Science, 210, pp.1253-1255. 1980. 
Yin, X., A.S. Hoffman and P.S. Stayton. Poly(N-isopropylacrylamide-copropylacrylic 
acid) copolymers that respond sharply to temperature and pH, Biomacromolecules, 7, 
pp.1381-1385. 2006. 
Yoo, H.S. and T.G. Park. Folate-receptor-targeted delivery of doxorubicin 
nanoaggregates stabilized by doxorubicine-PEG-folate conjugate, J. Control. Release, 
100, pp.247-56. 2004. 
Zalipsky, S., M. Qazen, J.A. Walker, N. Mullah, Y.P. Quinn and S.K. Huang. New 
detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers 
regenerating natural phospholipid, diacyl phosphatidylethanolamine, Bioconjug. 
Chem., 10, pp.703-707. 1999. 
Zhang, L., F.X. Gu, J.M. Chan, A.Z. Wang, R. Langer and O.C. Farokhzad. 
Nanoparticles in medicine: therapeutic applications and developments, Clin. 
Pharmacol. Ther., 83, pp.761-769. 2008a. 
Zhang, L., J.M. Chan, F.X. Gu, J.-W. Rhee, A.Z. Wang, A.F. Radovic-Moreno, F. 
Alexis, R. Langer and O.C. Farokhzad. Self-assembled lipid-polymer hybrid 
nanoparticles: a robust drug delivery platform, ACS Nano, 2, pp.1696-1702. 2008b. 
Zhang, Z. and S.S. Feng. The drug encapsulation efficiency, in vitro drug Release, 
cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl 
polyethylene glycol succinate nanoparticles, Biomaterials, 27, pp.4025-4033. 2006. 
Zhang, Z. and S.S. Feng. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer 
for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug 
release, Biomaterials, 27, pp.262-270. 2006a.  
Zhang, Z., S.H. Lee and S.S. Feng. Folate-decorated poly(lactide-co-glycolide)-
vitamin E TPGS nanoparticles for targeted drug delivery, Biomaterials, 28, pp.1889-
1899. 2007.  
Zhang, Z., S.H. Lee, C.W. Gan and S.S. Feng. In vitro and in vivo investigation on 
PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy, 
Pharm. Res., 25, pp.1925-1935. 2008.  
Zhao, H.Z., and L.Y.L. Yung. Selectivity of folate conjugated polymer micelles 
against different tumor cells, Int. J. Pharm., 349, pp.256-268. 2008. 
Zhao, H.Z., and L.Y.L. Yung. Addition of TPGS to folate-conjugated polymer 
micelles for selective tumor targeting, J. Biomed. Mater. Res., 91A, pp.505-518. 2009. 
 192 
 
Zhao, Y., J. Neuzil and K. Wu. Review: Vitamin E analogues as mitochondria-
targeting compounds: From the bench to the bedside? Mol. Nutr. Food Res., 53, 
pp.129-139. 2009. 
Zhen, X.M., G.P. Martin and C. Marriott. The controlled delivery of drugs to the lung, 
Int. J. Pharm., 124, pp.149-164. 1995. 
Zheng, D.H., D. Li, X.W. Lu and Z.Q. Feng. Enhanced antitumor efficiency of 
docetaxel-loaded nanoparticles in a human ovarian xenograft model with lower 
systemic toxicities by intratumoral delivery, Oncol. Rep. 23, pp.717-724. 2010. 
Zweers, M.L.T., G.H.M. Engbers, D.W. Grijpma and J. Feijen. In vitro degradation of 
nanoparticles prepared from polymers based on dl-lactide, glycolide and poly(ethylene 





LIST OF PUBLICATIONS 
JOURNAL PUBLICATIONS 
Liu Y, Siow JYF, Feng SS*. Chemotherapeutic engineering on nanoparticles of 
biodegradable polymers for anticancer drug delivery: Effects of newly applied 
surfactant macromolecules. Submitted. 
Liu Y, Mi Y, Zhao J, Feng SS*. Multifunctional silica nanoparticles for targeted 
delivery of hydrophobic imaging and therapeutic agents. Accepted by Int J Pharm. 
Liu Y, Mi Y, Feng SS*. Editorial: Nanotechnology for multimodal imaging. 
Nanomedicine 2011;6:1141-1144. 
Mi Y, Li K, Liu Y, Pu KY, Liu B, Feng SS*. Herceptin Functionalized Polyhedral 
Oligomeric Silsesquioxane - Conjugated Oligomers - Silica/Iron Oxide Nanoparticles 
for Tumor Cell Sorting and Detection. Biomaterials 2011;32:8226-8233. 
Li K, Jiang Y, Ding D, Zhang X, Liu Y, Hua J, Feng SS, Liu B*. Folic acid-
functionalized two-photon absorbing nanoparticles for targeted MCF-7 cancer cell 
imaging. Chem Commun 2011;47:7323-7325. 
Pan J, Mi Y, Wan D, Liu Y, Feng SS, Gong J*. PEGylated liposome coated 
QDs/mesoporous silica core-shell nanoparticles for molecular imaging. Chem 
Commun 2011;47:3442-3444. 
Mi Y, Liu Y, Feng SS*. Research highlights: Herceptin®-conjugated nanocarriers for 
targeted imaging and treatment of HER2-positive cancer. Nanomedicine 2011;6:311-
315. 
Mi Y, Liu Y, Feng SS*. Formulation of Docetaxel by folic acid-conjugated D-α-
tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for 
targeted and synergistic chemotherapy. Biomaterials 2011;32:4058-4066. 
Li K, Liu Y, Pu KY, Feng SS, Zhan R, Liu B*. Polyhedral oligomeric silsesquioxanes-
containing conjugated polymer loaded PLGA nanoparticles with Trastuzumab 
(Herceptin) functionalization for HER2-positive cancer Cell detection. Adv Funct 
Mater 2011;21:287-294. 
Liu Y, Li K, Liu B, Feng SS*. Leading Opinion: A strategy for precision engineering 
of nanoparticles of biodegradable copolymers for quantitative control of targeted drug 
delivery. Biomaterials 2010;31:9145-9155. 
Liu Y, Feng SS*. Research highlights: Multimodal imaging for cancer detection. 
Nanomedicine 2010;5:687-691. 
Liu Y, Pan J, Feng SS*. Nanoparticles of lipid monolayer shell and biodegradable 
polymer core for controlled release of paclitaxel: Effects of surfactants on particles 
size, characteristics and in vitro performance. Int J Pharm 2010;395:243-250. 
 194 
 
Pan J, Liu Y, Feng SS*. Multifunctional biodegradable copolymer nanoparticles blend 
for cancer diagnosis. Nanomedicine 2010;5:347-360. 
Liu Y, Li K, Pan J, Liu B, Feng SS*. Folic acid conjugated nanoparticles of mixed 
lipid monolayer shell and biodegradable polymer core for targeted delivery of 
Docetaxel. Biomaterials 2010;31:330-338. (Top 25 Hottest Article published on 
Biomaterials in Q3 2009.) 
Li K, Pan J, Feng SS, Wu AW, Pu KY, Liu Y, Liu B*. Generic strategy of preparing 
fluorescent conjugated-polymer-loaded poly(DL-lactide-co-Glycolide) nanoparticles 
for targeted cell imaging. Adv Funct Mater 2009;19:3535-3542. 
CONFERENCE PUBLICATIONS 
Liu Y*, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer 
core for anticancer drug delivery. The 13th Asia Pacific Confederation of Chemical 
Engineering Congress. Oct. 2010, Taipei, ROC. 
Liu Y*, Feng SS. The synergistic effect of herceptin and docetaxel in polylactide-D-α-
tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles. Symposium on 
Innovative Polymers for Controlled Delivery. Sept. 2010, Suzhou, PRC. (Contributed 
as an inside cover image of conference proceeding book) 
Phyo WM, Liu Y, Mi Y, Feng SS*. Formulations of lipid shell and polymer core 
nanoparticles for drug delivery. MRS-S Trilateral Conference on Advances in 
Nanoscience: Energy, Water and Healthcare. Aug. 2010, Singapore. 
Liu Y*, Feng SS. Formulation of phospholipid coated PLGA nanoparticles for 
anticancer drug delivery. International Conference on Materials for Advanced 
Technologies 2009. Jun. 2009, Singapore. 
BOOK CHAPTERS 
Sun B, Rachmawati H, Liu Y, Zhao J, Feng SS. Antibody-Conjugated Nanoparticles 
of Biodegradable Polymers for Targeted Drug Delivery. Bionanotechnology II. In 
press. 
 
 
